<SEC-DOCUMENT>0001193125-23-253882.txt : 20231011
<SEC-HEADER>0001193125-23-253882.hdr.sgml : 20231011
<ACCEPTANCE-DATETIME>20231011081329
ACCESSION NUMBER:		0001193125-23-253882
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20231010
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231011
DATE AS OF CHANGE:		20231011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tempest Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001544227
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				451472564
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35890
		FILM NUMBER:		231319454

	BUSINESS ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 400
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		415-798-8589

	MAIL ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 400
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Millendo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20181207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OvaScience, Inc.
		DATE OF NAME CHANGE:	20120308
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d547808d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tpst="http://www.tempesttx.com/20231010" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-10-10_to_2023-10-10">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-10-10_to_2023-10-10">0001544227</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CurrentFiscalYearEndDate_duration_2023-10-10_to_2023-10-10" name="dei:CurrentFiscalYearEndDate" contextRef="duration_2023-10-10_to_2023-10-10">--12-31</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="tpst-20231010.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-10-10_to_2023-10-10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-10</xbrli:startDate> <xbrli:endDate>2023-10-10</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-10-10_to_2023-10-10">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt:datemonthdayyearen">October&#160;10, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-10-10_to_2023-10-10">Tempest Therapeutics, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-10-10_to_2023-10-10">001-35890</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-10-10_to_2023-10-10">45-1472564</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification No.)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-10-10_to_2023-10-10">2000 Sierra Point Parkway</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-10-10_to_2023-10-10">Suite 400</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-10-10_to_2023-10-10">Brisbane</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-10-10_to_2023-10-10">94005</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-10-10_to_2023-10-10">(415)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-10-10_to_2023-10-10">798-8589</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-10_to_2023-10-10">Common Stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-10_to_2023-10-10">TPST</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;10, 2023, the Board of Directors (the &#8220;Board&#8221;) of Tempest Therapeutics, Inc. (&#8220;Tempest&#8221; or the &#8220;Company&#8221;), a Delaware corporation, declared a dividend of one preferred share purchase right (&#8220;Right&#8221;) to purchase <span style="white-space:nowrap">one-thousandth</span> of one share of the Company&#8217;s newly designated Preferred Shares (as defined below) for each outstanding share of common stock, par value $0.001 per share, of the Company (&#8220;Company Common Stock&#8221;) to the stockholders of record as of the close of business on October&#160;23, 2023 (the &#8220;Record Date&#8221;), and adopted a limited duration stockholder rights plan (the &#8220;Rights Plan&#8221;), effective immediately, as set forth in the Rights Agreement, dated as of October&#160;10, 2023 (the &#8220;Rights Agreement&#8221;), by and between the Company and Computershare Trust Company, N.A., as Rights Agent. The Rights Agent currently serves as the Company&#8217;s transfer agent with respect to the Company Common Stock and also has been appointed transfer agent with respect to the Series A Junior Participating Preferred Stock, par value $0.001 per share (each, a &#8220;Preferred Share&#8221; and collectively, the &#8220;Preferred Shares&#8221;), if any, that may be issued pursuant to the exercise of rights under the Rights Agreement. The Rights will expire on October&#160;10, 2024 or, if Tempest&#8217;s stockholders approve the Rights Plan, on October&#160;10, 2026 (&#8220;Final&#160;Expiration Date&#8221;), unless the rights are earlier redeemed or exchanged by the Company. The Company does not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general terms, the Rights Agreement works by imposing a significant penalty upon any person or group that acquires beneficial ownership of 10% (15% in the case of a passive institutional investor) or more of the outstanding shares of Company Common Stock without the approval of the Board. The Rights Agreement was adopted in response to the significant and ongoing dislocation in the trading price of the Company Common Stock and not in response to a specific takeover threat. The Board adopted the Rights Agreement to enable all stockholders of the Company to realize the long-term value of their investment. The Rights Agreement should reduce the likelihood that any person or group gains control of Tempest through open market accumulation without paying all stockholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of all stockholders. The Rights Agreement does not prevent the Board from engaging with parties or accepting an acquisition proposal if the Board believes that it is in the best interests of Tempest and its stockholders. The Rights Agreement is similar to other plans adopted by publicly held companies in comparable circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the terms of the Rights Agreement follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Rights</span>. The Rights will not be exercisable and will trade with shares of the Company Common Stock until the earlier to occur of (a)&#160;the tenth calendar day (or such later date as may be determined by the Board) after a person or group acquires beneficial ownership of 10% (15% in the case of a passive institutional investor) or more of our outstanding Company Common Stock (an &#8220;Acquiring Person&#8221;) or (b)&#160;the tenth business day (or such later date as may be determined by action of the Board prior to such time as any person or entity becomes an Acquiring Person) following the date of commencement of, or the first announcement of, an intention to commence, a tender offer or exchange offer, the consummation of which would result in any person or entity or group of persons or entities acting in concert becoming an Acquiring Person; provided, however, the term &#8220;Acquiring Person&#8221; is subject to certain customary exceptions whereby certain stockholders that would have otherwise been an Acquiring Person are excluded from the definition of &#8220;Acquiring Person&#8221;. Any stockholders with beneficial ownership of Company Common Stock above the applicable threshold as of the time of this announcement are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights.&#160;Prior to exercise, the Right does not give its holder any dividend, voting or liquidation rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The date when the Rights separate from Company Common Stock and become exercisable is referred to herein as the &#8220;Distribution Date&#8221;. Until that date, Company Common Stock certificates or, in the case of uncertificated shares, notations in the book-entry account system, will evidence the Rights, and any transfer of shares of Company Common Stock will constitute a transfer of Rights. After the Distribution Date, the Rights will be evidenced by separate book-entry credits or by Rights certificates that the Company will mail to all eligible, certificated holders of Company Common Stock. Any Rights held by an Acquiring Person are null and void and may not be exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exercise Price</span>. After the Distribution Date, each Right will entitle the holder to purchase <span style="white-space:nowrap">one-thousandth</span> (1/1000<sup style="font-size:75%; vertical-align:top">th</sup>) of a Preferred Share for $25.00, subject to adjustment (the&#160;&#8220;Exercise Price&#8221;). Each <span style="white-space:nowrap">one-thousandth</span> (1/1000<sup style="font-size:75%; vertical-align:top">th</sup>)&#8195;of a Preferred Share has economic terms similar to that of one share of Company Common Stock. The Exercise Price </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payable, and the number of Preferred Shares or other securities or other property issuable upon exercise of the Rights will be subject to adjustment from time to time to prevent dilution in the event of a stock dividend on, or a subdivision, combination or reclassification of, the Preferred Shares. The exercise of Rights to purchase Preferred Shares will at all times be subject to the availability of a sufficient number of authorized but unissued Preferred Shares. Notwithstanding the foregoing, with certain exceptions, no adjustment in the Exercise Price will be required until cumulative adjustments require an adjustment of at least 1% in such Exercise Price. No fractional Preferred Shares will be issued (other than fractions which are integral multiples of the number of one <span style="white-space:nowrap">one-hundredth</span> (1/100<sup style="font-size:75%; vertical-align:top">th</sup>) of a Preferred Share issuable upon the exercise of one Right, which may, at the Company&#8217;s election, be evidenced by depositary receipts), and in lieu thereof, an adjustment in cash will be made based on the market price of the Preferred Shares on the last trading day prior to the date of exercise. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Beneficial Ownership</span>. Certain synthetic interests in securities created by derivative positions &#8212; whether or not such interests are considered to be ownership of underlying shares of Company Common Stock or are reportable for purposes of Regulation 13D of the Securities Exchange Act of 1934, as amended &#8212; are treated as beneficial ownership of the number of shares of Company Common Stock equivalent to the economic exposure created by the derivative position, to the extent actual shares of Company Common Stock are directly or indirectly held by counterparties to the derivatives contracts. Swaps dealers unassociated with any control intent or intent to evade the purposes of the Rights Agreement are excepted from such imputed beneficial ownership. In addition, shares held by affiliates and associates of an Acquiring Person, including shares that are subject of, or the reference securities for,&#160;or that underline, any derivative position of such persons, will be deemed to be beneficially owned by the Acquiring Person. In addition, any securities beneficially owned by a third party with whom the Acquiring Person has any agreement, arrangement or understanding (whether or not in writing)&#160;(i) for the purpose of acquiring, holding or voting securities of the Company or (ii)&#160;to cooperate in obtaining, changing or influencing control of the Company, will be deemed to be beneficially owned by the Acquiring Person. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Consequences of a Person or Group Becoming an Acquiring Person. </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic"><span style="white-space:nowrap">Flip-In</span></span>. If a person or group becomes an Acquiring Person, all holders of Rights except the Acquiring Person or its affiliates may, for the Exercise Price, purchase shares of Company Common Stock with a market value of twice the Exercise Price. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Exchange</span>. In lieu of <span style="white-space:nowrap">&#8220;flip-in&#8221;</span> feature described above, the Board may, at its option at any time after a person or group becomes an Acquiring Person, exchange the Rights (other than Rights owned by the Acquiring Person or its affiliates), in whole or in part, for shares of Company Common Stock at an exchange ratio of one share of Company Common Stock per Right (subject to adjustment). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Flip-Over</span>. If the Company is later acquired in a merger or similar transaction after the Distribution Date, all holders of Rights except the Acquiring Person or its affiliates may purchase, for the Exercise Price, a number of shares of Company Common Stock of the person engaging in the transaction having a market value of twice the Exercise Price. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Company Preferred Share Provisions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Preferred Share, if issued: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">will not be redeemable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">when and if any dividend is declared on Company Common Stock, entitle the holder to a preferential quarterly dividend payment equal to 1,000 times the aggregate per share price of all cash and <span style="white-space:nowrap">non-cash</span> dividends declared per share of Company Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">will entitle the holder upon liquidation either to receive $1,000 plus an amount equal to accrued and unpaid dividends and distributions thereon or an aggregate amount per share equal to 1,000 times the aggregate amount to be distributed per share to holders of Company Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">will have 1,000 votes, voting together with the Company Common Stock; </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if shares of Company Common Stock are exchanged via merger, consolidation, or a similar transaction, will entitle the holder to a per share payment equal to 1,000 times the amount of consideration received per share of Company Common Stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Preferred Shares would rank junior to any other series of the Company&#8217;s preferred stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The value of <span style="white-space:nowrap">one-thousandth</span> interest in a Preferred Share is intended to approximate the value of one share of Company Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Expiration</span>. The Rights will expire on the Final Expiration Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption</span>. The Board may redeem the Rights for $0.001 per Right at any time prior to the earlier of (A)&#160;such time as any person or group becomes an Acquiring Person or (B)&#160;the close of business on the Final Expiration Date. Following the expiration of the above periods, the Rights become nonredeemable. If the Board redeems any Rights, it must redeem all of the Rights. Once the Rights are redeemed, the only right of the holders of Rights will be to receive the redemption price of $0.001 per Right. The redemption price will be adjusted if the Company effects a stock split or stock dividend of Company Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Dilution Provisions</span>. Rights will have the benefit of certain customary anti-dilution provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendments</span>. The terms of the Rights Agreement may be amended by the Board without the consent of the holders of the Rights. After a person or group becomes an Acquiring Person, the Board may not amend the Rights Agreement in a way that adversely affects holders of the Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Miscellaneous. </span>The Rights Agreement does not contain any dead-hand, slow-hand, <span style="white-space:nowrap">no-hand</span> or similar feature that limits the ability of a future Board to redeem the Rights. Until a Right is exercised, the holder thereof, as such, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary of the Rights Agreement set forth under this Item 1.01 is qualified in its entirety by reference to the complete terms and conditions of the Rights Agreement, which is filed as Exhibit 4.1 to this Current Report on Form <span style="white-space:nowrap">8-K,</span> and incorporated by reference into this Item 1.01. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;3.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Material Modification to Rights of Security Holders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item 1.01 above is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;5.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the adoption of the Rights Agreement referenced in Item 1.01 above, the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on October&#160;10, 2023. The Certificate of Designations is attached hereto as Exhibit 3.1 and is incorporated herein by reference. The information set forth under Item 1.01 above is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;11, 2023, the Company issued a press release entitled &#8220;Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study.&#8221; Also on October&#160;11, 2023, the Company issued a press release announcing the adoption of the Rights Agreement. The full text of the press releases is attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K,</span> and is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d547808dex31.htm">Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of the State of Delaware on October&#160;10, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d547808dex41.htm">Rights Agreement, dated as of October&#160;10, 2023, between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d547808dex991.htm">Press Release of Tempest Therapeutics, Inc., dated October&#160;11, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d547808dex992.htm">Press Release of Tempest Therapeutics, Inc., dated October&#160;11, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain schedules omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> Tempest will furnish supplementally a copy of any omitted schedule to the SEC upon request. Tempest may request confidential treatment pursuant to Rule <span style="white-space:nowrap">24b-2</span> of the Securities Exchange Act of 1934, as amended, for any exhibits so furnished. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;11, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Tempest Therapeutics, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Brady</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Stephen Brady</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d547808dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEMPEST THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, Stephen Brady, does hereby certify: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. That he is duly elected and acting Chief Executive Officer of Tempest Therapeutics, Inc., a Delaware corporation (the
&#147;<B><I>Corporation</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. That pursuant to the authority conferred upon the Board of Directors by the Restated
Certificate of Incorporation, as amended, of the said Corporation (the &#147;<B><I>Amended and Restated Certificate of Incorporation</I></B>&#148;), the said Board of Directors of the Corporation on October&nbsp;10, 2023 adopted the following
resolutions creating a series of 100,000 shares of Preferred Stock designated as Series A Junior Participating Preferred Stock: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, that pursuant to the authority vested in the Board of Directors of the corporation by the Amended and Restated
Certificate of Incorporation, the Board of Directors does hereby provide for the issue of a series of preferred stock of the Corporation (&#147;<B><I>Preferred Stock</I></B>&#148;) and does hereby fix and herein state and express the designations,
powers, preferences and relative and other special rights and the qualifications, limitations and restrictions of such series of Preferred Stock as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. Designation and Amount</B>. The shares of such series shall be designated as &#147;<B><I>Series A Junior
Participating Preferred Stock.</I></B>&#148; The Series A Junior Participating Preferred Stock shall have a par value of $0.001 per share, and the number of shares constituting such series shall be 100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. Proportional Adjustment</B>. In the event that the Corporation shall at any time after the issuance of any
share or shares of Series A Participating Preferred Stock (i)&nbsp;declare any dividend on the common stock, par value $0.001 per share, of the Corporation (&#147;<B><I>Common Stock</I></B>&#148;) payable in shares of Common Stock,
(ii)&nbsp;subdivide the outstanding Common Stock or (iii)&nbsp;combine the outstanding Common Stock into a smaller number of shares, then in each such case the Corporation shall simultaneously effect a proportional adjustment to the number of
outstanding shares of Series A Junior Participating Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3. Dividends and Distributions</B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Subject to the prior and superior right of the holders of any shares of any series of Preferred Stock ranking prior and
superior to the shares of Series A Junior Participating Preferred Stock with respect to dividends, the holders of shares of Series A Junior Participating Preferred Stock shall be entitled to receive when, as and if declared by the Board of Directors
out of funds legally available for the purpose, quarterly dividends payable in cash on the last day of March, June, September and December in each year (each such date being referred to herein as a &#147;<B><I>Quarterly Dividend Payment
Date</I></B>&#148;), commencing on the first Quarterly Dividend Payment Date after the first issuance of a share or fraction of a share of Series A Junior Participating Preferred Stock, in an amount per share (rounded to the nearest cent) equal to
1,000 times the aggregate per </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share amount of all cash dividends, and 1,000 times the aggregate per share amount (payable in kind) of all <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends or other distributions other
than a dividend payable in shares of Common Stock or a subdivision of the outstanding shares of Common Stock (by reclassification or otherwise), declared on the Common Stock since the immediately preceding Quarterly Dividend Payment Date, or, with
respect to the first Quarterly Dividend Payment Date, since the first issuance of any share or fraction of a share of Series A Junior Participating Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Corporation shall declare a dividend or distribution on the Series A Junior Participating Preferred Stock as provided in
paragraph (a)&nbsp;above immediately after it declares a dividend or distribution on the Common Stock (other than a dividend payable in shares of Common Stock). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Dividends shall begin to accrue on outstanding shares of Series A Junior Participating Preferred Stock from the Quarterly Dividend
Payment Date next preceding the date of issue of such shares of Series A Junior Participating Preferred Stock, unless the date of issue of such shares is prior to the record date for the first Quarterly Dividend Payment Date, in which case dividends
on such shares shall begin to accrue from the date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the determination of holders of shares of Series A Junior
Participating Preferred Stock entitled to receive a quarterly dividend and before such Quarterly Dividend Payment Date, in either of which events such dividends shall begin to accrue from such Quarterly Dividend Payment Date. Accrued but unpaid
dividends shall not bear interest. Dividends paid on the shares of Series A Junior Participating Preferred Stock in an amount less than the total amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">share-by-share</FONT></FONT> basis among all such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of shares of Series A
Junior Participating Preferred Stock entitled to receive payment of a dividend or distribution declared thereon, which record date shall be no more than 30 days prior to the date fixed for the payment thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. Voting Rights.</B> The holders of shares of Series A Junior Participating Preferred Stock shall have the
following voting rights: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Each share of Series A Junior Participating Preferred Stock shall entitle the holder thereof to 1,000
votes on all matters submitted to a vote of the stockholders of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Except as otherwise provided herein or by law,
the holders of shares of Series A Junior Participating Preferred Stock and the holders of shares of Common Stock shall vote together as one class on all matters submitted to a vote of stockholders of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Except as required by law, the holders of Series A Junior Participating Preferred Stock shall have no special voting rights and
their consent shall not be required (except to the extent that they are entitled to vote with holders of Common Stock as set forth herein) for taking any corporate action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. Certain Restrictions</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Corporation shall not declare any dividend on, make any distribution on, or redeem or purchase or otherwise acquire for
consideration any shares of Common Stock after the first issuance of a share or fraction of a share of Series A Junior Participating Preferred Stock unless concurrently therewith it shall declare a dividend on the Series A Junior Participating
Preferred Stock as required by Section&nbsp;3 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Whenever quarterly dividends or other dividends or distributions payable
on the Series A Junior Participating Preferred Stock as provided in Section&nbsp;3 are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on shares of Series A Junior Participating Preferred
Stock outstanding shall have been paid in full, the Corporation shall not </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>declare or pay dividends on, make any other
distributions on, or redeem or purchase or otherwise acquire for consideration any shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Junior Participating Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>declare or pay dividends on, or make any other distributions on any shares of stock ranking on a parity (either as to dividends or
upon liquidation, dissolution or winding up) with the Series A Junior Participating Preferred Stock, except dividends paid ratably on the Series A Junior Participating Preferred Stock and all such parity stock on which dividends are payable or in
arrears in proportion to the total amounts to which the holders of all such shares are then entitled; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>redeem or purchase or
otherwise acquire for consideration shares of any stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Junior Participating Preferred Stock, provided that the Corporation may at any time
redeem, purchase or otherwise acquire shares of any such parity stock in exchange for shares of any stock of the Corporation ranking junior (either as to dividends or upon dissolution, liquidation or winding up) to the Series A Junior Participating
Preferred Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>purchase or otherwise acquire for consideration any shares of Series A Junior Participating Preferred Stock,
or any shares of stock ranking on a parity with the Series A Junior Participating Preferred Stock, except in accordance with a purchase offer made in writing or by publication (as determined by the Board of Directors) to all holders of such shares
upon such terms as the Board of Directors, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and classes, shall determine in good faith will result in fair and equitable
treatment among the respective series or classes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>The Corporation shall not permit any subsidiary of the Corporation to
purchase or otherwise acquire for consideration any shares of stock of the Corporation unless the Corporation could, under paragraph (a)&nbsp;of this Section&nbsp;5, purchase or otherwise acquire such shares at such time and in such manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. Reacquired Shares</B>. Any shares of Series A Junior
Participating Preferred Stock purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and canceled promptly after the acquisition thereof. All such shares shall upon their cancellation become authorized but
unissued shares of Preferred Stock and may be reissued as part of a new series of Preferred Stock to be created by resolution or resolutions of the Board of Directors, subject to the conditions and restrictions on issuance set forth herein and in
the Amended and Restated Certificate of Incorporation of the Corporation, as then amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. Liquidation,
Dissolution or Winding Up</B>. Upon any liquidation, dissolution or winding up of the Corporation, no distribution shall be made to the holders of shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up)
to the Series A Junior Participating Preferred Stock unless, prior thereto, the holders of shares of Series A Junior Participating Preferred Stock shall have received the greater of (a) $1,000 per share, plus an amount equal to accrued and unpaid
dividends and distributions thereon, whether or not declared, to the date of such payment and (b)&nbsp;an aggregate amount per share, subject to the provision for adjustment hereinafter set forth, equal to 1,000 times the aggregate amount to be
distributed per share to holders of shares of Common Stock plus an amount equal to any accrued and unpaid dividends on such shares of Series A Junior Participating Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. Consolidation, Merger, etc</B>. In case the Corporation shall enter into any consolidation, merger,
combination or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or securities, cash and/or any other property, then in any such case the shares of Series A Junior Participating Preferred Stock shall
at the same time be similarly exchanged or changed in an amount per share equal to 1,000 times the aggregate amount of stock, securities, cash and/or any other property (payable in kind), as the case may be, into which or for which each share of
Common Stock is changed or exchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9. No Redemption</B>. The shares of Series A Junior Participating
Preferred Stock shall not be redeemable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10. Ranking</B>. The Series A Junior Participating Preferred Stock
shall rank junior to all other series of the Corporation&#146;s Preferred Stock as to the payment of dividends and the distribution of assets, unless the terms of any such series shall provide otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. Amendment</B>. The Amended and Restated Certificate of Incorporation of the Corporation shall not be further
amended in any manner which would materially alter or change the powers, preference or special rights of the Series A Junior Participating Preferred Stock so as to affect them adversely without the affirmative vote of the holders of a majority of
the outstanding shares of Series A Junior Participating Preferred Stock, voting separately as a series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.
Fractional Shares</B>. Series A Junior Participating Preferred Stock may be issued in fractions of a share which shall entitle the holder, in proportion to such holder&#146;s fractional shares, to exercise voting rights, receive dividends,
participate in distributions and to have the benefit of all other rights of holders of Series A Junior Participating Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED FURTHER</B>, that the President, Chief Executive Officer or Chief Financial
Officer and the Secretary of this corporation be, and they hereby are, authorized and directed to prepare and file a Certificate of Designation of Rights, Preferences and Privileges in accordance with the foregoing resolution and the provisions of
Delaware law and to take such actions as they may deem necessary or appropriate to carry out the intent of the foregoing resolution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further declare under penalty of perjury that the matters set forth in the foregoing Certificate of Designation are true and correct of my
own knowledge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executed at Brisbane, California on October&nbsp;10, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Tempest Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Stephen Brady</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen Brady</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d547808dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;10, 2023 </B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CERTAIN DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">APPOINTMENT OF RIGHTS AGENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ISSUANCE OF RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">FORM OF RIGHT CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">COUNTERSIGNATURE AND REGISTRATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">TRANSFER, SPLIT UP, COMBINATION AND EXCHANGE OF RIGHT CERTIFICATES; MUTILATED, DESTROYED, LOST OR STOLEN RIGHT CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EXERCISE OF RIGHTS; PURCHASE PRICE; EXPIRATION DATE OF RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CANCELLATION AND DESTRUCTION OF RIGHT CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AVAILABILITY OF PREFERRED SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PREFERRED SHARES RECORD DATE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ADJUSTMENT OF PURCHASE PRICE, NUMBER OF SHARES OR NUMBER OF RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CERTIFICATE OF ADJUSTED PURCHASE PRICE OR NUMBER OF SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CONSOLIDATION, MERGER OR SALE OR TRANSFER OF ASSETS OR EARNING POWER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">FRACTIONAL RIGHTS AND FRACTIONAL SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">RIGHTS OF ACTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGREEMENT OF RIGHT HOLDERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">RIGHT CERTIFICATE HOLDER NOT DEEMED A STOCKHOLDER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CONCERNING THE RIGHTS AGENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">MERGER OR CONSOLIDATION OR CHANGE OF NAME OF RIGHTS AGENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">DUTIES OF RIGHTS AGENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CHANGE OF RIGHTS AGENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ISSUANCE OF NEW RIGHT CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;23.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">REDEMPTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;24.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EXCHANGE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;25.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">NOTICE OF CERTAIN EVENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;26.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">NOTICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;27.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SUPPLEMENTS AND AMENDMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;28.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DETERMINATION AND ACTIONS BY THE BOARD OF DIRECTORS, ETC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;29.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SUCCESSORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;30.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>BENEFITS OF THIS AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;31.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEVERABILITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;32.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GOVERNING LAW; FORUM SELECTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;33.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COUNTERPARTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;34.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DESCRIPTIVE HEADINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;35.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FORCE MAJEURE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;36.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INTERPRETIVE MATTERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT A - FORM OF CERTIFICATE OF DESIGNATION </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT B - FORM OF RIGHT CERTIFICATE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT C - SUMMARY OF
RIGHTS TO PURCHASE PREFERRED SHARES </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this &#147;<B><I>Agreement</I></B>&#148;) is dated
as of October&nbsp;10, 2023 (the &#147;<B><I>Agreement Date</I></B>&#148;) and is made between <B>T<SMALL>EMPEST</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and
<B>C<SMALL>OMPUTERSHARE</SMALL> T<SMALL>RUST</SMALL> C<SMALL>OMPANY</SMALL>, N.A,</B> as rights agent (&#147;<B><I>Rights Agent</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors of the Company (the &#147;<B><I>Board</I></B>&#148;) has authorized and declared a dividend of one preferred share
purchase right (a &#147;<B><I>Right</I></B>&#148;) for each Common Share (as such term is hereinafter defined) outstanding at the Close of Business (as such term is hereinafter defined) on October&nbsp;23, 2023 (the &#147;<B><I>Record
Date</I></B>&#148;), each Right representing the right to purchase one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share (as such term is hereinafter defined), subject to adjustment upon the terms and subject to the
conditions herein set forth, and has further authorized and directed the issuance of one Right with respect to each Common Share that shall become outstanding between the Record Date and the earliest to occur of the Close of Business on the
Distribution Date, the Redemption Date and the Close of Business on the Final Expiration Date (as such terms are hereinafter defined); <I>provided, however</I>, that Rights may be issued with respect to Common Shares that shall become outstanding
after the Close of Business on the Distribution Date and prior to the earlier of the Redemption Date and the Close of Business on the Final Expiration Date in accordance with the provisions of Section&nbsp;22 hereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, in consideration of the premises and the mutual agreements herein set forth, the parties hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;1.</B><B> </B><B>C<SMALL>ERTAIN</SMALL> D<SMALL>EFINITIONS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the following terms have the meanings indicated: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>Agreement</I></B>&#148; shall have the meaning set forth in the first paragraph hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Agreement Date</I></B>&#148; shall have the meaning set forth in the first paragraph hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Acquiring Person</I></B>&#148; shall mean any Person who or that, together with all Affiliates and Associates of such
Person, without the prior written approval of the Board, shall be the Beneficial Owner of 10% or more of the Common Shares then outstanding; <I>provided, however</I>, the term &#147;Acquiring Person&#148; shall be deemed to exclude: (i)&nbsp;the
Company; (ii)&nbsp;any Subsidiary of the Company; (iii)&nbsp;any employee benefit or compensation plan of the Company or of any Subsidiary of the Company; (iv)&nbsp;any Person holding Common Shares for or pursuant to the terms of any such employee
benefit plan or compensation plan of the Company or any Subsidiary of the Company, but solely to the extent such Common Shares are held for or pursuant to the terms of any such plan; or (v)&nbsp;a Passive Institutional Investor (but only if such
Person remains a &#147;Passive Institutional Investor&#148; in accordance with the definition thereof or divests sufficient Common Shares after ceasing to be a Passive Institutional Investor as contemplated by the definition thereof
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(and following such divestment, such Person shall no longer be a Passive Institutional Investor)). Notwithstanding the foregoing: (A)&nbsp;any Person who or that, together with its Affiliates and
Associates, (x)&nbsp;is, as of the time of the first public announcement of the declaration of the Rights dividend, the Beneficial Owner of 10% (or, in the case of a Person that would otherwise be a Passive Institutional Investor but for such
ownership, 15%) or more of the Common Shares outstanding and (y)&nbsp;continuously maintains its level of Beneficial Ownership at or above 10% (or, in the case of a Person that would otherwise be a Passive Institutional Investor but for such
ownership, 15%) of the Common Shares then outstanding from and after the first public announcement of the declaration of the Rights dividend shall not be deemed to be an &#147;Acquiring Person&#148; until such time after such first public
announcement that any such Person shall become the Beneficial Owner of one or more additional Common Shares (other than by the declaration or payment of any dividend on the Common Shares payable in Common Shares) and shall then beneficially own 10%
(or, in the case of a Person that would otherwise be a Passive Institutional Investor but for such ownership 15%) or more of the Common Shares then outstanding; and (B)&nbsp;no Person shall become an &#147;Acquiring Person&#148; (x) as the result of
an acquisition of Common Shares by the Company that, by reducing the number of shares outstanding, increases the proportionate number of shares beneficially owned by such Person to 10% (15% in the case of a Person who would otherwise be a Passive
Institutional Investor but for such acquisition of Common Shares by the Company) or more of the Common Shares then outstanding (<I>provided, however</I>, that if a Person shall become the Beneficial Owner of 10% (15% in the case of a Person that
would otherwise be a Passive Institutional Investor but for such acquisition) or more of the Common Shares then outstanding by reason of share purchases by the Company and, following written notice from, or public disclosure by, the Company of such
share purchases by the Company, shall become the Beneficial Owner of one or more additional Common Shares (other than by the declaration or payment of any dividend on the Common Shares payable in Common Shares) without the prior written approval of
the Board and shall then be the Beneficial Owner of 10% (15% in the case of a Person that would otherwise be a Passive Institutional Investor but for such ownership) or more of the Common Shares then outstanding, then such Person shall be deemed to
be an &#147;Acquiring Person&#148;) or (y)&nbsp;if the Board determines in good faith that a Person who would otherwise be an &#147;Acquiring Person,&#148; as defined pursuant to the foregoing provisions of this Section&nbsp;1(c), has become such
inadvertently, and such Person does not, with such Person&#146;s Affiliates and Associates, become the Beneficial Owner of one or more additional Common Shares after learning of or having been informed of such Person becoming (save for this clause)
an Acquiring Person, and, only if requested by the Company, such Person divests, as promptly as practicable (as determined in good faith by the Board), following receipt of written notice from the Company of such event, Beneficial Ownership of a
sufficient number of Common Shares so that such Person would no longer be an Acquiring Person, as defined pursuant to the foregoing provisions of this Section&nbsp;1(c), then such Person shall not be deemed to be an &#147;Acquiring Person&#148; for
any purposes of this Agreement; <I>provided, however</I>, that if such Person shall again become the Beneficial Owner of 10% (15% in the case of a Person who would otherwise be a Passive Institutional Investor but for such ownership) or more of the
Common Shares then outstanding, such Person shall be deemed an &#147;Acquiring Person,&#148; subject to the exceptions set forth in this Section&nbsp;1(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#147;<B>Affiliate</B>&#148; and &#147;<B>Associate</B>&#148; shall have the respective meanings ascribed to such terms in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act as in effect on the Agreement Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> A Person shall be deemed the &#147;<B>Beneficial Owner</B>&#148; of, and shall be
deemed to &#147;<B>beneficially own</B>,&#148; and shall be deemed to have &#147;<B>Beneficial Ownership</B>&#148; of, any securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> that such Person, or any of such Person&#146;s Affiliates or Associates, is deemed to beneficially own within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act as in effect on the Agreement Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> that such Person or any of
such Person&#146;s Affiliates or Associates, has or shares (A)&nbsp;the right or the obligation to acquire (whether such right is exercisable, or such obligation is required to be performed, immediately or only after the passage of time or upon the
satisfaction or occurrence of one or more conditions) pursuant to any agreement, arrangement or understanding, whether or not in writing (other than customary agreements with and between underwriters and selling group members with respect to a bona
fide public offering of securities), or upon the exercise of conversion rights, exchange rights, rights (other than the Rights), warrants or options, or otherwise; <I>provided, however</I>, that a Person shall not be deemed the Beneficial Owner of,
to beneficially own, or to have Beneficial Ownership of securities tendered pursuant to a tender or exchange offer made pursuant to, and in accordance with, the applicable rules and regulations promulgated under the Exchange Act by or on behalf of
such Person or any of such Person&#146;s Affiliates or Associates until such tendered securities are accepted for purchase or exchange; or (B)&nbsp;the right or power to vote (directly or indirectly) pursuant to any agreement, arrangement or
understanding, whether or not in writing; <I>provided, however</I>, that a Person shall not be deemed the Beneficial Owner of, to beneficially own, or to have Beneficial Ownership of any security if the agreement, arrangement or understanding to
vote such security (1)&nbsp;arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and regulations promulgated under
the Exchange Act and (2)&nbsp;is not also then reportable on Schedule 13D under the Exchange Act (or any comparable or successor report); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> that are beneficially owned, directly or indirectly, by any other Person (or an Affiliate or Associate thereof) with which such
Person (or any of such Person&#146;s Affiliates or Associates), has (A)&nbsp;any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public
offering of securities), whether or not in writing, for the purpose of acquiring, holding, voting (except to the extent contemplated by the proviso to Section&nbsp;1(e)(ii)(B) hereof) or disposing of any securities of the issuer of such securities
or (B)&nbsp;any agreement, arrangement or understanding, whether or not in writing, to cooperate in obtaining, changing or influencing control of the issuer of such securities; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> which are the subject of, or the reference securities for, or that underlie, any Derivative Position of such Person or any of such
Person&#146;s Affiliates or Associates, with the number of Common Shares deemed beneficially owned in respect of a Derivative Position being the notional or other number of Common Shares in respect of such Derivative Position that is specified in
(A)&nbsp;one or more filings with the Securities and Exchange Commission by such Person or any of such Person&#146;s Affiliates or Associates or (B)&nbsp;the documentation evidencing such Derivative Position as the basis upon which the value or
settlement amount of such Derivative Position, or the opportunity of the holder of such Derivative Position to profit or share in any profit, is to be calculated in whole or in part (whichever of (A)&nbsp;or (B) is greater), or if no such number of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Shares is specified in such filings or documentation (or such documentation is not available to the Board), as determined by the Board in its sole discretion; <I>provided, however</I>,
that the number of securities beneficially owned by each Counterparty (including its Affiliates and Associates) under a Derivatives Contract shall for purposes of this clause (iv)&nbsp;be deemed to include all securities that are beneficially owned,
directly or indirectly, by any other Counterparty (or any of such other Counterparty&#146;s Affiliates or Associates) under any Derivatives Contract to which such first Counterparty (or any of such first Counterparty&#146;s Affiliates or Associates)
is a Receiving Party, with this proviso being applied to successive Counterparties as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing:
(i)&nbsp;the phrase &#147;then outstanding,&#148; when used with reference to a Person&#146;s Beneficial Ownership of securities of the Company, shall mean the number of such securities then issued and outstanding together with the number of such
securities not then actually issued and outstanding that such Person would be deemed to beneficially own hereunder; (ii)&nbsp;nothing contained in this Section&nbsp;1(e) shall cause a Person ordinarily engaged in business as an underwriter of
securities to be deemed the &#147;Beneficial Owner&#148; of, or to &#147;beneficially own&#148;, or to have &#147;Beneficial Ownership&#148; of, any securities acquired or to be acquired in either (A)&nbsp;a bona fide firm underwriting pursuant to
an underwriting agreement entered into by the Company and such Person or (B)&nbsp;a bona fide offering of securities pursuant to Rule 144A under the Securities Act pursuant to a purchase agreement entered into by the Company and such Person; and
(iii)&nbsp;no director or officer of the Company shall be deemed to beneficially own securities beneficially owned by any other director or officer of the Company solely due to their capacities as a director, officer, agent or employee of the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Board</I></B>&#148; shall have the meaning set forth in the Recitals hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Book-Entry</I></B>&#148; shall mean any uncertificated share represented by book-entry. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Business Day</I></B>&#148; shall mean any day other than a Saturday, a Sunday, or a day on which banking institutions in
the State of New York are authorized or obligated by law or executive order to close. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Close of
Business</I></B>&#148; on any given date shall mean 5:00 p.m., New York, New York time, on such date; <I>provided, however</I>, that if such date is not a Business Day it shall mean 5:00 p.m., New York, New York time, on the next succeeding Business
Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Common Shares</I></B>&#148; shall mean the shares of common stock, par value $0.001 per share, of the Company;
<I>provided, however</I>, that, &#147;Common Shares,&#148; when used in this Agreement in connection with a specific reference to any Person other than the Company, shall mean the shares of the class or series of capital stock (or equity interest)
with the greatest voting power of such other Person or, if such other Person is a Subsidiary of another Person, the Person or Persons that ultimately control such first-mentioned Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Company</I></B>&#148; shall have the meaning set forth in the first paragraph hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>current per share market price</I></B>&#148; shall have the meaning set forth in Section&nbsp;11(d) hereof, except as
otherwise set forth in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Current Value</I></B>&#148; shall have the meaning set forth in
Section&nbsp;11(a)(iii) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Derivatives Contract</I></B>&#148; shall mean a contract between two
parties (the &#147;<B><I>Receiving Party</I></B>&#148; and the &#147;<B><I>Counterparty</I></B>&#148;) that is designed to produce economic benefits and risks to the Receiving Party that correspond substantially to the ownership by the Receiving
Party of a number of Common Shares specified or referenced in such contract, regardless of whether obligations under such contract are required or permitted to be settled through the delivery of cash, Common Shares or other property, without regard
to any short or other position that hedges the economic effect of such Derivatives Contract under the same or any other Derivatives Contract. For the avoidance of doubt, interests in broad-based index options, broad-based index futures and
broad-based publicly traded market baskets of stocks approved for trading by the appropriate federal governmental authority shall not be deemed to be Derivatives Contracts.<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B>&#147;<B><I>Derivative Position</I></B>&#148; shall mean any Derivatives Contract or any other option, warrant, convertible
security, stock appreciation right, or other security, contract right or derivative position or similar right (other than, for the avoidance of doubt, the Rights, but including any &#147;swap&#148; transaction with respect to any security, other
than a broad based market basket or index), whether or not presently exercisable, that has an exercise price or conversion privilege or a settlement payment or mechanism at a price related to the value of the Common Shares or a value determined in
whole or in part with reference to, or derived in whole or in part from, the value of the Common Shares and that increases in value as the market price or value of the Common Shares increases or that provides an opportunity, directly or indirectly,
to profit or share in any profit derived from any increase in the value of the Common Shares, in each case regardless of whether (i)&nbsp;it conveys any voting rights in such Common Shares to any Person, (ii)&nbsp;it is required to be, or capable of
being, settled through delivery of Common Shares or (iii)&nbsp;any Person (including the holder of such Derivative Position) may have entered into other transactions that hedge its economic effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>Distribution Date</I></B>&#148; shall have the meaning set forth in Section&nbsp;3(a) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>earning power</I></B>&#148; shall have the meaning set forth in Section&nbsp;13(a) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Equivalent Preferred Shares</I></B>&#148; shall have the meaning set forth in Section&nbsp;11(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>Exchange Act</I></B>&#148; shall mean the Securities Exchange Act of 1934, as amended and as in effect on the date in
question, unless otherwise specifically provided. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>Exchange Property</I></B>&#148;<B> </B>shall have the meaning set
forth in Section&nbsp;24(e) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Exchange Ratio</I></B>&#148; shall have the meaning set forth in
Section&nbsp;24(a) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>Exchange Recipient</I></B>&#148; shall have the meaning set forth in Section&nbsp;24(e)
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#147;<B><I>Final Expiration Date</I></B>&#148; shall mean one year unless Stockholder Approval has been obtained prior
to such date, in which case &#147;Final Expiration Date&#148; shall mean three years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I>Ownership
Statement</I></B>&#148; shall mean, with respect to any Book-Entry Common Share, the current ownership statement issued to the record holder thereof in lieu of a certificate representing such Common Share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>Passive Institutional Investor</I></B>&#148; shall mean any Person
who or that, together with all Affiliates and Associates of such Person, is the Beneficial Owner of less than 15% of the Common Shares then outstanding and who or that is entitled to file and files or has filed, a statement on Schedule 13G under the
Exchange Act (or any comparable or successor report) pursuant to Rule <FONT STYLE="white-space:nowrap">13d-1(b)(1)</FONT> or <FONT STYLE="white-space:nowrap">13d-1(c)(1)</FONT> under the Exchange Act, as in effect on the Record Date, with respect to
the Common Shares that are beneficially owned by such Person, but only so long as (x)&nbsp;such Person is eligible to report such ownership on Schedule 13G under the Exchange Act (or any comparable or successor report), and (y)&nbsp;such Person has
not reported and is not required to report such ownership on Schedule 13D under the Exchange Act (or any comparable or successor report). Notwithstanding anything to the contrary in this Agreement, a former Passive Institutional Investor that should
report (or reports) or becomes required to report Beneficial Ownership of Common Shares on Schedule 13D will not be deemed to be an Acquiring Person by reason of ceasing to be a Passive Institutional Investor if (but only if): (i) at the time it
should report (or reports) or becomes required to report Beneficial Ownership of Common Shares on Schedule 13D, that formerly Passive Institutional Investor has Beneficial Ownership of less than 15% of the Common Shares then outstanding; or
(ii)&nbsp;(A) it divests as promptly as practicable (but in any event not later than 15 Business Days after reporting or becoming required to report on Schedule 13D) Beneficial Ownership of a sufficient number of Common Shares so that it would no
longer be an Acquiring Person, and (B)&nbsp;prior to reducing its Beneficial Ownership to below 15%, it does not increase its Beneficial Ownership of the Common Shares then outstanding (other than by reason of share purchases by the Company) above
the lowest Beneficial Ownership of such Person at any time during the <FONT STYLE="white-space:nowrap">15-Business</FONT> Day period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I>Person</I></B>&#148; shall mean any individual, firm, corporation, limited liability company, partnership, joint
venture, association, trust, syndicate, unincorporated organization or other entity, and shall include any successor (by merger or otherwise) of such entity, as well as any group under Rule <FONT STYLE="white-space:nowrap">13d-5(b)(1)</FONT> of the
Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Preferred Shares</I></B>&#148; shall mean shares of Series A Junior Participating Preferred Stock,
par value $0.001 per share, of the Company, having the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions set forth as <U>Exhibit A</U> hereto, as the same may be amended from time to time and,
to the extent that there are not a sufficient number of shares of Series A Junior Participating Preferred Stock authorized to permit the full exercise of the Rights, any other series of preferred stock of the Company designated for such purpose
containing terms substantially similar to the terms of the Series A Junior Participating Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B>
&#147;<B><I>Principal Party</I></B>&#148; means (i)&nbsp;in the case of any transaction described in clause (i)&nbsp;or (ii) of&nbsp;Section 13(a), (A) the Person that is the issuer of the securities into which the Common Shares are converted in the
consolidation or merger, or, if there is more than one such issuer, the issuer whose Common Shares have the greatest aggregate market value of shares outstanding; or (B)&nbsp;if no securities are so issued, (1)&nbsp;the Person that is the other
party to the consolidation or merger, if such Person survives the consolidation or merger, or, if there is more than one such Person, the Person whose Common Shares has the greatest aggregate market value of shares outstanding; (2)&nbsp;if the
Person that is the other party to the merger does not survive such consolidation or merger, the Person that does survive such consolidation or merger (including the Company if it survives); or (3)&nbsp;the Person resulting from the consolidation or
merger; and (ii)&nbsp;in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the case of any transaction described in clause (iii)&nbsp;of&nbsp;Section 13(a), the Person that is the party receiving the greatest portion of the assets, cash flow or earning power transferred
pursuant to such transaction or transactions, or, if more than one Person that is a party to such transaction or transactions receives the same portion of the assets or earning power so transferred and each such portion would, were it not for the
other equal portions, constitute the greatest portion of the assets or earning power so transferred, or if the Person receiving the greatest portion of the assets or earning power cannot be determined, whichever of such Persons is the issuer of
Common Shares having the greatest aggregate market value of shares outstanding. For purposes of this definition, if the shares of Common Shares of such Person are not at such time, or have not been continuously over the preceding <FONT
STYLE="white-space:nowrap">12-month</FONT> period, registered pursuant to Section&nbsp;12 of the Exchange Act, then if such Person is (x)&nbsp;a direct or indirect Subsidiary of another Person whose Common Shares is and has been so registered, the
term &#147;Principal Party&#148; will refer to such other Person, (y)&nbsp;a direct or indirect Subsidiary of more than one Person whose shares of Common Shares is and has been so registered, the term &#147;Principal Party&#148; will refer to
whichever of such Persons is the issuer of Common Shares having the greatest aggregate market value of shares outstanding, or (z)&nbsp;owned, directly or indirectly, by a joint venture formed by two or more Persons that are not owned, directly or
indirectly, by the same Person, the rules set forth in clauses (x)&nbsp;and (y) above will apply to each of the owners having an interest in the venture as if the Person owned by the joint venture was a Subsidiary of both or all of such joint
venturers, and the Principal Party in each such case must bear the obligations set forth in Section&nbsp;13 in the same ratio as its interest in such Person bears to the total of such interests. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#147;<B><I>Purchase Price</I></B>&#148; shall have the meaning set forth in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><I>Record Date</I></B>&#148; shall have the meaning set forth in the Recitals hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><I>Redemption Date</I></B>&#148; shall have the meaning set forth in Section&nbsp;23(c) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><I>Redemption Price</I></B>&#148; shall have the meaning set forth in the Section&nbsp;23(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#147;<B><I>Right</I></B>&#148; shall have the meaning set forth in the Recitals hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><I>Right Certificate</I></B>&#148; shall have the meaning set forth in Section&nbsp;3(a) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Rights Agent</I></B>&#148; shall have the meaning set forth in the first paragraph hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;11(a)(ii) Trigger Date</I></B>&#148; shall have the meaning set forth in
Section&nbsp;11(a)(iii). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#147;<B><I>Securities Act</I></B>&#148; shall mean the Securities Act of 1933, as amended and as in
effect on the date in question, unless otherwise specifically provided. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#147;<B><I>Security</I></B>&#148; shall have the
meaning set forth in Section&nbsp;11(d)(i) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#147;<B><I>Shares Acquisition Date</I></B>&#148; shall mean the earlier of
the date of (i)&nbsp;public announcement by the Company or an Acquiring Person that an Acquiring Person has become such and (ii)&nbsp;public disclosure of facts by the Company or an Acquiring Person indicating that an Acquiring Person has become
such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#147;<B><I>Signature Guarantee</I></B>&#148; shall mean any guaranty of
signature by an &#147;eligible guarantor institution&#148; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#147;signature guarantee program&#148; or insurance program in addition to, or in
substitution for, the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> &#147;<B><I>Stockholder Approval</I></B>&#148; shall mean the approval or ratification by the
stockholders of the Company of this Agreement (as amended from time to time or as contemplated to be in effect following such Stockholder Approval) as demonstrated by the votes cast in favor of any such approval or ratification proposal exceeding
the votes cast against such proposal at a duly held meeting of stockholders of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B>
&#147;<B><I>Subsidiary</I></B>&#148; of any Person shall mean any corporation or other entity of which a (i)&nbsp;a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by such Person or
(ii)&nbsp;an amount of securities or other ownership interests having ordinary voting power sufficient to elect at least a majority of the directors or other Persons having similar functions of such corporation or other entity are at the time,
directly or indirectly, beneficially owned, or otherwise controlled by such Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#147;<B><I>Substitution
Period</I></B>&#148; shall have the meaning set forth in Section&nbsp;11(a)(iii). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> &#147;<B><I>Summary of Rights</I></B>&#148;
shall have the meaning set forth in Section&nbsp;3(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> &#147;<B><I>Trading Day</I></B>&#148; shall have the meaning set
forth in Section&nbsp;11(d)(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> &#147;<B><I>Trust Agreement</I></B>&#148; shall have the meaning set forth in
Section&nbsp;24(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;2.</B><B> </B><B>A<SMALL>PPOINTMENT</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL>
A<SMALL>GENT</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company hereby appoints the Rights Agent to act as agent for the Company in accordance with the express
terms and conditions hereof (and no implied terms or conditions), and the Rights Agent hereby accepts such appointment. The Company may from time to time appoint such <FONT STYLE="white-space:nowrap">co-Rights</FONT> Agents as it may deem necessary
or desirable (the term &#147;Rights Agent&#148; being used herein to refer, collectively, to the Rights Agent together with any such <FONT STYLE="white-space:nowrap">co-Rights</FONT> Agents), upon ten (10)&nbsp;calendar days&#146; prior written
notice to the Rights Agent. In the event the Company appoints one or more <FONT STYLE="white-space:nowrap">co-Rights</FONT> Agents, the respective duties of the Rights Agent and any <FONT STYLE="white-space:nowrap">co-Rights</FONT> Agents shall be
as the Company reasonably determines, provided that such duties are consistent with the terms and conditions of this Agreement and that contemporaneously with such appointment the Company shall notify, in writing, the Rights Agent and any <FONT
STYLE="white-space:nowrap">co-Rights</FONT> Agents of any such duties. The Rights Agent shall have no duty to supervise, and shall in no event be liable for, the acts or omissions of any such <FONT STYLE="white-space:nowrap">co-Rights</FONT> Agent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;3.</B> <B>I<SMALL>SSUANCE</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Until the earlier of the Close of Business on the (i)&nbsp;tenth calendar day after the Shares Acquisition Date (including any such
date that is after the Agreement Date and prior to the issuance of the Rights) or, in the event that the Board determines on or before such tenth calendar day to effect an exchange in accordance with Section&nbsp;24 and determines in accordance with
Section&nbsp;24(e) that a later date is advisable, such later date that is not more than twenty (20)&nbsp;calendar days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
after the Shares Acquisition Date and (ii)&nbsp;the tenth Business Day (or such later date as may be determined by action of the Board prior to such time as any Person becomes an Acquiring
Person) after the date of the commencement by any Person (other than the Company, any Subsidiary of the Company, any employee benefit or compensation plan of the Company or of any Subsidiary of the Company or any Person holding Common Shares for or
pursuant to the terms of any such plan) of, or of the first public announcement of the intention of any Person (other than any of the Persons referred to in the preceding parenthetical) to commence, a tender or exchange offer the consummation of
which would result in any Person becoming an Acquiring Person (the Close of Business on the earlier of such dates being herein referred to as the &#147;<B><I>Distribution Date</I></B>&#148;); <I>provided, however</I>, that, if such earlier date is
prior to the Record Date, the Distribution Date shall be the Close of Business on the Record Date): (A) the Rights will be evidenced by the certificates for Common Shares (which certificates shall also be deemed to be Right Certificates) or, in the
case of uncertificated shares, by the balances indicated in the book-entry account system of the transfer agent for the Book-Entry Common Shares (together with a transaction advise with respect to such shares), registered in the names of the holders
thereof and not by separate Right Certificates; (B)&nbsp;the registered holders of Common Shares shall also be the registered holders of the Rights issued with respect thereto; and (C)&nbsp;the Rights (and the right to receive Right Certificates
therefor) will be transferable only in connection with the transfer of Common Shares. As soon as practicable after the Distribution Date, the Company will prepare and execute, the Rights Agent will countersign, and the Company will send or cause to
be sent (and the Rights Agent will, if requested and provided with all necessary information and documents at the expense of the Company, send by such means as the Company may select), to each record holder of Common Shares (other than any Acquiring
Person or any Associate or Affiliate of an Acquiring Person) as of the Close of Business on the Distribution Date, at the address of such holder shown on the records of the Company or transfer agent or registrar for the Common Shares (and if the
Rights Agent is not the transfer agent or registrar for the Common Shares, the Company shall, as promptly as practicable, provide such information to the Rights Agent in a form reasonably satisfactory to the Rights Agent), a Right Certificate, in
substantially the form of <U>Exhibit</U><U></U><U>&nbsp;B</U> hereto (a &#147;<B><I>Right Certificate</I></B>&#148;), evidencing one Right for each Common Share so held, subject to the adjustment provisions of Section&nbsp;11; <I>provided</I>,
<I>however</I>, that the Company may implement such procedures as it deems appropriate in its sole discretion, to minimize the possibility that Rights are sent to Persons for whom the Rights would be null and void under Section&nbsp;11(a)(ii)
hereof. Despite the foregoing, the Company may elect to use book entry positions in lieu of physical certificates, in which case, the &#147;Right Certificates&#148; shall be deemed to mean the book entry position representing the related Rights. As
of and after the Distribution Date, the Rights will be evidenced solely by such Right Certificates. The Company shall as promptly as practicable notify the Rights Agent in writing upon the occurrence of the Distribution Date, the Redemption Date or
the Final Expiration Date and, if such notification is given orally, the Company shall confirm the same in writing on or prior to the Business Day next following. Until such written notice is received by the Rights Agent, the Rights Agent may
presume conclusively for all purposes that the Distribution Date, Redemption Date or the Final Expiration Date, as applicable, has not occurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> On the Record Date, or as soon as practicable thereafter, the Company will send (directly or through the Rights Agent or its
transfer agent, at the expense of the Company and if the Rights agent or transfer agent is directed by the Company and provided with all necessary information and documents) a copy of a Summary of Rights to Purchase Preferred Shares, in
substantially the form of <U>Exhibit</U><U></U><U>&nbsp;C</U> hereto (the &#147;<B><I>Summary of Rights</I></B>&#148;), by first-class, postage-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prepaid mail, to each record holder of Common Shares as of the Close of Business on the Record Date (other than any Acquiring Person or any Associate or Affiliate of an Acquiring Person), at the
address of such holder shown on the records of the Company or transfer agent or registrar for Common Shares (and if the Rights Agent is not the transfer agent or registrar for the Common Shares, the Company shall, as promptly as practicable, provide
such information to the Rights Agent in a form reasonably satisfactory to the Rights Agent). With respect to certificates for Common Shares or Book-Entry Common Shares outstanding as of the Record Date, until the Close of Business on the
Distribution Date, the Rights will be evidenced by such certificates registered in the names of the holders thereof (or, for shares participating in the direct registration system, by notations in the respective book entry accounts for the Common
Shares). Until the Close of Business on the Distribution Date (or the earlier of the Redemption Date and the Close of Business on the Final Expiration Date), the surrender for transfer of any certificate for Common Shares or the transfer of any
Book-Entry Common Shares outstanding on the Record Date shall also constitute the transfer of the Rights associated with the Common Shares represented thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Certificates for Common Shares that become outstanding (including reacquired Common Shares referred to in the penultimate sentence
of this Section&nbsp;3(c)) after the Record Date but prior to the earliest of the Close of Business on the Distribution Date, the Redemption Date or the Close of Business on the Final Expiration Date shall have impressed on, printed on, written on
or otherwise affixed to them a legend in substantially the following form: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THIS CERTIFICATE ALSO EVIDENCES AND ENTITLES THE HOLDER HEREOF
TO CERTAIN RIGHTS AS SET FORTH IN A RIGHTS AGREEMENT BETWEEN TEMPEST THERAPEUTICS, INC. (THE &#147;COMPANY&#148;) AND COMPUTERSHARE TRUST COMPANY, N.A., AS RIGHTS AGENT (THE &#147;RIGHTS AGENT&#148;), DATED AS OF OCTOBER&nbsp;10, 2023, AS AMENDED
FROM TIME TO TIME (THE &#147;RIGHTS AGREEMENT&#148;), THE TERMS OF WHICH ARE HEREBY INCORPORATED HEREIN BY REFERENCE AND A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE COMPANY. UNDER CERTAIN CIRCUMSTANCES, AS SET FORTH IN THE
RIGHTS AGREEMENT, SUCH RIGHTS WILL BE EVIDENCED BY SEPARATE CERTIFICATES AND WILL NO LONGER BE EVIDENCED BY THIS CERTIFICATE. THE COMPANY WILL DELIVER TO THE HOLDER OF THIS CERTIFICATE A COPY OF THE RIGHTS AGREEMENT WITHOUT CHARGE AFTER RECEIPT OF A
WRITTEN REQUEST THEREFOR ADDRESSED TO THE SECRETARY OF THE COMPANY. AS DESCRIBED IN THE RIGHTS AGREEMENT, RIGHTS HELD BY OR ISSUED TO ANY PERSON WHO IS OR BECOMES AN ACQUIRING PERSON OR AN AFFILIATE OR ASSOCIATE THEREOF, (AS DEFINED IN THE RIGHTS
AGREEMENT), WHETHER CURRENTLY HELD BY OR ON BEHALF OF SUCH PERSON OR BY ANY SUBSEQUENT HOLDER, SHALL BECOME NULL AND VOID. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any Book-Entry Common Shares, a legend substantially similar to such legend
shall be included in the Ownership Statement in respect of such Common Share or in a notice to such record holder of such Common Share in accordance with applicable law. With respect to the Common Shares, until the earliest of the Close of Business
on the Distribution Date, the Redemption Date or the Close of Business on the Final Expiration Date, the Rights associated with the Common Shares represented by such certificates or Book-Entry Shares shall be evidenced by such certificates or
book-entry notation (including any Ownership Statement) alone, and the transfer of any Common Shares, whether by transfer of such certificate or in book-entry, shall also constitute the transfer of the Rights associated with the Common Shares
represented thereby. In the event that the Company purchases or acquires any Common Shares after the Record Date but prior to Close of Business on the Distribution Date, any Rights associated with such Common Shares shall be deemed canceled and
retired so that the Company shall not be entitled to exercise any Rights associated with the Common Shares that are no longer outstanding. Notwithstanding this Section&nbsp;3(c), the omission of a legend shall not affect the enforceability of any
part of this Agreement or the rights of any holder of the Rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Notwithstanding anything to the contrary contained herein,
Common Shares and Rights (and any securities issuable on their exercise) may be issued and transferred by book-entry and not represented by physical certificates. Where Common Shares and Rights (and any securities issuable on their exercise) are
held in uncertificated form, references in this Agreement to Right Certificates shall be deemed to refer to the notations in the book entry accounts reflecting ownership of such shares and, the Company and Rights Agent shall cooperate in all
reasonable respects to give effect to the intent of the provisions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;4.</B> <B>F<SMALL>ORM</SMALL>
<SMALL>OF</SMALL> R<SMALL>IGHT</SMALL> C<SMALL>ERTIFICATES</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Right Certificates (and the form of
election to purchase Preferred Shares, the form of assignment and the form of certification to be printed on the reverse thereof) shall be substantially the same as <I>Exhibit</I><I></I><I>&nbsp;B</I> hereto and may have such marks of identification
or designation and such legends, summaries or endorsements printed thereon as the Company may deem appropriate (but which do not affect the rights, duties, liabilities or responsibilities of the Rights Agent) and as are not inconsistent with the
provisions of this Agreement, or as may be required to comply with any applicable law or with any rule or regulation made pursuant thereto or with any rule or regulation of the Financial Industry Regulatory Authority or any stock exchange quotation
system on which the Rights may from time to time be listed, or to conform to usage. Subject to the other provisions of this Agreement, the Right Certificates shall entitle the holders thereof to purchase such number of one <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share as shall be set forth therein at the Purchase Price, but the number of such one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share and the Purchase Price
shall be subject to adjustment as provided herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Any Right Certificate issued pursuant to Section&nbsp;3(a) or
Section&nbsp;22 hereof that represents Rights that are null and void pursuant to the second paragraph of Section&nbsp;11(a)(ii) hereof and any Right Certificate issued pursuant to Section&nbsp;6 or Section&nbsp;11 hereof upon transfer, exchange,
replacement or adjustment of any other Right Certificate referred to in this sentence shall contain (to the extent feasible) substantially the following legend: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE RIGHTS REPRESENTED BY THIS RIGHT CERTIFICATE ARE OR WERE BENEFICIALLY OWNED BY A PERSON WHO WAS OR BECAME AN ACQUIRING PERSON OR AN
AFFILIATE OR ASSOCIATE OF AN ACQUIRING PERSON (AS SUCH TERMS ARE DEFINED IN THE RIGHTS AGREEMENT). ACCORDINGLY, THIS RIGHT CERTIFICATE AND THE RIGHTS REPRESENTED HEREBY ARE NULL AND VOID. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Section&nbsp;11(a)(ii) hereof shall be operative whether or not the
foregoing legend is contained on any such Right Certificate. The Company shall instruct the Rights Agent in writing of the Right that should be so legended. The Company shall give written notice to the Rights Agent as soon as practicable after it
becomes aware of the existence and identity of any Acquiring Person or any Associate or Affiliate of an Acquiring Person thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;5.</B><B> </B><B>C<SMALL>OUNTERSIGNATURE</SMALL> <SMALL>AND</SMALL> R<SMALL>EGISTRATION</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Right Certificates shall be executed on behalf of the Company by its Chairman of the Board, its Chief Executive Officer, its President, its Chief
Financial Officer, or any of its Vice Presidents, either manually or by electronic signature, and shall be attested by the Secretary of the Company, either manually or by electronic signature. The Right Certificates shall be countersigned by the
Rights Agent either manually or by electronic signature and shall not be valid for any purpose unless so countersigned. In case any officer of the Company who shall have signed any of the Right Certificates shall cease to be such an officer before
countersignature by the Rights Agent and issuance and delivery by the Company, such Right Certificates, nevertheless, may be countersigned by the Rights Agent and issued and delivered by the Company with the same force and effect as though the
person who signed such Right Certificates had not ceased to be such an officer; and any Right Certificate may be signed on behalf of the Company by any person who, at the actual date of the execution of such Right Certificate, shall be a proper
officer of the Company to sign such Right Certificate, although at the date of the execution of this Agreement any such person was not such an officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Distribution Date and receipt by the Rights Agent of notice to that effect, the Rights Agent will keep or cause to be kept, at
its office designated for such purpose, books for registration and transfer of the Right Certificates issued hereunder. Such books shall show the names and addresses of the respective holders of the Right Certificates, the number of Rights evidenced
on its face by each of the Right Certificates, the certificate number of each Right Certificate and the date of each of the Right Certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;6.</B><B> </B><B>T<SMALL>RANSFER</SMALL>, S<SMALL>PLIT</SMALL> U<SMALL>P</SMALL>, C<SMALL>OMBINATION</SMALL> <SMALL>AND</SMALL>
E<SMALL>XCHANGE</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHT</SMALL> C<SMALL>ERTIFICATES</SMALL>; M<SMALL>UTILATED</SMALL>, D<SMALL>ESTROYED</SMALL>, L<SMALL>OST</SMALL> <SMALL>OR</SMALL> S<SMALL>TOLEN</SMALL> R<SMALL>IGHT</SMALL>
C<SMALL>ERTIFICATES</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Section&nbsp;11(a)(ii), Section&nbsp;14 and Section&nbsp;24 hereof, at any
time after the Close of Business on the Distribution Date, and at or prior to the earlier of the Redemption Date and the Close of Business on the Final Expiration Date, any Right Certificate or Right Certificates (other than Right Certificates
representing Rights that have become null and void pursuant to Section&nbsp;11(a)(ii) hereof or that have been exchanged pursuant to Section&nbsp;24 hereof) may be transferred, split up, combined or exchanged for another Right Certificate or Right
Certificates, entitling the registered holder to purchase a like number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share (or such other security as contemplated herein) as the Right Certificate or Right Certificates
surrendered then entitled such holder to purchase. Any registered holder desiring to transfer, split up, combine or exchange any Right Certificate or Right Certificates shall make such request in writing delivered to the Rights Agent, and shall
surrender the Right Certificate or Right </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Certificates to be transferred, split up, combined or exchanged at the office of the Rights Agent designated for such purpose. The Right Certificates are transferable only on the registry books
of the Rights Agent. Neither the Rights Agent nor the Company shall be obligated to take any action whatsoever with respect to the transfer, split up, combination or exchange of any such surrendered Right Certificate or Right Certificates until the
registered holder shall have (i)&nbsp;properly completed and duly executed the certificate contained in the form of assignment set forth on the reverse side of each such Right Certificate accompanied by a Signature Guarantee, (ii)&nbsp;provided such
additional evidence of the identity of the Beneficial Owner (or former Beneficial Owner) or Affiliates or Associates thereof and other documentation as the Company or the Rights Agent shall reasonably request and (iii)&nbsp;paid a sum sufficient to
cover any tax or charge that may be imposed in connection with any such transfer in accordance with Section&nbsp;9 and to the Company in the manner required by this Agreement. Thereupon the Rights Agent shall, subject to the terms of this Agreement,
countersign and deliver to the Person entitled thereto a Right Certificate or Right Certificates, as the case may be, as so requested, registered in such name or names as may be designated by the surrendering registered holder. The Company may
require payment of a sum sufficient to cover any tax or charge that may be imposed in connection with any transfer, split up, combination or exchange of Right Certificates. The Rights Agent shall promptly forward any such sum collected by it to the
Company or to such Person or Persons as the Company shall specify by written notice. The Rights Agent shall have no duty to deliver any Rights Certificate unless and until it is satisfied that all such payments have been made and shall have no duty
or obligation to take any action with respect to a Right holder under this Agreement that requires the payment by such Rights holder of applicable taxes and/or charges unless and until the Rights Agent is satisfied that all such taxes and/or charges
have been paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt by the Company and the Rights Agent of evidence reasonably satisfactory to them of the loss, theft,
destruction or mutilation of a Right Certificate, and, in case of loss, theft or destruction, of indemnity, including an open penalty surety bond, or security reasonably satisfactory to them, and, at the Company&#146;s request, reimbursement to the
Company and the Rights Agent of all reasonable expenses incidental thereto, and upon surrender to the Rights Agent and cancellation of the Right Certificate if mutilated, the Company will issue, execute and deliver a new Right Certificate of like
tenor to the Rights Agent for countersignature and delivery to the registered holder in lieu of the Right Certificate so lost, stolen, destroyed or mutilated. Notwithstanding any other provision hereof, the Company and the Rights Agent may amend
this Agreement to provide for uncertificated Rights in addition to or in place of Rights evidenced by Right Certificates, to the extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;7. E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>; E<SMALL>XPIRATION</SMALL>
D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The registered holder of any Right Certificate may exercise the
Rights evidenced thereby (except as otherwise provided herein) in whole or in part at any time after the Distribution Date upon surrender of the Right Certificate, with the form of election to purchase on the reverse side thereof properly completed
and duly executed, to the Rights Agent at the office of the Rights Agent designated for such purpose, accompanied by a Signature Guarantee and such other documentation as the Rights Agent may reasonably request, together with payment of the Purchase
Price in cash, or by certified check, cashier&#146;s check, bank draft or money order payable to the order of the Company for each one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share (or such other number of shares or
other securities) as to which the Rights are exercised, prior to the earliest of (i)&nbsp;the Close of Business on the Final Expiration Date, (ii)&nbsp;the Redemption Date, and (iii)&nbsp;the time at which the right to exercise such Rights is
terminated as provided in Section&nbsp;24 hereof. Except for those provisions herein which expressly survive the termination of this Agreement, this Agreement shall terminate at such time as the Rights are no longer exercisable hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The purchase price for each one
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share pursuant to the exercise of a Right shall initially be $25.00 (the &#147;<B><I>Purchase Price</I></B>&#148;), shall be subject to adjustment from time to time as provided in
Section&nbsp;11 and Section&nbsp;13 hereof and shall be payable in lawful money of the United States of America in accordance with Section&nbsp;7(c) below. In no event shall the Purchase Price to be paid upon the exercise of one Right be less than
the aggregate par value of the shares of capital stock of the Company issuable upon the exercise of such Right. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Except as
otherwise provided herein, upon receipt of a Right Certificate representing exercisable Rights, with the form of election to purchase properly completed and duly executed, accompanied by payment of the Purchase Price for the shares to be purchased
and an amount equal to any applicable tax or charge required to be paid by the holder of such Right Certificate in accordance with Section&nbsp;9 hereof by cash, certified check, cashier&#146;s check, bank draft or money order payable to the order
of the Company, the Rights Agent shall thereupon promptly (i)&nbsp;(A) requisition from any transfer agent for the Preferred Shares certificates for the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Shares to be
purchased and the Company hereby irrevocably authorizes its transfer agent to comply with all such requests, or (B)&nbsp;if the Company, in its sole discretion, shall have elected to deposit the Preferred Shares issuable upon exercise of the Rights
hereunder into a depository, and provides written notice of such election to the Rights Agent, requisition from the depositary agent depositary receipts representing such number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a
Preferred Share as are to be purchased (in which case certificates for the Preferred Shares represented by such receipts shall be deposited by the transfer agent with the depositary agent) and the Company hereby directs the depositary agent to
comply with such request, (ii)&nbsp;when necessary to comply with this Agreement, requisition from the Company the amount of cash to be paid in lieu of issuance of fractional shares in accordance with Section&nbsp;14 hereof, (iii)&nbsp;after receipt
of such certificates or depositary receipts, cause the same to be delivered to or upon the order of the registered holder of such Right Certificate, registered in such name or names as may be designated by such holder and (iv)&nbsp;when necessary to
comply with this Agreement, after receipt, deliver such cash to or upon the order of the registered holder of such Right Certificate. In the event that the Company is obligated to issue securities of the Company other than Preferred Shares
(including Common Shares) pursuant to Section&nbsp;11(a) hereof, the Company will make all arrangements necessary so that such other securities are available for distribution by the Rights Agent, if and when necessary to comply with this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the case of an exercise of the Rights by a holder pursuant to Section&nbsp;11(a)(ii) hereof, the Rights Agent, if
requested and provided with all necessary information and documents, shall return such Right Certificate to the registered holder thereof after imprinting, stamping or otherwise indicating thereon that the rights represented by such Right
Certificate no longer include the rights provided by Section&nbsp;11(a)(ii) hereof, and, if fewer than all the Rights represented by such Right Certificate were so exercised, the Rights Agent shall indicate on the Right Certificate the number of
Rights represented thereby that continue to include the rights provided by Section&nbsp;11(a)(ii) hereof. Until so received, the Rights Agent shall have no duties or obligations with respect to such securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> In case the registered holder of any Right Certificate shall exercise fewer than
all the Rights evidenced thereby (other than a partial exercise of rights pursuant to Section&nbsp;11(a)(ii) as described in Section&nbsp;7(c) hereof), a new Right Certificate evidencing Rights equivalent to the Rights remaining unexercised shall be
issued by the Rights Agent to the registered holder of such Right Certificate or to the duly authorized assigns of such holder, subject to the provisions of Section&nbsp;14 hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Notwithstanding anything in this Agreement to the contrary, neither the Rights Agent nor the Company shall be obligated to undertake
any action with respect to a registered holder of Rights upon the occurrence of any purported exercise as set forth in this Section&nbsp;7 unless such registered holder shall have (i)&nbsp;properly completed and duly executed the certification
following the form of election to purchase set forth on the reverse side of the Right Certificate surrendered for such exercise, (ii)&nbsp;tendered the Purchase Price (and an amount equal to any applicable tax or charge required to be paid by the
holder of such Right Certificate in accordance with Section&nbsp;9) to the Company in the manner set forth in Section&nbsp;7(c), and (iii)&nbsp;provided such additional evidence of the identity of the Beneficial Owner (or former Beneficial Owner) or
Affiliates or Associates thereof as the Company or the Rights Agent shall reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;8.</B><B>
</B><B>C<SMALL>ANCELLATION</SMALL> <SMALL>AND</SMALL> D<SMALL>ESTRUCTION</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHT</SMALL> C<SMALL>ERTIFICATES</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Right Certificates surrendered for the purpose of exercise, transfer, split up, combination or exchange shall, if surrendered to the Company or to any of
its agents, be delivered to the Rights Agent for cancellation or in canceled form, or, if delivered or surrendered to the Rights Agent, shall be canceled by it, and no Right Certificates shall be issued in lieu thereof except as expressly permitted
by any of the provisions of this Agreement. The Company shall deliver to the Rights Agent for cancellation and retirement, and the Rights Agent shall so cancel and retire, any other Right Certificate purchased or acquired by the Company otherwise
than upon the exercise thereof. At the Company&#146;s expense, the Rights Agent shall deliver all canceled Right Certificates to the Company, or shall, at the written request of the Company, destroy such canceled Right Certificates, and in such case
shall deliver a certificate of destruction thereof to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;9.</B><B> </B><B>A<SMALL>VAILABILITY</SMALL>
<SMALL>OF</SMALL> P<SMALL>REFERRED</SMALL> S<SMALL>HARES</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees that it will cause to be reserved
and kept available out of its authorized and unissued Preferred Shares or any Preferred Shares held in its treasury the number of Preferred Shares that will be sufficient to permit the exercise in full of all outstanding Rights in accordance with
Section&nbsp;7 hereof. The Company covenants and agrees that it will take all such action as may be necessary to ensure that all Preferred Shares (or Common Shares and other securities, as the case may be) delivered upon exercise of Rights shall, at
the time of delivery of the certificates for such Preferred Shares (or Common Shares and other securities, as the case may be) (subject to payment of the Purchase Price), be duly and validly authorized and issued and fully paid and nonassessable
shares or other securities. So long as the shares of Preferred Stock issuable upon the exercise of Rights may be listed or admitted to trading on any national securities exchange, the Company shall use its best efforts to cause, from and after such
time as the Rights become exercisable, all shares reserved for such issuance to be listed or admitted to trading on such exchange upon official notice of issuance upon such exercise. From and after such time as the Rights become exercisable, the
Company shall use its best efforts, if then necessary to permit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the issuance of shares of Preferred Stock upon the exercise of Rights, to register and qualify such shares of Preferred Stock under the Securities Act and any applicable state securities or
&#147;Blue Sky&#148; laws (to the extent exemptions therefrom are not available), cause such registration statement and qualifications to become effective as soon as possible after such filing and keep such registration and qualifications effective
(with a prospectus at all times meeting the requirements of the Securities Act) until the earlier of the date as of which the Rights are no longer exercisable for such securities and the Final Expiration Date. The Company may temporarily suspend,
for a period of time not to exceed 120 days, the exercisability of the Rights in order to prepare and file a registration statement under the Securities Act and permit it to become effective. Upon any such suspension, the Company shall issue a
public announcement stating that the exercisability of the Rights has been temporarily suspended, as well as a public announcement at such time as the suspension is no longer in effect. The Company shall provide written notice to the Rights Agent,
attaching a copy of any such public announcement, promptly following issuance of such announcement under the immediately preceding sentence. Notwithstanding any provision of this Agreement to the contrary, the Rights shall not be exercisable in any
jurisdiction unless the requisite qualification in such jurisdiction shall have been obtained and until a registration statement under the Securities Act shall have been declared effective, unless an exemption therefrom is available. The Company
further covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges that may be payable in respect of the issuance or delivery of the Right Certificates or of any Preferred Shares (or Common
Shares and other securities, as the case may be) upon the exercise of Rights. The Company shall not, however, be required to pay any tax or charge that may be payable in respect of any transfer or delivery of Right Certificates to a Person other
than, or the issuance or delivery of certificates or depositary receipts for the Preferred Shares (or Common Shares and other securities as the case may be) in a name other than that of, the registered holder of the Right Certificate evidencing
Rights surrendered for exercise or to issue or to deliver any certificates or depositary receipts for Preferred Shares (or Common Shares and other securities as the case may be) upon the exercise of any Rights until any such tax or charge shall have
been paid (any such tax or charge being payable by the holder of such Right Certificate at the time of surrender) or until it has been established to the Company&#146;s or the Rights Agent&#146;s satisfaction that no such tax or charge is due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;10.</B><B> </B><B>P<SMALL>REFERRED</SMALL> S<SMALL>HARES</SMALL> R<SMALL>ECORD</SMALL> D<SMALL>ATE</SMALL></B><SMALL></SMALL>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Person in whose name any certificate for Preferred Shares or other securities is issued upon the exercise of Rights shall for all purposes be deemed
to have become the holder of record of the Preferred Shares or other securities represented thereby on, and such certificate shall be dated, the date upon which the Right Certificate evidencing such Rights was duly surrendered with the forms of
election and certification properly completed and duly executed and payment of the Purchase Price (and any applicable taxes or charges) was duly made; <I>provided, however</I>, that if the date of such surrender and payment is a date upon which the
Preferred Shares or other securities transfer books of the Company are closed, such Person shall be deemed to have become the record holder of such shares on, and such certificate shall be dated, the next succeeding Business Day on which the
Preferred Shares or other securities transfer books of the Company are open. Prior to the exercise of the Rights evidenced thereby, the holder of a Right Certificate, as such, shall not be entitled to any rights of a holder of Preferred Shares or
other securities for which the Rights shall be exercisable, including, without limitation, the right to vote, to receive dividends or other distributions, or to exercise any preemptive rights, and shall not be entitled to receive any notice of any
proceedings of the Company, except as provided herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;11.</B><B> </B><B>A<SMALL>DJUSTMENT</SMALL> <SMALL>OF</SMALL>
P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>, N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL> <SMALL>OR</SMALL> N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Price, the number of Preferred Shares or other securities or assets covered by each Right and the number of Rights outstanding are subject to
adjustment from time to time as provided in this Section&nbsp;11. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>(i)</B> In the event the Company shall at any time after
the Agreement Date (A)&nbsp;declare a dividend on the Preferred Shares payable in Preferred Shares, (B)&nbsp;subdivide or split the outstanding Preferred Shares, (C)&nbsp;combine or consolidate the outstanding Preferred Shares into a smaller number
of Preferred Shares or (D)&nbsp;issue any shares of its capital stock in a reclassification of the Preferred Shares (including any such reclassification in connection with a share exchange, consolidation or merger in which the Company is the
continuing or surviving entity), except as otherwise provided in this Section&nbsp;11(a), the Purchase Price in effect at the time of the record date for such dividend or of the effective date of such subdivision, split, combination, consolidation
or reclassification, and the number and kind of shares of capital stock issuable on such date, shall be proportionately adjusted so that the holder of any Right exercised after such time shall be entitled to receive the aggregate number and kind of
shares of capital stock that, if such Right had been exercised immediately prior to such date and at a time when the Preferred Shares transfer books of the Company were open, such holder would have owned upon such exercise and been entitled to
receive by virtue of such dividend, subdivision, split, combination, consolidation or reclassification; <I>provided, however</I>, that in no event shall the consideration to be paid upon the exercise of one Right be less than the aggregate par value
of the shares of capital stock of the Company issuable upon exercise of one Right. If an event occurs that would require an adjustment under both Section&nbsp;11(a)(i) and Section&nbsp;11(a)(ii) hereof, the adjustment provided for in this
Section&nbsp;11(a)(i) shall be in addition to, and shall be made prior to any adjustment required pursuant to Section&nbsp;11(a)(ii) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Subject to Section&nbsp;24 hereof, in the event any Person becomes an Acquiring Person, each holder of a Right shall thereafter
have a right to receive, upon exercise thereof at a price equal to the then current Purchase Price multiplied by the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share for which a Right is then exercisable, in
accordance with the terms of this Agreement and in lieu of Preferred Shares, such number of Common Shares as shall equal the result obtained by (A)&nbsp;multiplying the then current Purchase Price by the number of one
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share for which a Right is then exercisable and dividing that product by (B) 50% of the then current per share market price of the Common Shares (determined pursuant to
Section&nbsp;11(d) hereof) on the date such Person became an Acquiring Person; <I>provided, however</I>, that if the transaction that would otherwise give rise to the foregoing adjustment is also subject to the provisions of Section&nbsp;13 hereof,
then only the provisions of Section&nbsp;13 hereof shall apply and no adjustment shall be made pursuant to this Section&nbsp;11(a)(ii). In the event that any Person shall become an Acquiring Person and the Rights shall then be outstanding, the
Company shall not take any action that would eliminate or diminish the benefits intended to be afforded by the Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this Agreement to the contrary, from and after the time any
Person becomes an Acquiring Person, any Rights (x)&nbsp;beneficially owned by such Acquiring Person or an Associate or Affiliate of such Acquiring Person or (y)&nbsp;that were beneficially owned by such Acquiring Person or an Associate or Affiliate
of such Acquiring Person and are beneficially owned by (A)&nbsp;a transferee of such Acquiring Person (or of any such Associate or Affiliate) who received such Rights after the earlier of the date the Acquiring Person became such and the
Distribution Date or (B)&nbsp;a transferee of such Acquiring Person (or of any such Associate or Affiliate) who received such Rights prior to or on the earlier of the date the Acquiring Person became such and the Distribution Date and pursuant to
either (1)&nbsp;a transfer (whether or not for consideration) from the Acquiring Person (or of any such Associate or Affiliate) to holders of equity interests in such transferring Person or to any Person with whom the Acquiring Person (or of any
such Associate or Affiliate) has any continuing agreement, arrangement or understanding, whether or not in writing, regarding the transferred Rights or (2)&nbsp;a transfer that the Board has determined is part of a plan, arrangement or
understanding, whether or not in writing, that has as a primary purpose or effect the avoidance of this Section&nbsp;11(a)(ii), shall become null and void without any further action and no holder of such Rights shall have any rights whatsoever with
respect to such Rights, whether under any provision of this Agreement or otherwise. The Company shall use all reasonable efforts to ensure that the provisions of this Section&nbsp;11(a)(ii) and Section&nbsp;4(b) hereof are complied with, but neither
the Company nor the Rights Agent shall have liability to any holder of Right Certificates or other Person (without limiting the rights of the Rights Agent hereunder) as a result of the Company&#146;s failure to make any determinations hereunder with
respect to an Acquiring Person or its Affiliates, Associates or transferees. The Company shall give the Rights Agent written notice of the identity of any such Person, Associate or Affiliate and the nominee of any of the foregoing promptly after it
becomes aware of such identity, and the Rights Agent may rely conclusively on such notice in carrying out its duties under this Agreement. Until such written notice is received by the Rights Agent, the Rights Agent may assume conclusively for all
purposes that no such Acquiring Person exists. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In lieu of issuing Common Shares in accordance with Section&nbsp;11(a)(ii)
hereof, the Company may, if the Board determines that such action is necessary or appropriate and not contrary to the interests of holders of Rights, elect to (and, in the event that the Board has not exercised the exchange right contained in
Section&nbsp;24(c) hereof and there are not sufficient treasury shares and authorized but unissued Common Shares to permit the exercise in full of the Rights in accordance with Section&nbsp;11(a)(ii) hereof, the Company shall) take all such action
as may be necessary to authorize, issue or pay, upon the exercise of the Rights, cash (including by way of a reduction of the Purchase Price), property, debt or other equity securities (including, without limitation, shares, or units of shares, of
preferred stock, such as the Preferred Shares, which the Board has deemed to have essentially the same value or economic rights as Common Shares) or any combination thereof having an aggregate value equal to the value of the Common Shares that
otherwise would have been issuable pursuant to Section&nbsp;11(a)(ii) hereof (the &#147;<B><I>Current Value</I></B>&#148;), which aggregate value shall be determined by the Board upon consideration of the advice of a nationally recognized investment
banking firm selected by the Board; <I>provided, however</I>, if the Company shall not have made adequate provision to deliver value if required pursuant to the first parenthetical of this sentence within thirty (30)&nbsp;days following the first
occurrence of an event triggering the rights to purchase Common Shares described in Section&nbsp;11(a)(ii) (the &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;11(a)(ii) Trigger Date</I></B>&#148;), then the Company shall be obligated to
deliver, upon the surrender for exercise of a Right and without requiring payment of the Purchase Price, Common Shares (to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent available) and then, if necessary, cash, which shares and cash have an aggregate value equal to the excess of the Current Value over the Purchase Price. For purposes of the preceding
sentence, Current Value shall be determined pursuant to Section&nbsp;11(d) hereof. If the Board of the Company shall determine in good faith that it is likely that sufficient additional Common Shares could be authorized for issuance upon exercise in
full of the Rights, the thirty (30)&nbsp;day period set forth above may be extended to the extent necessary, but not more than ninety (90)&nbsp;days after the Section&nbsp;11(a)(ii) Trigger Date, in order that the Company may seek stockholder
approval for the authorization of such additional shares (such period, as it may be extended, the &#147;<B><I>Substitution Period</I></B>&#148;). To the extent that the Company determines that some action need or should be taken pursuant to this
Section&nbsp;11(a)(iii), the Company (x)&nbsp;shall provide, subject to Section&nbsp;7(e) hereof and the last paragraph of Section&nbsp;11(a)(ii) hereof, that such action shall apply uniformly to all outstanding Rights, and (y)&nbsp;may suspend the
exercisability of the Rights until the expiration of the Substitution Period in order to seek any authorization of additional shares and/or to decide the appropriate form of distribution to be made pursuant to this Section&nbsp;11(a)(iii) and to
determine the value thereof. In the event of any such suspension, the Company shall issue a public announcement stating that the exercisability of the Rights has been temporarily suspended. The Company shall promptly notify the Rights Agent in
writing upon the occurrence of such suspension, and if such notification is given orally, the Company shall confirm the same in writing on or prior to the Business Day next following. Until such notice is received by the Rights Agent, the Rights
Agent may presume conclusively that no such suspension has occurred. The Board may, but shall not be required to, establish procedures to allocate the right to receive Common Shares upon the exercise of the Rights among the holders of Rights
pursuant to this Section&nbsp;11(a)(iii). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In case the Company shall fix a record date for the issuance of rights, options or
warrants to all holders of Preferred Shares entitling them to subscribe for or purchase Preferred Shares (or shares having the same designations and the powers, preferences and rights, and the qualifications, limitations and restrictions as the
Preferred Shares (&#147;<B><I>Equivalent Preferred Shares</I></B>&#148;)) or securities convertible into Preferred Shares or Equivalent Preferred Shares at a price per Preferred Share or Equivalent Preferred Share (or having a conversion price per
share, if a security convertible into Preferred Shares or Equivalent Preferred Shares) less than the then current per share market price of the Preferred Shares on such record date, the Purchase Price to be in effect after such record date shall be
determined by multiplying the Purchase Price in effect immediately prior to such record date by a fraction, the numerator of which shall be the number of Preferred Shares outstanding on such record date plus the number of Preferred Shares that the
aggregate offering price of the total number of Preferred Shares or Equivalent Preferred Shares so to be offered (or the aggregate initial conversion price of the convertible securities so to be offered) would purchase at such current market price
and the denominator of which shall be the number of Preferred Shares outstanding on such record date plus the number of additional Preferred Shares or Equivalent Preferred Shares to be offered for subscription or purchase (or into which the
convertible securities so to be offered are initially convertible); <I>provided, however</I>, that in no event shall the consideration to be paid upon the exercise of one Right be less than the aggregate par value of the shares of capital stock of
the Company issuable upon exercise of one Right. In case such subscription price may be paid in a consideration part or all of which shall be in a form other than cash, the value of such consideration shall be as determined in good faith by the
Board, whose determination shall be described in a written statement filed with the Rights Agent. Preferred Shares owned by or held for the account of the Company shall not be deemed outstanding for the purpose of any such computation. Such
adjustment shall be made successively whenever such a record date is fixed; and in the event that such rights, options or warrants are not so issued, the Purchase Price shall be adjusted to be the Purchase Price that would then be in effect if such
record date had not been fixed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In case the Company shall fix a record date for the making of a distribution to
all holders of the Preferred Shares (including any such distribution made in connection with a consolidation or merger in which the Company is the continuing or surviving entity) of evidences of indebtedness or assets (other than a regular quarterly
cash dividend or a dividend payable in Preferred Shares) or subscription rights or warrants (excluding those referred to in Section&nbsp;11(b) hereof), the Purchase Price to be in effect after such record date shall be determined by multiplying the
Purchase Price in effect immediately prior to such record date by a fraction, the numerator of which shall be the then current per share market price of the Preferred Shares on such record date, less the fair market value (as determined in good
faith by the Board, whose determination shall be described in a written statement filed with the Rights Agent) of the portion of the assets or evidences of indebtedness so to be distributed or of such subscription rights or warrants applicable to
one Preferred Share and the denominator of which shall be such current per share market price of the Preferred Shares; <I>provided, however</I>, that in no event shall the consideration to be paid upon the exercise of one Right be less than the
aggregate par value of the shares of capital stock of the Company to be issued upon exercise of one Right. Such adjustments shall be made successively whenever such a record date is fixed; and in the event that such distribution is not so made, the
Purchase Price shall again be adjusted to be the Purchase Price that would then be in effect if such record date had not been fixed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>(i)</B> For the purpose of any computation hereunder, the &#147;<B><I>current per share market price</I></B>&#148; of any
security (a &#147;<B><I>Security</I></B>&#148; for the purpose of this Section&nbsp;11(d)(i)) on any date shall be deemed to be the average of the daily closing prices per share of such Security for the thirty (30)&nbsp;consecutive Trading Days
immediately prior to, but not including, such date; <I>provided, however</I>, that in the event that the current per share market price of the Security is determined during a period following the announcement by the issuer of such Security of
(A)&nbsp;a dividend or distribution on such Security payable in shares of such Security or securities convertible into such shares, or (B)&nbsp;any subdivision, combination or reclassification of such Security or securities convertible into such
shares and prior to, but not including, the expiration of thirty (30)&nbsp;Trading Days after the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date for such dividend or distribution, or the record date for such subdivision, combination or
reclassification, then, and in each such case, the current per share market price shall be appropriately adjusted to reflect the current market price per share equivalent of such Security. The closing price for each day shall be the last sale price,
regular way, or, in case no such sale takes place on such day, the average of the closing bid and asked prices, regular way, in either case as reported in the principal consolidated transaction reporting system with respect to securities listed or
admitted to trading on The New York Stock Exchange or The Nasdaq Stock Market or, if the Security is not listed or admitted to trading on The New York Stock Exchange or The Nasdaq Stock Market, as reported in the principal consolidated transaction
reporting system with respect to securities listed on the principal national securities exchange on which the Security is listed or admitted to trading or, if the Security is not listed or admitted to trading on any national securities exchange, the
last quoted price or, if not so quoted, the average of the high bid and low asked prices in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, as reported in the OTC Bulletin Board, the Pink
OTC Markets, Inc. or such other system then in use, or, if on any such date the Security is not quoted by any such organization, the average of the closing bid and asked prices as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
furnished by a professional market maker making a market in the Security selected by the Board or, if on any such date no professional market maker is making a market in the Security, the price
as determined in good faith by the Board. The term &#147;<B><I>Trading Day</I></B>&#148; shall mean a day on which the principal national securities exchange on which the Security is listed or admitted to trading is open for the transaction of
business or, if the Security is not listed or admitted to trading on any national securities exchange, a Business Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> For the
purpose of any computation hereunder, the &#147;<B><I>current per share market price</I></B>&#148; of the Preferred Shares shall be determined in accordance with the method set forth in Section&nbsp;11(d)(i) hereof. If the Preferred Shares are not
publicly traded, the &#147;current per share market price&#148; of the Preferred Shares shall be conclusively deemed to be the current per share market price of the Common Shares as determined pursuant to Section&nbsp;11(d)(i) hereof (appropriately
adjusted to reflect any stock split, stock dividend or similar transaction occurring after the Agreement Date) multiplied by one thousand. If neither the Common Shares nor the Preferred Shares are publicly traded, &#147;current per share market
price&#148; shall mean the fair value per share as determined in good faith by the Board, whose determination shall be set forth in a written statement filed with the Rights Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> No adjustment in the Purchase Price shall be required unless such adjustment would require an increase or decrease of at least 1% in
the Purchase Price; <I>provided, however</I>, that any adjustments that by reason of this Section&nbsp;11(e) are not required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this
Section&nbsp;11 shall be made to the nearest cent or to the nearest one <FONT STYLE="white-space:nowrap">one-hundred</FONT> thousandth of a Preferred Share or one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of any other share or security
as the case may be. Notwithstanding the first sentence of this Section&nbsp;11(e), any adjustment required by this Section&nbsp;11 shall be made no later than the earlier of (i)&nbsp;three years from the date of the transaction that requires such
adjustment and (ii)&nbsp;the date of the expiration of the right to exercise any Rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> If as a result of an adjustment made
pursuant to Section&nbsp;11(a) hereof, the holder of any Right thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than Preferred Shares, thereafter the number of such other shares so receivable
upon exercise of any Right shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Preferred Shares contained in Section&nbsp;11(a) through
Section&nbsp;11(c) hereof, inclusive, and the provisions of Section&nbsp;7, Section&nbsp;9, Section&nbsp;10, Section&nbsp;13 and Section&nbsp;14 hereof with respect to the Preferred Shares shall apply on like terms to any such other shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> All Rights originally issued by the Company subsequent to any adjustment made to the Purchase Price hereunder shall evidence the
right to purchase, at the adjusted Purchase Price, the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share purchasable from time to time hereunder upon exercise of the Rights, all subject to further adjustment
as provided herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> Unless the Company shall have exercised its election as provided in Section&nbsp;11(i) hereof, upon each
adjustment of the Purchase Price as a result of the calculations made in Section&nbsp;11(b) and Section&nbsp;11(c) hereof, each Right outstanding immediately prior to the making of such adjustment shall thereafter evidence the right to purchase, at
the adjusted Purchase Price, that number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share (calculated to the nearest one <FONT STYLE="white-space:nowrap">one-hundred</FONT> thousandth of a Preferred Share) obtained
by (i)&nbsp;multiplying (x) the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share covered by a Right immediately prior to this adjustment by (y)&nbsp;the Purchase Price in effect immediately prior to such
adjustment of the Purchase Price and (ii)&nbsp;dividing the product so obtained by the Purchase Price in effect immediately after such adjustment of the Purchase Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The Company may elect on or after the date of any adjustment of the Purchase
Price to adjust the number of Rights, in substitution for any adjustment in the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share purchasable upon the exercise of a Right. Each of the Rights outstanding after
such adjustment of the number of Rights shall be exercisable for the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share for which a Right was exercisable immediately prior to such adjustment. Each Right held of
record prior to such adjustment of the number of Rights shall become that number of Rights (calculated to the nearest one <FONT STYLE="white-space:nowrap">one-thousandth)</FONT> obtained by dividing the Purchase Price in effect immediately prior to
adjustment of the Purchase Price by the Purchase Price in effect immediately after adjustment of the Purchase Price. The Company shall make a public announcement (with prompt written notice thereof to the Rights Agent; and until such written notice
is received by the Rights Agent, the Rights Agent may presume conclusively that no such election has occurred) of its election to adjust the number of Rights, indicating the record date for the adjustment, and, if known at the time, the amount of
the adjustment to be made. This record date may be the date on which the Purchase Price is adjusted or any day thereafter, but, if the Right Certificates have been issued, shall be at least ten (10)&nbsp;days later than the date of the public
announcement. If Right Certificates have been issued, upon each adjustment of the number of Rights pursuant to this Section&nbsp;11(i), the Company shall, as promptly as practicable, cause to be distributed to holders of record of Right Certificates
on such record date Right Certificates evidencing, subject to Section&nbsp;14 hereof, the additional Rights to which such holders shall be entitled as a result of such adjustment, or, at the option of the Company, shall cause to be distributed to
such holders of record in substitution and replacement for the Right Certificates held by such holders prior to the date of adjustment, and upon surrender thereof, if required by the Company, new Right Certificates evidencing all the Rights to which
such holders shall be entitled after such adjustment. Right Certificates to be so distributed shall be issued, executed, delivered and countersigned by the Rights Agent in the manner provided for herein and shall be registered in the names of the
holders of record of Right Certificates on the record date specified in the public announcement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> Irrespective of any adjustment
or change in the Purchase Price or the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share issuable upon the exercise of the Rights, the Right Certificates theretofore and thereafter issued may continue to
express the Purchase Price and the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share that was expressed in the initial Right Certificates issued hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> Before taking any action that would cause an adjustment reducing the Purchase Price below one
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of the then par value, if any, of the Preferred Shares issuable upon exercise of the Rights, the Company shall take any corporate action that may, in the opinion of its counsel, be necessary to
enable the Company to validly and legally issue fully paid and nonassessable Preferred Shares at such adjusted Purchase Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> In any case in which this Section&nbsp;11 shall require that an adjustment in the
Purchase Price be made effective as of a record date for a specified event, the Company may elect to defer (with prompt written notice thereof to the Rights Agent; and until such written notice is received by the Rights Agent, the Rights Agent may
presume conclusively that no such election has occurred) until the occurrence of such event the issuing to the holder of any Right exercised after such record date of the Preferred Shares and other capital stock or securities of the Company, if any,
issuable upon such exercise on the basis of the Purchase Price in effect prior to such adjustment; <I>provided, however</I>, that the Company shall deliver to such holder a due bill or other appropriate instrument evidencing such holder&#146;s right
to receive such additional shares upon the occurrence of the event requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> The Company covenants and agrees
that, after the Distribution Date, it will not, except as permitted by this Agreement, take (or permit any Subsidiary to take) any action the purpose of which is to, or if at the time such action is taken it is reasonably foreseeable that the effect
of such action is to, materially diminish or eliminate the benefits intended to be afforded by the Rights. Any such action taken by the Company during any period after any Person becomes an Acquiring Person but prior to the Distribution Date shall
be null and void unless such action could be taken under this Section&nbsp;11(m) from and after the Distribution Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>
Notwithstanding anything in this Section&nbsp;11 to the contrary, the Company shall be entitled to make such reductions in the Purchase Price, in addition to those adjustments expressly required by this Section&nbsp;11, as and to the extent that it
in its sole discretion shall determine to be advisable in order that any (i)&nbsp;combination or subdivision of the Preferred Shares, (ii)&nbsp;issuance wholly for cash of any Preferred Shares at less than the current market price,
(iii)&nbsp;issuance wholly for cash of Preferred Shares or securities that by their terms are convertible into or exchangeable for Preferred Shares, (iv)&nbsp;dividends on Preferred Shares payable in Preferred Shares or (v)&nbsp;issuance of rights,
options or warrants referred to hereinabove in Section&nbsp;11(b), hereafter made by the Company to holders of its Preferred Shares shall not be taxable to such stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> In the event that at any time after the Agreement Date and prior to the Distribution Date, the Company shall (i)&nbsp;declare or pay
any dividend on the Common Shares payable in Common Shares or (ii)&nbsp;effect a subdivision, split, combination or consolidation of the Common Shares (by reclassification or otherwise other than by payment of dividends in Common Shares) into a
greater or lesser number of Common Shares, then in any such case (A)&nbsp;the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share purchasable after such event upon proper exercise of each Right shall be
determined by multiplying the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share so purchasable immediately prior to such event by a fraction, the numerator of which is the number of Common Shares outstanding
immediately before such event and the denominator of which is the number of Common Shares outstanding immediately after such event, (B)&nbsp;each Common Share outstanding immediately after such event shall have issued with respect to it that number
of Rights that each Common Share outstanding immediately prior to such event had issued with respect to it, and (C)&nbsp;the Purchase Price immediately prior to the record date for such dividend or the effective date of such subdivision, split,
combination or consolidation of the Common Shares (by reclassification or otherwise other than by payment of dividends in Common Shares) shall be adjusted so that the Purchase Price after such event shall be determined by multiplying the Purchase
Price in effect immediately prior to such event by a fraction, the numerator of which is the number of Common Shares outstanding immediately prior to such event and the denominator of which is the number of Common Shares outstanding immediately
after such event. The adjustments provided for in this Section&nbsp;11(o) shall be made successively whenever such a dividend is declared or paid or such a subdivision, combination or consolidation is effected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;12.</B><B> </B><B>C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL>
A<SMALL>DJUSTED</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL> <SMALL>OR</SMALL> N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever an adjustment is made or any event affecting the Rights or their exercisability (including without limitation an event that causes Rights to become
null and void) occurs as provided in Section&nbsp;11 and Section&nbsp;13 hereof, the Company shall as promptly as practicable (a)&nbsp;prepare a certificate setting forth such adjustment or describing such event, and a brief, reasonably detailed
statement of the facts, computations and methodology accounting for such adjustment, (b)&nbsp;file with the Rights Agent and with each transfer agent for the Common Shares or the Preferred Shares a copy of such certificate and (c)&nbsp;if such
adjustment occurs following a Distribution Date, mail a brief summary thereof to each holder of a Right Certificate in accordance with Section&nbsp;25 and Section&nbsp;26 hereof. The Rights Agent shall be fully protected in relying on any such
certificate and on any adjustment or statement therein contained and shall have no duty or liability with respect to, and shall not be deemed to have knowledge of, any adjustment or any such event unless and until it shall have received such
certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;13.</B><B> </B><B>C<SMALL>ONSOLIDATION</SMALL>, M<SMALL>ERGER</SMALL> <SMALL>OR</SMALL> S<SMALL>ALE</SMALL>
<SMALL>OR</SMALL> T<SMALL>RANSFER</SMALL> <SMALL>OF</SMALL> A<SMALL>SSETS</SMALL> <SMALL>OR</SMALL> E<SMALL>ARNING</SMALL> P<SMALL>OWER</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event that, at any time after a Person becomes an Acquiring Person, directly or indirectly, (i)&nbsp;the Company shall
consolidate with, or merge with and into, any other Person, (ii)&nbsp;any Person shall consolidate with the Company, or merge with and into the Company and the Company shall be the continuing or surviving corporation of such merger and, in
connection with such merger, all or part of the Common Shares shall be changed into or exchanged for stock or other securities of any other Person (or the Company) or cash or any other property, or (iii)&nbsp;the Company shall sell or otherwise
transfer (or one or more of its Subsidiaries shall sell or otherwise transfer), in one or more transactions, assets or earning power aggregating 50% or more of the assets or earning power of the Company and its Subsidiaries (taken as a whole) to any
other Person other than the Company or one or more of its wholly-owned Subsidiaries, then, and in each such case, proper provision shall be made so that (A)&nbsp;each holder of a Right (except as otherwise provided herein) shall thereafter have the
right to receive, upon the exercise thereof at a price equal to the then current Purchase Price multiplied by the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share for which a Right is then exercisable, in
accordance with the terms of this Agreement and in lieu of Preferred Shares, such number of Common Shares of the Principal Party (free and clear of all liens, encumbrances, rights of first refusal and other adverse claims) as shall equal the result
obtained by (x)&nbsp;multiplying the then current Purchase Price by the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share for which a Right is then exercisable and dividing that product by (y) 50% of the then
current per share market price of the Common Shares of the Principal Party (determined pursuant to Section&nbsp;11(d) hereof) on the date of consummation of such consolidation, merger, sale or transfer; (B)&nbsp;the Principal Party shall thereafter
be liable for, and shall assume, by virtue of such consolidation, merger, sale or transfer, all the obligations and duties of the Company pursuant to this Agreement; (C)&nbsp;the term &#147;Company&#148; shall thereafter be deemed to refer to the
Principal Party; and (D)&nbsp;the Principal Party shall take such steps (including the reservation of a sufficient number of its Common Shares in accordance with Section&nbsp;9 hereof) in connection with such consummation as may be necessary to
assure that the provisions hereof shall thereafter be applicable, as nearly as reasonably may be, in relation to the Common Shares thereafter deliverable upon the exercise of the Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company covenants and agrees that it shall not consummate any such
consolidation, merger, sale or transfer unless prior thereto the Company and the Principal Party shall have executed and delivered to the Rights Agent an agreement confirming that the requirements of this Section&nbsp;13 shall promptly be performed
in accordance with their terms and that such consolidation, merger, sale or transfer of assets shall not result in a default by the Principal Party under this Agreement as the same shall have been assumed by the Principal Party pursuant to this
Section&nbsp;13 and providing that, as soon as practicable after executing such agreement pursuant to this Section&nbsp;13, the Principal Party will: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) prepare and file a registration statement under the Securities Act, if necessary, with respect to the Rights and the securities
purchasable upon exercise of the Rights on an appropriate form, use its best efforts to cause such registration statement to become effective as soon as practicable after such filing and use its best efforts to cause such registration statement to
remain effective (with a prospectus at all times meeting the requirements of the Securities Act) until the Final Expiration Date and similarly comply with applicable state securities laws; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) use its best efforts, if the Common Shares of the Principal Party shall be listed or admitted to trading on the New York Stock Exchange,
The Nasdaq Stock Market or another national securities exchange, to list or admit to trading (or continue the listing of) the Rights and the securities purchasable upon exercise of the Rights on the New York Stock Exchange, The Nasdaq Stock Market
or such other national securities exchange, or, if the Common Shares of the Principal Party shall not be listed or admitted to trading on the New York Stock Exchange, The Nasdaq Stock Market or another national securities exchange, to cause the
Rights and the securities receivable upon exercise of the Rights to be authorized for quotation on any other system then in use; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)
deliver to holders of the Rights historical financial statements for the Principal Party which comply in all respects with the requirements for registration on Form 10 (or any successor form) under the Exchange Act; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) obtain waivers of any rights of first refusal or preemptive rights in respect of the Common Shares of the Principal Party subject to
purchase upon exercise of outstanding Rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In case the Principal Party has a provision in any of its authorized securities
or in its certificate of incorporation or bylaws or other instrument governing its affairs, which provision would have the effect of (i)&nbsp;causing such Principal Party to issue (other than to holders of Rights pursuant to this Section&nbsp;13),
in connection with, or as a consequence of, the consummation of a transaction referred to in this Section&nbsp;13, Common Shares (or equivalents thereof) of such Principal Party at less than the then current market price per share thereof
(determined pursuant to Section&nbsp;11(d) hereof) or securities exercisable for, or convertible into, Common Shares (or equivalents thereof) of such Principal Party at less than such then current market price, or (ii)&nbsp;providing for any special
payment, tax or similar provision in connection with the issuance of the Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares of such Principal Party pursuant to the provisions of Section&nbsp;13, then, in such event, the Company hereby agrees with each holder of Rights that it shall not consummate any such
transaction unless prior thereto the Company and such Principal Party shall have executed and delivered to the Rights Agent a supplemental agreement providing that the provision in question of such Principal Party shall have been canceled, waived or
amended, or that the authorized securities shall be redeemed, so that the applicable provision will have no effect in connection with, or as a consequence of, the consummation of the proposed transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Company shall not enter into any transaction of the kind referred to in this Section&nbsp;13 if (i)&nbsp;at the time of such
transaction there are any rights, warrants, instruments or securities outstanding or any agreements or arrangements which, as a result of the consummation of such transaction, would eliminate or substantially diminish the benefits intended to be
afforded by the Rights, (ii)&nbsp;prior to, simultaneously with or immediately after such consolidation, merger, sale, transfer or other transaction, the shareholders of the Person who constitutes, or would constitute, the Principal Party shall have
received a distribution of Rights previously owned by such Person or any of its Affiliates or Associates or (iii)&nbsp;the form or nature of organization of the Principal Party would preclude or limit the exercisability of the Rights. The provisions
of this Section&nbsp;13 shall similarly apply to successive mergers or consolidations or sales or other transfers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> For purposes
hereof, the &#147;<B>earning power</B>&#148; of the Company and its Subsidiaries shall be determined in good faith by the Board of Directors on the basis of the operating earnings of each business operated by the Company and its Subsidiaries during
the three fiscal years preceding the date of such determination (or, in the case of any business not operated by the Company or any Subsidiary during three full fiscal years preceding such date, during the period such business was operated by the
Company or any Subsidiary). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;14.</B> <B>F<SMALL>RACTIONAL</SMALL> R<SMALL>IGHTS</SMALL> <SMALL>AND</SMALL>
F<SMALL>RACTIONAL</SMALL> S<SMALL>HARES</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company shall not be required to issue fractions of
Rights or to distribute Right Certificates that evidence fractional Rights. In lieu of such fractional Rights, there shall be paid to the registered holders of the Right Certificates with regard to which such fractional Rights would otherwise be
issuable, an amount in cash equal to the same fraction of the current market value of a whole Right. For the purposes of this Section&nbsp;14(a), the current market value of a whole Right shall be the closing price of the Rights for the Trading Day
immediately prior to the date on which such fractional Rights would have been otherwise issuable. The closing price for any day shall be the last sale price, regular way, or, in case no such sale takes place on such day, the average of the closing
bid and asked prices, regular way, in either case as reported in the principal consolidated transaction reporting system with respect to securities listed or admitted to trading on The New York Stock Exchange or The Nasdaq Stock Market, or if the
Rights are not listed or admitted to trading on The New York Stock Exchange or The Nasdaq Stock Market, as reported in the principal consolidated transaction reporting system with respect to securities listed on the principal national securities
exchange on which the Rights are listed or admitted to trading or, if the Rights are not listed or admitted to trading on any national securities exchange, the last quoted price or, if not so quoted, the average of the high bid and low asked prices
in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, as reported in the OTC Bulletin Board, the Pink OTC Markets, Inc. or such other system then in use or, if on any such date the Rights are
not quoted by any such organization, the average of the closing bid and asked prices as furnished by a professional market maker making a market in the Rights selected by the Board, or if on any such date no such market maker is making a market in
the Rights, the fair value of the Rights on such date as determined in good faith by the Board shall be used. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company shall not be required to issue fractions of Preferred Shares (other
than fractions that are integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share) upon exercise of the Rights or to distribute certificates that evidence fractional Preferred Shares (other than fractions
that are integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share). Fractions of Preferred Shares in integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share
may, at the election of the Company, be evidenced by depositary receipts; <I>provided, however</I>, that holders of such depositary receipts shall have all of the designations and the powers, preferences and rights, and the qualifications,
limitations and restrictions to which they are entitled as beneficial owners of the Preferred Shares represented by such depositary receipts. In lieu of fractional Preferred Shares that are not integral multiples of one <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share, the Company shall pay to the registered holders of Right Certificates at the time such Rights are exercised as herein provided an amount in cash equal to the same fraction of the
current market value of one Preferred Share. For the purposes of this Section&nbsp;14(b), the current market value of a Preferred Share shall be the closing price of a Preferred Share (as determined pursuant to the second sentence of
Section&nbsp;11(d)(i) hereof) for the Trading Day immediately prior to the date of such exercise; <I>provided, however</I>, that if the Preferred Shares are not publicly traded at the time of such exercise, the current market value of a Preferred
Share shall be determined in accordance with Section&nbsp;11(d)(ii) hereof for the Trading Day immediately prior to the date of such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Following the occurrence of one of the transactions or events specified in Section&nbsp;11 hereof giving rise to the right to
receive Common Shares or other securities (other than Preferred Shares) upon the exercise of a Right, the Company shall not be required to issue fractions of Common Shares or other securities upon exercise of the Rights or to distribute certificates
that evidence fractional Common Shares or other securities. In lieu of fractional Common Shares or other securities, the Company may pay to the registered holders of Right Certificates at the time such Rights are exercised as herein provided an
amount in cash equal to the same fraction of the current market value of one Common Share or one such other security. For purposes of this Section&nbsp;14(c), the current market value shall be the closing price for one Common Share or such other
security, as applicable (as determined pursuant to the second sentence of Section&nbsp;11(d)(i) hereof) for the Trading Day immediately prior to the date of such exercise; <I>provided, however</I>, that if such other security is not publicly traded
at the time of such exercise, such security shall have the value of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> (subject to appropriate adjustment in the case of a subdivision or combination) of a Preferred Share as determined
pursuant to Section&nbsp;14(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The holder of a Right by the acceptance of the Right expressly waives any right such
holder may have to receive any fractional Rights or any fractional shares upon exercise of a Right (except as provided above). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>
Whenever a payment for fractional Rights or fractional shares is to be made by the Rights Agent under this Agreement, the Company shall (i)&nbsp;promptly prepare and deliver to the Rights Agent a certificate setting forth in reasonable detail the
facts related to such payments and the prices or formulas utilized in calculating such payments, and (ii)&nbsp;provide sufficient monies to the Rights Agent in the form of fully collected funds to make such payments. The Rights Agent shall be fully
protected in relying upon such a certificate and shall have no duty with respect to, and shall not be deemed to have knowledge of any payment for fractional Rights or fractional shares under any Section of this Agreement relating to the payment of
fractional Rights or fractional shares unless and until the Rights Agent shall have received such a certificate and sufficient monies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;15.</B><B> </B><B>R<SMALL>IGHTS</SMALL> <SMALL>OF</SMALL>
A<SMALL>CTION</SMALL></B><SMALL></SMALL>.<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> All rights of action in respect of this Agreement, excepting the rights of
action given to the Rights Agent under Section&nbsp;18 and Section&nbsp;20 and any other Section hereof, are vested in the respective registered holders of the Right Certificates (and, prior to the Distribution Date, the registered holders of the
Common Shares) and any registered holder of any Right Certificate (or, prior to the Distribution Date, of the Common Shares), without the consent of the Rights Agent or of the holder of any other Right Certificate (or, prior to the Distribution
Date, of the Common Shares), may, in such holder&#146;s own behalf and for such holder&#146;s own benefit, enforce, and may institute and maintain any suit, action or proceeding against the Company to enforce, or otherwise act in respect of, such
holder&#146;s right to exercise the Rights evidenced by such Right Certificate in the manner provided in such Right Certificate and in this Agreement. Without limiting the foregoing or any remedies available to the holders of Rights, it is
specifically acknowledged that the holders of Rights would not have an adequate remedy at law for any breach by the Company of this Agreement and will be entitled to specific performance of the obligations hereunder, and injunctive relief against
actual or threatened violations of the obligations of the Company under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Notwithstanding anything in this
Agreement to the contrary, neither the Company nor the Rights Agent shall have any liability to any holder of a Right or other Person as a result of the inability of the Company or the Rights Agent to perform any of its obligations under this
Agreement by reason of any preliminary or permanent injunction or other order, judgment, decree or ruling (whether interlocutory or final) issued by a court of competent jurisdiction or by a governmental, regulatory, self-regulatory or
administrative agency or commission, or any statute, rule, regulation or executive order promulgated or enacted by any governmental authority, prohibiting or otherwise restraining performance of such obligation; provided, however, that the Company
shall use all reasonable efforts to oppose any action for any such injunction order, judgment, decree or ruling and to have any such injunction, order, judgment, decree or ruling lifted or otherwise overturned as soon as possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;16.</B><B> </B><B>A<SMALL>GREEMENT</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHT</SMALL> H<SMALL>OLDERS</SMALL></B><SMALL></SMALL>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Every holder of a Right, by accepting the same, consents and agrees with the Company and the Rights Agent and with every other holder of a Right that:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> prior to the Distribution Date, the Rights will be transferable only in connection with the transfer of the Common Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> after the Distribution Date, the Right Certificates are transferable (subject to the provisions of this Agreement) only on the
registry books of the Rights Agent if surrendered at the office of the Rights Agent designated for such purpose, duly endorsed or accompanied by a proper instrument of transfer and with all appropriate forms and certificates fully executed,
accompanied by a Signature Guarantee and such other documents as the Rights Agent may request; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> subject to Section&nbsp;6 and Section&nbsp;7(e) hereof, the Company and the
Rights Agent may deem and treat the Person in whose name the Right Certificate (or, prior to the Distribution Date, the associated Common Shares certificate (or Book-Entry Common Share)) is registered as the absolute owner thereof and of the Rights
evidenced thereby (notwithstanding any notations of ownership or writing on the Right Certificates or the associated Common Shares certificate (or Ownership Statements or other notices provided to holders of Book-Entry Common Shares) made by anyone
other than the Company or the Rights Agent) for all purposes whatsoever, and neither the Company nor the Rights Agent shall be affected by any notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;17.</B><B> </B><B>R<SMALL>IGHT</SMALL> C<SMALL>ERTIFICATE</SMALL> H<SMALL>OLDER</SMALL> N<SMALL>OT</SMALL> D<SMALL>EEMED</SMALL>
<SMALL>A</SMALL> S<SMALL>TOCKHOLDER</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No holder, as such, of any Right Certificate shall be entitled to vote, receive dividends
or be deemed for any purpose the holder of the Preferred Shares or any other securities of the Company that may at any time be issuable on the exercise or exchange of the Rights represented thereby, nor shall anything contained herein or in any
Right Certificate be construed to confer upon the holder of any Right Certificate, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any
meeting thereof, or to give or withhold consent to any corporate action, or to receive notice of meetings or other actions affecting stockholders (except as provided in Section&nbsp;25 hereof), or to receive dividends or subscription rights, or
otherwise, until the Right or Rights evidenced by such Right Certificate shall have been exercised or exchanged in accordance with the provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;18.</B><B> </B><B>C<SMALL>ONCERNING</SMALL> <SMALL>THE</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GENT</SMALL></B><SMALL></SMALL>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company agrees to pay to the Rights Agent reasonable compensation for all services rendered by it hereunder in accordance with a fee schedule to be
mutually agreed upon and, from time to time, on demand of the Rights Agent, its reasonable expenses and counsel fees (including counsel fees incurred under Section&nbsp;20(a) below) and other disbursements incurred in the preparation, negotiation,
delivery, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder as detailed on <U>Schedule A</U> to this Agreement. The Company also agrees to indemnify the Rights Agent for, and to hold
it harmless against, any loss, liability, damage, judgment, fine, penalty, claim, demand, settlement, claim, cost or expense (including, without limitation, the reasonable fees and expenses of legal counsel and reasonable fees and expenses arising
directly or indirectly from enforcing its rights hereunder) that may be paid, incurred or to which it may become subject, without gross negligence, bad faith or willful misconduct on the part of the Rights Agent (which gross negligence, bad faith or
willful misconduct must be determined by a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction) for any action taken, suffered or omitted to be taken by the Rights Agent in connection with the
execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or of enforcing its rights
under this Agreement. The provisions of this Section&nbsp;18 and Section&nbsp;20 below shall survive the termination of this Agreement, the exercise or expiration of the Rights and the resignation, replacement or removal of the Rights Agent and the
exercise, termination and expiration of the Rights. The Rights Agent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be authorized and protected and shall incur no liability for, or in respect of any action taken, suffered or omitted to be taken by it in connection with its acceptance and administration
of this Agreement and the exercise and performance of its duties hereunder, in reliance upon any Right Certificate or certificate for the Preferred Shares or Common Shares or for other securities of the Company, instrument of assignment or transfer,
power of attorney, endorsement, affidavit, letter, notice, direction, consent, certificate, statement, or other paper or document believed by it to be genuine and to be signed, executed and, where necessary, verified or acknowledged, by the proper
Person or Persons, or otherwise upon the advice of counsel as set forth in Section&nbsp;20 hereof. The Rights Agent shall not be deemed to have any knowledge of any event of which it was to receive notice thereof hereunder, and the Rights Agent
shall be fully protected and shall incur no liability for failing to take any action in connection therewith, unless and until it has received such notice in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;19.</B><B> </B><B>M<SMALL>ERGER</SMALL> <SMALL>OR</SMALL> C<SMALL>ONSOLIDATION</SMALL> <SMALL>OR</SMALL> C<SMALL>HANGE</SMALL>
<SMALL>OF</SMALL> N<SMALL>AME</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GENT</SMALL></B><SMALL></SMALL>.<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>
Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a
party, or any Person succeeding to the shareholder services or corporate trust business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper
or document or any further act on the part of any of the parties hereto, provided that such Person would be eligible for appointment as a successor Rights Agent under the provisions of Section&nbsp;21 hereof. The purchase of all or substantially all
of the Rights Agent&#146;s assets employed in the performance of the transfer agent activities shall be deemed a merger or consolidation for purposes of this Section&nbsp;19. In case at the time such successor Rights Agent shall succeed to the
agency created by this Agreement any of the Right Certificates shall have been countersigned but not delivered, any such successor Rights Agent may adopt the countersignature of the predecessor Rights Agent and deliver such Right Certificates so
countersigned; and in case at that time any of the Right Certificates shall not have been countersigned, any successor Rights Agent may countersign such Right Certificates either in the name of the predecessor Rights Agent or in the name of the
successor Rights Agent; and in all such cases such Right Certificates shall have the full force provided in the Right Certificates and in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In case at any time the name of the Rights Agent shall be changed and at such time any of the Right Certificates shall have been
countersigned but not delivered, the Rights Agent may adopt the countersignature under its prior name and deliver Right Certificates so countersigned; and in case at that time any of the Right Certificates shall not have been countersigned, the
Rights Agent may countersign such Right Certificates either in its prior name or in its changed name; and in all such cases such Right Certificates shall have the full force provided in the Right Certificates and in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;20.</B><B> </B><B>D<SMALL>UTIES</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GENT</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Rights Agent undertakes to perform only the duties and obligations expressly imposed by this Agreement (and no implied duties) upon the following terms
and conditions, by all of which the Company and the holders of Right Certificates, by their acceptance thereof, shall be bound: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Rights Agent may consult with legal counsel of its choice (who may be legal
counsel for the Company or an employee of the Rights Agent or <FONT STYLE="white-space:nowrap">in-house</FONT> counsel of the Rights Agent or otherwise), and the advice or opinion of such counsel shall be full and complete authorization and
protection to the Rights Agent and the Rights Agent shall incur no liability for in respect of any action taken, suffered or omitted to be taken by it in the absence of bad faith in accordance with such advice or opinion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Whenever in the performance of its duties under this Agreement the Rights Agent shall deem it necessary or desirable that any fact
or matter (including without limitation, the identity of an Acquiring Person and the determination of the current per share market price of any security) be proved or established by the Company prior to taking, suffering or omitting to take any
action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by any one of the Chairman of the Board, the Chief
Executive Officer, the President, the Chief Financial Officer, any Vice President, Secretary or the Treasurer of the Company and delivered to the Rights Agent; and such certificate shall be full and complete authorization and protection to the
Rights Agent and the Rights Agent shall incur no liability for or in respect of any action taken, suffered or omitted to be taken by it in the absence of bad faith under the provisions of this Agreement in reliance upon such certificate. The Rights
Agent shall have no duty to act without such certificate as set forth in this Section&nbsp;20(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Rights Agent shall be
liable hereunder to the Company and any other Person only for its own gross negligence, bad faith or willful misconduct (which gross negligence, bad faith or willful misconduct must be determined by a final,
<FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction). Anything to the contrary notwithstanding, in no event shall the Rights Agent be liable for special, punitive, indirect, consequential or
incidental loss or damage of any kind whatsoever (including but not limited to lost profits or reputational harm), even if the Rights Agent has been advised of the likelihood of such loss or damage. Notwithstanding anything to the contrary herein,
any liability of the Rights Agent under this Agreement will be limited to the amount of fees (but not including reimbursed costs) paid by the Company to the Rights Agent during the twelve (12)&nbsp;months immediately preceding the event for which
recovery from the Rights Agent is being sought. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Rights Agent shall not be liable for or by reason of any of the statements
of fact or recitals contained in this Agreement or in the Right Certificates (except its countersignature thereof) or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company only.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Rights Agent shall not have any liability for or be under any responsibility in respect of the validity of this Agreement
or the execution and delivery hereof (except the due execution hereof by the Rights Agent) or in respect of the legality or validity or execution of any Right Certificate (except its countersignature thereof); nor shall it be liable or responsible
for any breach by the Company of any covenant or condition contained in this Agreement or in any Right Certificate; nor shall it be liable or responsible for any change in the exercisability of the Rights (including the Rights becoming null and void
pursuant to Section&nbsp;11(a)(ii) hereof) or any change or adjustment in the terms of the Rights (including the manner, method or amount thereof) provided for in Section&nbsp;3, Section&nbsp;11, Section&nbsp;13, Section&nbsp;23 or Section&nbsp;24
hereof, or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ascertaining of the existence of facts that would require any such calculation, change or adjustment (except with respect to the exercise of Rights evidenced by Right Certificates after receipt
of a certificate pursuant to Section&nbsp;12, upon which the Rights Agent may rely, hereof describing such change or adjustment, upon which the Rights Agent may conclusively rely); nor shall it by any act hereunder be deemed to make any
representation or warranty as to the authorization or reservation of any Preferred Shares to be issued pursuant to this Agreement or any Right Certificate or as to whether any Preferred Shares will, when issued, be validly authorized and issued,
fully paid and nonassessable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> The Rights Agent shall not be liable or responsible for any failure of the Company to comply with
any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including obligations under applicable regulation or law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any holder of
Rights with respect to any action or default by the Company, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon
the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> The Company will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and
delivered all such further and other acts, instruments and assurances as may reasonably be required or requested by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The Rights Agent is hereby authorized and directed to accept instructions with respect to the performance of its duties hereunder
from any person reasonably believed by the Rights Agent to be the Chief Executive Officer, the Chief Financial Officer and the General Counsel, and to apply to such officers for advice or instructions in connection with its duties, and such
instructions shall be full authorization and protection to the Rights Agent and the Rights Agent shall not be liable or responsible for or in respect of any action taken, suffered or omitted to be taken by it in accordance with instructions of any
such officer or for any delay in acting while waiting for those instructions. The Rights Agent shall be fully authorized and protected in relying upon the most recent instructions received by it from any such officer. Any application by the Rights
Agent for written instructions from the Company may, at the option of the Rights Agent, set forth in writing any action proposed to be taken, suffered or omitted to be taken by the Rights Agent under this Agreement and the date on or after which
such action shall be taken or suffered or such omission shall be effective. The Rights Agent shall not be liable for any action taken or suffered by or omission of or for any delay in acting while waiting for advice or instructions, the Rights Agent
in accordance with a proposal included in any such application on or after the date specified therein (which date shall not be less than five (5)&nbsp;Business Days after the date any officer of the Company actually receives such application, unless
any such officer shall have consented in writing to an earlier date) unless, prior to taking any such action (or the effective date in the case of an omission), the Rights Agent shall have received written instructions in response to such
application specifying the action to be taken, suffered or omitted to be taken. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> If, with respect to any Right Certificate surrendered to the Rights Agent for
exercise or transfer, the certificate contained in the form of assignment or the form of election to purchase set forth on the reverse thereof, as the case may be, has either not been completed, not executed or has been altered, the Rights Agent
shall not take any further action with respect to such requested exercise or transfer without first consulting with the Company; provided, however that Rights Agent shall not be liable for any delays arising from the duties under this
Section&nbsp;20(g). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> The Rights Agent and any stockholder, affiliate, director, officer or employee of the Rights Agent may buy,
sell or deal in any of the Rights or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as
though it were not Rights Agent under this Agreement. Nothing herein shall preclude the Rights Agent or any such stockholder, affiliate, director, officer, employee, agent or representative of the Rights Agent from acting in any other capacity for
the Company or for any other Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> The Rights Agent may execute and exercise any of the rights or powers hereby vested in it
or perform any duty hereunder either itself (through its directors, officers and employees) or by or through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for any act, omission, default, neglect or misconduct
of any such attorneys or agents or for any loss to the Company or any other Person resulting from any such act, omission, default, neglect or misconduct, absent gross negligence or bad faith in the selection and continued employment thereof (which
gross negligence or bad faith must be determined by a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial
liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it reasonably believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured
to it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> The Rights Agent shall have no responsibility to the Company, any holders of Rights or any other Person for interest or
earnings on any moneys held by the Rights Agent pursuant to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> The Rights Agent shall not be required to take
notice or be deemed to have notice of any event or condition hereunder, including any event or condition that may require action by the Rights Agent, unless the Rights Agent shall be specifically notified in writing of such event or condition by the
Company, and all notices or other instruments required by this Agreement to be delivered to the Rights Agent must, in order to be effective, be received by the Rights Agent as specified in Section&nbsp;26 hereof, and in the absence of such notice so
delivered, the Rights Agent may conclusively assume no such event or condition exists. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> The Rights Agent may rely on and be
fully authorized and protected in acting or failing to act upon (a)&nbsp;any Signature Guarantee or (b)&nbsp;any law, act, regulation or any interpretation of the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> In the event the Rights Agent believes any ambiguity or uncertainty exists
hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Rights Agent hereunder, the Rights Agent, may (upon notice to the Company of such ambiguity or uncertainty), in its sole
discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to Company, the holder of any Rights Certificate or any other Person for refraining from taking such action, unless the Rights Agent receives
written instructions signed by the Company which eliminates such ambiguity or uncertainty to the satisfaction of Rights Agent.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;21.</B><B> </B><B>C<SMALL>HANGE</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GENT</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Rights Agent or any successor Rights Agent may resign and be discharged from its duties under this Agreement upon thirty (30)&nbsp;days&#146; notice in
writing mailed to the Company and, in the event that the Rights Agent or one of its affiliates is not also the transfer agent for the Company, to each transfer agent for the Common Shares or Preferred Shares known to the Rights Agent by registered
or certified mail and the Company shall be responsible for sending any required notice. The Company may remove the Rights Agent or any successor Rights Agent, in each case, with or without cause, upon thirty (30)&nbsp;days&#146; notice in writing,
mailed to the Rights Agent or successor Rights Agent, as the case may be, and to each transfer agent for the Common Shares or Preferred Shares by registered or certified mail, and, if after the Distribution Date, to the holders of the Right
Certificates by first-class mail. If the Rights Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Rights Agent. If the Company shall fail to make such appointment within a
period of thirty (30)&nbsp;days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent or by the holder of a Right Certificate (which holder
shall, with such notice, submit such holder&#146;s Right Certificate for inspection by the Company), then the registered holder of any Right Certificate may apply to the court referenced in Section&nbsp;32 of this Agreement or, solely if such court
declines jurisdiction, any court of competent jurisdiction for the appointment of a new Rights Agent. Any successor Rights Agent, whether appointed by the Company or by such a court, shall be either (a)&nbsp;a Person organized and doing business
under the laws of the United States or of any state of the United States that is authorized under such laws to exercise corporate trust or stock transfer powers and is subject to supervision or examination by federal or state authority and that has,
along with its Affiliates, at the time of its appointment as Rights Agent a combined capital and surplus or net assets, on a consolidated basis, of at least $50&nbsp;million or (b)&nbsp;an Affiliate of such Person. After appointment, the successor
Rights Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Rights Agent without further act or deed; but the predecessor Rights Agent shall deliver and transfer to the successor
Rights Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed reasonably necessary for the purpose, but such predecessor Rights Agent shall not be required to make any additional
expenditure or assume any additional liability in connection with the foregoing. Not later than the effective date of any such appointment the Company shall file notice thereof in writing with the predecessor Rights Agent and each transfer agent for
the Common Shares or Preferred Shares, and, if after the Distribution Date, mail a notice thereof in writing to the registered holders of the Right Certificates. Failure to give any notice provided for in this Section&nbsp;21, however, or any defect
therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be. In the event that the transfer agency relationship in effect between the
Company and the Rights Agent terminates, the Rights Agent will be deemed to have resigned automatically and be discharged from its duties under this Agreement as of the effective date of such termination, and the Company shall be responsible for
sending any required notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;22.</B><B> </B><B>I<SMALL>SSUANCE</SMALL> <SMALL>OF</SMALL> N<SMALL>EW</SMALL>
R<SMALL>IGHT</SMALL> C<SMALL>ERTIFICATES</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any of the provisions of this Agreement or of the Rights to the
contrary, the Company may, at its option, issue new Right Certificates evidencing Rights in such form as may be approved by the Board to reflect any adjustment or change in the Purchase Price and the number or kind or class of shares or other
securities or property purchasable under the Right Certificates made in accordance with the provisions of this Agreement. In addition, in connection with the issuance or sale of Common Shares following the Distribution Date and prior to the earlier
of the Redemption Date and the Close of Business on the Final Expiration Date, the Company (a)&nbsp;shall with respect to Common Shares so issued or sold pursuant to the exercise of stock options or under any employee plan or arrangement in
existence prior to the Distribution Date, or upon the exercise, conversion or exchange of securities, notes or debentures issued by the Company and in existence prior to the Distribution Date, and (b)&nbsp;may, in any other case, if deemed necessary
or appropriate by the Board, issue Right Certificates representing the appropriate number of Rights in connection with such issuance or sale; <I>provided, however</I>, that (i)&nbsp;the Company shall not be obligated to issue any such Right
Certificates if, and to the extent that, the Company shall be advised by counsel that such issuance would create a significant risk of material adverse tax consequences to the Company or the Person to whom such Right Certificate would be issued, and
(ii)&nbsp;no Right Certificate shall be issued if, and to the extent that, appropriate adjustment shall otherwise have been made in lieu of the issuance thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;23.</B><B> </B><B>R<SMALL>EDEMPTION</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Neither the Company nor any of its Affiliates or Associates may redeem, acquire or purchase for value any Rights at any time in any
manner (i)&nbsp;other than that specifically set forth in this Section&nbsp;23 or in Section&nbsp;24 hereof, or (ii)&nbsp;other than in connection with the purchase of Common Shares prior to the Distribution Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may, at its option, at any time prior to the earlier of (A)&nbsp;such time as any Person becomes an Acquiring Person, and
(B)&nbsp;the Close of Business on the Final Expiration Date, redeem all but not less than all of the then outstanding Rights at a redemption price of $0.001 per Right (rounded up to the nearest whole $0.01 in the case of any holder whose holdings
are not in a multiple of ten), appropriately adjusted to reflect any stock split, stock dividend or similar transaction occurring after the Agreement Date (such redemption price being hereinafter referred to as the &#147;<B><I>Redemption
Price</I></B>&#148;), and the Company may, at its option, pay the Redemption Price in Common Shares (based on the &#147;current <FONT STYLE="white-space:nowrap">per-share</FONT> market price,&#148; as such term is defined in Section&nbsp;11(d)
hereof, of the Common Shares at the time of redemption), cash or any other form of consideration (or a mix of any of the foregoing) deemed appropriate by the Board. The redemption of the Rights by the Board may be made effective at such time, on
such basis and subject to such conditions as the Board in its sole discretion may establish. Notwithstanding anything contained in this Agreement to the contrary, the Rights shall not be exercisable pursuant to Section&nbsp;11(a)(ii) hereof prior to
the expiration or termination of the Company&#146;s right of redemption under this Section&nbsp;23(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Immediately upon the time of the effectiveness of the redemption of the Rights
pursuant to Section&nbsp;23(b) hereof or such earlier time as may be determined by the Board in the action ordering such redemption (although not earlier than the time of such action) (such time, the &#147;<B>Redemption Date</B>&#148;), and without
any further action and without any notice, the right to exercise the Rights will terminate and the only right thereafter of the holders of Rights shall be to receive the Redemption Price. The Company shall promptly give public notice of any such
redemption (with prompt written notice thereof to the Rights Agent; and until such written notice is received by the Rights Agent, the Rights Agent may presume conclusively that no such redemption has occurred); <I>provided, however</I>, that the
failure to give, or any defect in, any such notice shall not affect the validity of such redemption. Within ten (10)&nbsp;days after such action of the Board ordering the redemption of the Rights pursuant to Section&nbsp;23(b) hereof, the Company
shall mail a notice of redemption to all the holders of the then outstanding Rights at their last addresses as they appear upon the registry books of the Rights Agent or, prior to the Distribution Date, on the registry books of the transfer agent
for the Common Shares, <I>provided, however</I>, that failure to give, or any defect in, any such notice shall not affect the validity of such redemption. Any notice that is mailed in the manner herein provided shall be deemed given, whether or not
the holder receives the notice. Each such notice of redemption will state the method by which the payment of the Redemption Price will be made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Notwithstanding Section&nbsp;23(c) hereof, the Company may, at its option, discharge all of its obligations with respect to any
redemption of the Rights by (i)&nbsp;issuing a press release announcing the manner of redemption of the Rights (with prompt written notice thereof to the Rights Agent; and until such written notice is received by the Rights Agent, the Rights Agent
may presume conclusively that no such discharge has occurred) and (ii)&nbsp;mailing payment of the Redemption Price to the registered holders of the Rights at their last addresses as they appear on the registry books of the Rights Agent or, prior to
the Distribution Date, on the registry books of the transfer agent for the Common Shares, and upon such action, all outstanding Right Certificates shall be null and void without any further action by the Company. In the event the Company elects to
discharge all of its obligations with respect to any redemption of Rights by mailing payment of the Redemption Price to the registered holders of the Rights as set forth in the preceding sentence, the dollar amount sent to each such registered
holder representing the full Redemption Price to which such registered holder is entitled shall be rounded up to the nearest whole cent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;24.</B><B> </B><B>E<SMALL>XCHANGE</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may, at its option, at any time after any Person becomes an Acquiring Person, exchange all or part of the then outstanding
and exercisable Rights (which shall not include Rights that have become void pursuant to the provisions of Section&nbsp;11(a)(ii) hereof) for Common Shares at an exchange ratio of one Common Share per Right, appropriately adjusted to reflect any
stock split, stock dividend or similar transaction occurring after the Agreement Date (such exchange ratio being hereinafter referred to as the &#147;<B><I>Exchange Ratio</I></B>&#148;). Notwithstanding the foregoing, the Board shall not be
empowered to effect such exchange at any time after any Person (other than the categories of Persons described in Section&nbsp;1(c)(i)-(iv) hereof), together with all Affiliates and Associates of such Person, becomes the Beneficial Owner of 50% or
more of the Common Shares then outstanding. From and after the occurrence of an event specified in Section&nbsp;13(a) hereof, any Rights that theretofore have not been exchanged pursuant to this Section&nbsp;24(a) shall thereafter be exercisable
only in accordance with Section&nbsp;13 hereof and may not be exchanged pursuant to this Section&nbsp;24(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Subject to Section&nbsp;24(c), immediately upon the action of the Board ordering
the exchange of any Rights pursuant to Section&nbsp;24(a) hereof and without any further action and without any notice, the right to exercise such Rights shall terminate and the only right thereafter of a holder of such Rights shall be to receive
that number of Common Shares equal to the number of such Rights held by such holder multiplied by the Exchange Ratio. The Company shall promptly give public notice (with prompt written notice thereof to the Rights Agent) of any such exchange;
<I>provided, however,</I> that the failure to give, or any defect in, such notice shall not affect the validity of such exchange. The Company promptly shall mail a notice of any such exchange to all of the holders of such Rights at their last
addresses as they appear upon the registry books of the Rights Agent; <I>provided, however,</I> that the failure to give, or any defect in, such notice shall not affect the validity of such exchange. Any notice that is mailed in the manner herein
provided shall be deemed given, whether or not the holder receives the notice. Each such notice of exchange will state the method by which the exchange of the Common Shares for Rights will be effected and, in the event of any partial exchange, the
number of Rights that will be exchanged. Any partial exchange shall be effected pro rata based on the number of Rights (other than Rights that have become void pursuant to the provisions of Section&nbsp;11(a)(ii) hereof) held by each holder of
Rights. The Company may establish procedures to determine those Rights (and the Beneficial Owner or Owners thereof) that may not be exchanged pursuant to this Section&nbsp;24 because such Rights have become void pursuant to the provisions of
Section&nbsp;11(a)(ii) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In lieu of issuing Common Shares in accordance with Section&nbsp;24(a) hereof, the Company may,
if the Board determines that such action is necessary or appropriate and not contrary to the interests of the holders of Rights (other than Rights that have become null and void in accordance with Section&nbsp;11(a)(ii)), elect to (and, in the event
that there are not sufficient treasury shares and authorized but unissued Common Shares to permit any exchange of the Rights in accordance with Section&nbsp;24(a) hereof, the Company shall) take all such action as may be necessary to authorize,
issue or pay, upon the exchange of the Rights, cash, property, Common Shares, other securities or any combination thereof having an aggregate value equal to the value of the Common Shares that otherwise would have been issuable pursuant to
Section&nbsp;24(a) hereof, which aggregate value shall be determined based upon the advice of a nationally recognized investment banking firm selected by the Board. For purposes of the preceding sentence, the value of the Common Shares shall be
determined pursuant to Section&nbsp;11(d) hereof. Following the Distribution Date, the Board may suspend the exercisability of the Rights for a period of up to <FONT STYLE="white-space:nowrap">one-hundred</FONT> twenty (120)&nbsp;days following the
Distribution Date to the extent that the Board has not determined whether to exercise the right of exchange under this Section&nbsp;24(c). In the event of any such suspension, the Company shall issue a public announcement stating that the
exercisability of the Rights has been temporarily suspended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Company shall not be required to issue fractions of Common Shares or to
distribute certificates that evidence fractional Common Shares. In lieu of such fractional Common Shares, the Company shall pay to the registered holders of the Right Certificates with regard to which such fractional Common Shares would otherwise be
issuable an amount in cash equal to the same fraction of the current market value of a whole Common Share. For the purposes of this Section&nbsp;24(d), the current market value of a whole Common Share shall be the closing price of a Common Share (as
determined pursuant to the second sentence of Section&nbsp;11(d)(i) hereof) for the Trading Day immediately after the date of the first public announcement by the Company that an exchange is to be effected pursuant to this Section&nbsp;24. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Notwithstanding anything in this Section&nbsp;24 to the contrary, the exchange of the Rights may be effected at such time, on such
basis and with such conditions as the Board in its sole discretion may establish. Without limiting the foregoing, the Board may (i)&nbsp;in lieu of transferring cash, property, Common Shares, other securities or any combination thereof contemplated
by this Section&nbsp;24 to the Persons entitled thereto (the &#147;<B><I>Exchange Recipients</I></B>&#148;) in connection with the exchange, issue, transfer or deposit all such cash, property, Common Shares, other securities or any combination
thereof (the &#147;<B><I>Exchange Property</I></B>&#148;) to or into a trust or other Person that is not controlled by the Company or any of its Affiliates or Associates to hold such Exchange Property for the benefit of the Exchange Recipients
pursuant to an agreement in such form and on such terms as the Board shall approve (a &#147;<B><I>Trust Agreement</I></B>&#148;), (ii) permit such trust or other Person to exercise all of the rights that a stockholder of record would possess with
respect to any Common Shares deposited in such trust or other Person and (iii)&nbsp;impose such procedures as it determines to be appropriate to verify that the Exchange Recipients are not Acquiring Persons or Affiliates or Associates of Acquiring
Persons as of any time period or periods established by the Board. In such event, such trust or other Person shall use commercially reasonable efforts to distribute the Exchange Property (and any dividends or other distributions thereon following
the date of deposit into such trust or with such other Person) to the Exchange Recipients as promptly as practicable after its receipt of such property, and the Exchange Recipients shall thereafter be entitled to receive the Exchange Property only
from such trust or other Person in accordance with the terms and subject to the conditions set forth in the Trust Agreement. If the Board determines, before the Distribution Date, to effect an exchange in accordance with this Section&nbsp;24, the
Board may delay the occurrence of the Distribution Date to such time no later than twenty (20)&nbsp;calendar days after the Shares Acquisition Date as the Board determines to be advisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;25.</B><B> </B><B>N<SMALL>OTICE</SMALL> <SMALL>OF</SMALL> C<SMALL>ERTAIN</SMALL> E<SMALL>VENTS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case the Company shall after the Distribution Date propose (i)&nbsp;to pay any dividend payable in stock of any class to the holders of its Preferred
Shares or to make any other distribution to the holders of its Preferred Shares (other than a regular quarterly cash dividend), (ii) to offer to the holders of its Preferred Shares rights or warrants to subscribe for or to purchase any additional
Preferred Shares or shares of stock of any class or any other securities, rights or options, (iii)&nbsp;to effect any reclassification of its Preferred Shares (other than a reclassification involving only the subdivision of outstanding Preferred
Shares), (iv) to effect any share exchange, consolidation or merger into or with, or to effect any sale or other transfer (or to permit one or more of its Subsidiaries to effect any sale or other transfer), in one or more transactions, of 50% or
more of the assets or earning power of the Company and its Subsidiaries (taken as a whole), to any other Person or Persons (other than the Company or any of its Subsidiaries in one or more transactions each of which complies with Section&nbsp;11(m)
hereof), (v) to effect the liquidation, dissolution or winding up of the Company, or (vi)&nbsp;to declare or pay any dividend on the Common Shares payable in Common Shares or to effect a subdivision, combination or consolidation of the Common Shares
(by reclassification or otherwise than by payment of dividends in Common Shares), then, in each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such case, the Company shall give to the Rights Agent and (to the extent practicable) each holder of a Right Certificate, in accordance with Section&nbsp;26 hereof, a notice of such proposed
action, which shall specify the record date for the purpose of such stock dividend, or distribution of rights or warrants, or the date on which such reclassification, share exchange, consolidation, merger, sale, transfer, liquidation, dissolution,
or winding up is to take place and the date of participation therein by the holders of the Common Shares or the Preferred Shares, if any such date is to be fixed, and such notice shall be so given in the case of any action covered by clause
(i)&nbsp;or (ii) above at least ten (10)&nbsp;days prior to the record date for determining holders of the Preferred Shares for purposes of such action, and in the case of any such other action, at least ten (10)&nbsp;days prior to the date of the
taking of such proposed action or the date of participation therein by the holders of the Common Shares or the Preferred Shares, whichever shall be the earlier. In case any event set forth in Section&nbsp;11(a)(ii) hereof shall occur, then the
Company shall as soon as practicable thereafter give to each holder of a Right Certificate and to the Rights Agent, in accordance with Section&nbsp;26 hereof, a notice of the occurrence of such event, which notice shall describe such event and the
consequences of such event to holders of Rights under Section&nbsp;11(a)(ii) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;26.</B><B>
</B><B>N<SMALL>OTICES</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices or demands authorized by this Agreement to be given or made by the Rights Agent or by the
holder of any Right Certificate to or on the Company shall be sufficiently given or made only if sent in a manner authorized by the Company in writing or if sent by overnight delivery source or first-class mail, postage prepaid, addressed (until
another address is filed in writing with the Rights Agent) as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Tempest Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2000 Sierra Point Parkway, Suite 400 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Brisbane, CA 94005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:
Chief Executive Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Section&nbsp;21 hereof, any notice or demand authorized by this Agreement to be given or made by the
Company or by the holder of any Right Certificate to or on the Rights Agent shall be sufficiently given or made if in writing and sent by overnight delivery source or first-class mail, postage prepaid, addressed (until another address is filed in
writing with the Company) as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">6200 S. Quebec St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Greenwood
Village, CO 80111 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Carolyn Beer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices or demands authorized by this Agreement to be given or made by the Company or the Rights Agent to the holder of any Right Certificate shall be
sufficiently given or made if sent by first-class mail, postage prepaid, addressed to such holder at the address of such holder as shown on the registry books of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;27.</B><B> </B><B>S<SMALL>UPPLEMENTS</SMALL> <SMALL>AND</SMALL>
A<SMALL>MENDMENTS</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to this Section&nbsp;27, the Company may, and the Rights Agent shall, if directed by the Company,
from time to time supplement or amend this Agreement without the approval of any holders of Right Certificates or any other securities of the Company in order to cure any ambiguity, to correct or supplement any provision contained herein which may
be defective or inconsistent with any other provisions herein, or to make any other changes which the Company may deem necessary or desirable, any such supplement or amendment to be evidenced by a writing signed by the Company (provided that the
Company has delivered to the Rights Agent a certificate from the Chief Executive Officer, the Chief Financial Officer or the General Counsel of the Company that states that the proposed supplement or amendment complies with the terms of this
Agreement) and the Rights Agent; <I>provided</I>, <I>however</I>, that, from and after such time as any Person becomes an Acquiring Person, this Agreement shall not be amended or supplemented in any manner which would (a)&nbsp;adversely affect the
interests of the holders of Rights as such (other than holders of Rights that have become null and void in accordance with Section&nbsp;11(a)(ii)), (b) cause this Agreement to be again subject to amendment or waiver other than in accordance with
this sentence or (c)&nbsp;again cause the Rights to become subject to redemption. For the avoidance of doubt, the Company shall be entitled to adopt and implement such procedures and arrangements (including with third parties) as it may deem
necessary or desirable to facilitate the exercise, exchange, trading, issuance or distribution of the Rights (and Preferred Shares) as contemplated hereby and to ensure that an Acquiring Person does not obtain the benefits thereof, and amendments in
respect of the foregoing shall not be deemed to adversely affect the interests of the holders of Rights. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent and the Company. Upon the delivery of a
certificate from an appropriate officer of the Company that states that the proposed supplement or amendment is in compliance with the terms of this Section&nbsp;27, the Rights Agent shall execute such supplement or amendment. Notwithstanding
anything contained in this Agreement to the contrary, the Rights Agent may, but shall not be obligated to, enter into any supplement or amendment that affects the Rights Agent&#146;s own rights, duties, obligations or immunities under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;28.</B><B> </B><B>D<SMALL>ETERMINATION</SMALL> <SMALL>AND</SMALL> A<SMALL>CTIONS</SMALL> <SMALL>BY</SMALL>
<SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>, E<SMALL>TC</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board shall have the
exclusive power and authority to administer this Agreement and to exercise all rights and powers specifically granted to the Board, or the Company, or as may be necessary or advisable in the administration of this Agreement, including without
limitation, the right and power to (i)&nbsp;interpret the provisions of this Agreement, and (ii)&nbsp;make all determinations deemed necessary or advisable for the administration of this Agreement (including a determination to redeem or not redeem
the Rights or to amend the Agreement). Without limiting any of the rights and immunities of the Rights Agent, all such actions, calculations, interpretations and determinations (including, for purposes of clause (y)&nbsp;below, all omissions with
respect to the foregoing) that are done or made by the Board in good faith, shall (x)&nbsp;be final, conclusive and binding on the Rights Agent and the holders of the Rights, and (y)&nbsp;not subject the Board to any liability to the holders of the
Rights. The Rights Agent is entitled always to assume the Board acted in good faith and shall be fully protected and incur no liability in reliance thereon. Notwithstanding anything herein to the contrary, in no event shall a determination of the
Board that may adversely affect the rights of the Rights Agent under this Agreement be binding upon the Rights Agent without the express written consent of the Rights Agent, in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;29.</B><B> </B><B>S<SMALL>UCCESSORS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All the covenants and provisions of this Agreement by or for the benefit of the Company or the Rights Agent shall bind and inure to the benefit of their
respective successors and assigns hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;30.</B><B> </B><B>B<SMALL>ENEFITS</SMALL> <SMALL>OF</SMALL>
<SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this Agreement shall be construed to give to any Person other than the
Company, the Rights Agent and the registered holders of the Right Certificates (and, prior to the Distribution Date, the registered holders of Common Shares) any legal or equitable right, remedy or claim under this Agreement; but this Agreement
shall be for the sole and exclusive benefit of the Company, the Rights Agent and the registered holders of the Right Certificates (and, prior to the Distribution Date, the Common Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;31.</B><B> </B><B>S<SMALL>EVERABILITY</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other authority to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated; <I>provided,</I> <I>however,</I> that notwithstanding
anything in this Agreement to the contrary, if any such term, provision, covenant or restriction is held by such court or authority to be invalid, void or unenforceable and the Board determines in its good faith judgment that severing the invalid
language from this Agreement would adversely affect the purpose or effect of this Agreement, the right of redemption set forth in Section&nbsp;23 hereof shall be reinstated (if earlier expired) and (without regard to whether earlier expired) shall
not expire until the Close of Business on the tenth Business Day following the date of such determination by the Board. Notwithstanding any other term of this Agreement, if any such excluded term, provision, covenant or restriction shall materially
and adversely affect the rights, immunities, liabilities duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign upon 10 days&#146; prior written notice to the Company pursuant to the requirements of Section&nbsp;26.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;32.</B><B> </B><B>G<SMALL>OVERNING</SMALL> L<SMALL>AW</SMALL>; F<SMALL>ORUM</SMALL>
S<SMALL>ELECTION</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement, the Rights and each Right Certificate issued hereunder shall be deemed to be a contract made
under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts made and performed entirely within such State. To the fullest extent permitted by law,
any claim relating to or brought pursuant to this Agreement by any person (including any record or beneficial owner of Common Shares or Preferred Shares, any registered or beneficial owner of a Right, any Acquiring Person or the Rights Agent) shall
be brought solely and exclusively in the Court of Chancery of the State of Delaware (or, if such court does not have jurisdiction, the Superior Court of the State of Delaware, or, if such other court does not have jurisdiction, the United States
District Court for the District of Delaware). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;33.</B><B> </B><B>C<SMALL>OUNTERPARTS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such
counterparts shall together constitute but one and the same instrument. A signature to this Agreement transmitted electronically shall have the same authority, effect, and enforceability as an original signature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;34.</B><B> </B><B>D<SMALL>ESCRIPTIVE</SMALL>
H<SMALL>EADINGS</SMALL></B><SMALL></SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Descriptive headings of the several Sections of this Agreement are inserted for convenience only and shall not
control or affect the meaning or construction of any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;35.</B><B> </B><B>F<SMALL>ORCE</SMALL>
M<SMALL>AJEURE</SMALL></B><SMALL></SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained herein, the Rights Agent shall not be liable for any delays
or failures in performance or responsibility resulting from acts beyond its reasonable control including, without limitation, any act or provision or any present or future law or regulation or governmental authority, acts of God, epidemics,
pandemics terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor
difficulties, war, or military or civil unrest. The Rights Agent shall provide the Company notice as soon as practicable in the event that any such delay or failure in performance occurs and keep the Company apprised of material developments with
respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION</B><B></B><B>&nbsp;36.</B><B> </B><B>I<SMALL>NTERPRETIVE</SMALL> M<SMALL>ATTERS</SMALL></B><SMALL></SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, each of the Company and the Rights Agent agrees that: (a)&nbsp;whenever the context requires, the singular number shall
include the plural, and vice versa; (b)&nbsp;the word &#147;extent&#148; in the phrase &#147;to the extent&#148; means the degree to which a subject or other thing extends, and does not simply mean &#147;if&#148;; (c) where a word or phrase is
defined in this Agreement, each of its other grammatical forms has a corresponding meaning unless the context otherwise requires; (d)&nbsp;the word &#147;or&#148; shall be deemed to mean &#147;or&#148; unless the Company and the Rights Agent
determines the context requires otherwise; (e)&nbsp;the meaning assigned to each capitalized term defined and used in this Agreement is equally applicable to both the singular and the plural forms of such term, and words denoting any gender include
all genders; and (f)&nbsp;the words &#147;include&#148; and &#147;including,&#148; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#147;without limitation.&#148; </P>
<P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto have caused this Agreement to be duly executed as of the day and year
first above written. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>T<SMALL>EMPEST</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>OMPUTERSHARE</SMALL> T<SMALL>RUST</SMALL> C<SMALL>OMPANY</SMALL>, N.A., A<SMALL>S</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GENT</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Brady</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Patrick Hayes</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stephen Brady</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Patrick Hayes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Manager, Client Management</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Rights Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>CHEDULE</SMALL> A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>F<SMALL>EE</SMALL> S<SMALL>CHEDULE</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL> A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIVILEGES OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A
JUNIOR PARTICIPATING PREFERRED STOCK OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEMPEST THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, Stephen Brady, does hereby certify: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. That he is duly elected and acting Chief Executive Officer of Tempest Therapeutics, Inc., a Delaware corporation (the
&#147;<B><I>Corporation</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. That pursuant to the authority conferred upon the Board of Directors by the Restated
Certificate of Incorporation, as amended, of the said Corporation (the &#147;<B><I>Amended and Restated Certificate of Incorporation</I></B>&#148;), the said Board of Directors of the Corporation on October&nbsp;10, 2023 adopted the following
resolutions creating a series of 100,000 shares of Preferred Stock designated as Series A Junior Participating Preferred Stock: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, that pursuant to the authority vested in the Board of Directors of the corporation by the Amended and Restated
Certificate of Incorporation, the Board of Directors does hereby provide for the issue of a series of preferred stock of the Corporation (&#147;<B><I>Preferred Stock</I></B>&#148;) and does hereby fix and herein state and express the designations,
powers, preferences and relative and other special rights and the qualifications, limitations and restrictions of such series of Preferred Stock as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <B>Designation and Amount</B>. The shares of such series shall be designated as &#147;<B><I>Series A
Junior Participating Preferred Stock.</I></B>&#148; The Series A Junior Participating Preferred Stock shall have a par value of $0.001 per share, and the number of shares constituting such series shall be 100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <B>Proportional Adjustment</B>. In the event that the Corporation shall at any time after the issuance of
any share or shares of Series A Participating Preferred Stock (i)&nbsp;declare any dividend on the common stock, par value $0.001 per share, of the Corporation (&#147;<B><I>Common Stock</I></B>&#148;) payable in shares of Common Stock,
(ii)&nbsp;subdivide the outstanding Common Stock or (iii)&nbsp;combine the outstanding Common Stock into a smaller number of shares, then in each such case the Corporation shall simultaneously effect a proportional adjustment to the number of
outstanding shares of Series A Junior Participating Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <B>Dividends and
Distributions</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the prior and superior right of the holders of any shares of any series of Preferred Stock
ranking prior and superior to the shares of Series A Junior Participating Preferred Stock with respect to dividends, the holders of shares of Series A Junior Participating Preferred Stock shall be entitled to receive when, as and if declared by the
Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash on the last day of March, June, September and December in each year (each such date being referred to herein as a &#147;<B><I>Quarterly Dividend
Payment Date</I></B>&#148;), commencing on the first Quarterly Dividend Payment Date after the first issuance of a share or fraction of a share of Series A Junior Participating Preferred </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock, in an amount per share (rounded to the nearest cent) equal to 1,000 times the aggregate per share amount of all cash dividends, and 1,000 times the aggregate per share amount (payable in
kind) of all <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends or other distributions other than a dividend payable in shares of Common Stock or a subdivision of the outstanding shares of Common Stock (by reclassification or otherwise),
declared on the Common Stock since the immediately preceding Quarterly Dividend Payment Date, or, with respect to the first Quarterly Dividend Payment Date, since the first issuance of any share or fraction of a share of Series A Junior
Participating Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Corporation shall declare a dividend or distribution on the Series A Junior Participating
Preferred Stock as provided in paragraph (a)&nbsp;above immediately after it declares a dividend or distribution on the Common Stock (other than a dividend payable in shares of Common Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Dividends shall begin to accrue on outstanding shares of Series A Junior Participating Preferred Stock from the Quarterly Dividend
Payment Date next preceding the date of issue of such shares of Series A Junior Participating Preferred Stock, unless the date of issue of such shares is prior to the record date for the first Quarterly Dividend Payment Date, in which case dividends
on such shares shall begin to accrue from the date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the determination of holders of shares of Series A Junior
Participating Preferred Stock entitled to receive a quarterly dividend and before such Quarterly Dividend Payment Date, in either of which events such dividends shall begin to accrue from such Quarterly Dividend Payment Date. Accrued but unpaid
dividends shall not bear interest. Dividends paid on the shares of Series A Junior Participating Preferred Stock in an amount less than the total amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">share-by-share</FONT></FONT> basis among all such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of shares of Series A
Junior Participating Preferred Stock entitled to receive payment of a dividend or distribution declared thereon, which record date shall be no more than 30 days prior to the date fixed for the payment thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Voting Rights.</B> The holders of shares of Series A Junior Participating Preferred Stock shall have
the following voting rights: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Each share of Series A Junior Participating Preferred Stock shall entitle the holder thereof to
1,000 votes on all matters submitted to a vote of the stockholders of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Except as otherwise provided herein or
by law, the holders of shares of Series A Junior Participating Preferred Stock and the holders of shares of Common Stock shall vote together as one class on all matters submitted to a vote of stockholders of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Except as required by law, the holders of Series A Junior Participating Preferred Stock shall have no special voting rights and
their consent shall not be required (except to the extent that they are entitled to vote with holders of Common Stock as set forth herein) for taking any corporate action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <B>Certain Restrictions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Corporation shall not declare any dividend on, make any distribution on, or redeem or purchase or otherwise acquire for
consideration any shares of Common Stock after the first issuance of a share or fraction of a share of Series A Junior Participating Preferred Stock unless concurrently therewith it shall declare a dividend on the Series A Junior Participating
Preferred Stock as required by Section&nbsp;3 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Whenever quarterly dividends or other dividends or distributions payable
on the Series A Junior Participating Preferred Stock as provided in Section&nbsp;3 are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on shares of Series A Junior Participating Preferred
Stock outstanding shall have been paid in full, the Corporation shall not </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> declare or pay dividends on, make any other
distributions on, or redeem or purchase or otherwise acquire for consideration any shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Junior Participating Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> declare or pay dividends on, or make any other distributions on any shares of stock ranking on a parity (either as to dividends
or upon liquidation, dissolution or winding up) with the Series A Junior Participating Preferred Stock, except dividends paid ratably on the Series A Junior Participating Preferred Stock and all such parity stock on which dividends are payable or in
arrears in proportion to the total amounts to which the holders of all such shares are then entitled; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> redeem or purchase or
otherwise acquire for consideration shares of any stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Junior Participating Preferred Stock, provided that the Corporation may at any time
redeem, purchase or otherwise acquire shares of any such parity stock in exchange for shares of any stock of the Corporation ranking junior (either as to dividends or upon dissolution, liquidation or winding up) to the Series A Junior Participating
Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> purchase or otherwise acquire for consideration any shares of Series A Junior Participating Preferred
Stock, or any shares of stock ranking on a parity with the Series A Junior Participating Preferred Stock, except in accordance with a purchase offer made in writing or by publication (as determined by the Board of Directors) to all holders of such
shares upon such terms as the Board of Directors, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and classes, shall determine in good faith will result in fair and
equitable treatment among the respective series or classes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Corporation shall not permit any subsidiary of the Corporation
to purchase or otherwise acquire for consideration any shares of stock of the Corporation unless the Corporation could, under paragraph (a)&nbsp;of this Section&nbsp;5, purchase or otherwise acquire such shares at such time and in such manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B> <B>Reacquired Shares</B>. Any shares of Series A Junior
Participating Preferred Stock purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and canceled promptly after the acquisition thereof. All such shares shall upon their cancellation become authorized but
unissued shares of Preferred Stock and may be reissued as part of a new series of Preferred Stock to be created by resolution or resolutions of the Board of Directors, subject to the conditions and restrictions on issuance set forth herein and in
the Amended and Restated Certificate of Incorporation of the Corporation, as then amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B>
<B>Liquidation, Dissolution or Winding Up</B>. Upon any liquidation, dissolution or winding up of the Corporation, no distribution shall be made to the holders of shares of stock ranking junior (either as to dividends or upon liquidation,
dissolution or winding up) to the Series A Junior Participating Preferred Stock unless, prior thereto, the holders of shares of Series A Junior Participating Preferred Stock shall have received the greater of (a) $1,000 per share, plus an amount
equal to accrued and unpaid dividends and distributions thereon, whether or not declared, to the date of such payment and (b)&nbsp;an aggregate amount per share, subject to the provision for adjustment hereinafter set forth, equal to 1,000 times the
aggregate amount to be distributed per share to holders of shares of Common Stock plus an amount equal to any accrued and unpaid dividends on such shares of Series A Junior Participating Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Consolidation, Merger, etc</B>. In case the Corporation shall enter into any consolidation, merger,
combination or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or securities, cash and/or any other property, then in any such case the shares of Series A Junior Participating Preferred Stock shall
at the same time be similarly exchanged or changed in an amount per share equal to 1,000 times the aggregate amount of stock, securities, cash and/or any other property (payable in kind), as the case may be, into which or for which each share of
Common Stock is changed or exchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B> <B>No Redemption</B>. The shares of Series A Junior
Participating Preferred Stock shall not be redeemable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B> <B>Ranking</B>. The Series A Junior
Participating Preferred Stock shall rank junior to all other series of the Corporation&#146;s Preferred Stock as to the payment of dividends and the distribution of assets, unless the terms of any such series shall provide otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>Amendment</B>. The Amended and Restated Certificate of Incorporation of the Corporation shall not be
further amended in any manner which would materially alter or change the powers, preference or special rights of the Series A Junior Participating Preferred Stock so as to affect them adversely without the affirmative vote of the holders of a
majority of the outstanding shares of Series A Junior Participating Preferred Stock, voting separately as a series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>Fractional Shares</B>. Series A Junior Participating Preferred Stock may be issued in fractions of a
share which shall entitle the holder, in proportion to such holder&#146;s fractional shares, to exercise voting rights, receive dividends, participate in distributions and to have the benefit of all other rights of holders of Series A Junior
Participating Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED FURTHER</B>, that the President, Chief Executive Officer or Chief Financial
Officer and the Secretary of this corporation be, and they hereby are, authorized and directed to prepare and file a Certificate of Designation of Rights, Preferences and Privileges in accordance with the foregoing resolution and the provisions of
Delaware law and to take such actions as they may deem necessary or appropriate to carry out the intent of the foregoing resolution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further declare under penalty of perjury that the matters set forth in the foregoing Certificate of Designation are true and correct of my
own knowledge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executed at Brisbane, California on&#8195;&#8195;&#8195; , 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Tempest Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stephen Brady</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL> B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>F<SMALL>ORM</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHT</SMALL> C<SMALL>ERTIFICATE</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificate No. R-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&#8195;</U> Rights</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>NOT EXERCISABLE AFTER THE FINAL EXPIRATION DATE (AS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>DEFINED IN THE AGREEMENT) OR EARLIER IF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>REDEMPTION OR EXCHANGE OCCURS. THE RIGHTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>ARE SUBJECT TO REDEMPTION AT $0.001 PER RIGHT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>AND TO EXCHANGE ON THE TERMS SET FORTH </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>IN THE AGREEMENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Right Certificate </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tempest Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This certifies that [&#149;], or registered assigns, is the registered owner of the number of Rights set forth above, each of which entitles
the owner thereof, subject to the terms, provisions and conditions of the Rights Agreement, dated as of October&nbsp;10, 2023 (the &#147;<B><I>Agreement</I></B>&#148;), between Tempest Therapeutics, Inc., a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), and Computershare Trust Company, N.A., as rights agent (and any successor rights agents, the &#147;<B><I>Rights Agent</I></B>&#148;), to purchase from the Company at any time after the Distribution Date (as such
term is defined in the Agreement) and prior to the Final Expiration Date (as such term is defined in the Agreement), at the Rights Agent&#146;s office designated for such purpose, or at the office of its successor as Rights Agent, one <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of a fully paid <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company (the
&#147;<B><I>Preferred</I></B> <B><I>Shares</I></B>&#148;), at a purchase price of $25.00 per one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share (the &#147;<B><I>Purchase</I></B> <B><I>Price</I></B>&#148;), upon
presentation and surrender of this Right Certificate with the Form of Election to Purchase duly executed. The number of Rights evidenced by this Right Certificate (and the number of one <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a
Preferred Share which may be purchased upon exercise hereof) set forth above, and the Purchase Price set forth above, are the number and Purchase Price as of October 10, 2023, based on the Preferred Shares as constituted at such date. As provided in
the Agreement, the Purchase Price and the number of one <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a Preferred Share which may be purchased upon the exercise of the Rights evidenced by this Right Certificate are subject to
modification and adjustment upon the happening of certain events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the time any Person becomes an Acquiring Person, any
Rights beneficially owned by such Acquiring Person or an Associate or Affiliate of such Acquiring Person, or certain transferees thereof, shall become null and void without any further action and no holder of such Rights shall have any rights
whatsoever with respect to such Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Right Certificate is subject to all of the terms, provisions and conditions of the
Agreement, which terms, provisions and conditions are hereby incorporated herein by reference and made a part hereof and to which Agreement reference is hereby made for a full description of the rights, limitations of rights, obligations, duties and
immunities hereunder of the Rights Agent, the Company and the holders of the Right Certificates. Copies of the Agreement are on file at the principal executive offices of the Company and the offices of the Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Right Certificate, with or without other Right Certificates, upon surrender at the principal office of the Rights Agent, may be exchanged
for another Right Certificate or Right Certificates of like tenor and date evidencing Rights entitling the holder to purchase a like aggregate number of Preferred Shares as the Rights evidenced by the Right Certificate or Right Certificates
surrendered shall have entitled such holder to purchase. If this Right Certificate shall be exercised in part, the holder shall be entitled to receive upon surrender hereof another Right Certificate or Right Certificates for the number of whole
Rights not exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Agreement, the Rights evidenced by this Right Certificate (i)&nbsp;may be redeemed
by the Company at a redemption price of $0.001 per Right or (ii)&nbsp;may be exchanged in whole or in part for Preferred Shares or shares of the Company&#146;s Common Stock, par value $0.001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional Preferred Shares will be issued upon the exercise of any Right or Rights evidenced hereby (other than fractions which are
integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share, which may, at the election of the Company, be evidenced by depositary receipts), but, in lieu thereof, a cash payment will be made, as provided in
the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of this Right Certificate shall be entitled to vote or receive dividends or be deemed for any purpose the holder
of the Preferred Shares or of any other securities of the Company which may at any time be issuable on the exercise or exchange hereof, nor shall anything contained in the Agreement or herein be construed to confer upon the holder hereof, as such,
any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action, or to receive notice of
meetings or other actions affecting stockholders (except as provided in the Agreement), or to receive dividends or subscription rights, or otherwise, until the Right or Rights evidenced by this Right Certificate shall have been exercised or
exchanged as provided in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Right Certificate shall not be valid or obligatory for any purpose until it shall have been
countersigned by the Rights Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS the facsimile signature of the proper officers of the Company and its corporate
seal. Dated as of <U>&#8195;</U> , 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attest:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tempest Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Countersigned:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Computershare Trust Company, N.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Reverse Side of Right Certificate </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF ASSIGNMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be executed by the registered holder if such </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">holder desires to transfer the Right Certificate.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED <U>&#8195;</U><U>&#8195;</U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U><U>&#8195;</U> hereby sells, assigns and </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">transfers&nbsp;unto&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Please print name and address of transferee) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">this Right Certificate, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint
<U>&#8195;</U><U>&#8195;</U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U><U>&#8195;</U> Attorney, to transfer the within Right Certificate on the books of the <FONT STYLE="white-space:nowrap">within-named</FONT> Company, with full power of
substitution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature Guaranteed: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Signatures must be guaranteed by a member or participant in the Medallion Signature Guarantee Program at a guarantee level acceptable to the
Company&#146;s Transfer Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby certifies that the Rights evidenced by this Right Certificate are not beneficially
owned by an Acquiring Person or an Affiliate or Associate thereof (as defined in the Agreement) and are not issued with respect to a Derivative Position described in clause (iv)&nbsp;of the definition of Beneficial Owner (as such terms are defined
in the Agreement).&#8195; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form of Reverse Side of Right Certificate &#150; continued </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF ELECTION TO PURCHASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be executed if holder desires to exercise </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rights represented by the Right Certificate.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: [&#149;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby
irrevocably elects to exercise <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> Rights represented by this Right Certificate to purchase the Preferred Shares issuable upon the exercise of such Rights and requests that certificates for such
Preferred Shares be issued in the name of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please insert social security </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or other identifying number </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(P<SMALL>LEASE</SMALL>
<SMALL>PRINT</SMALL> <SMALL>NAME</SMALL> <SMALL>AND</SMALL> <SMALL>ADDRESS</SMALL>) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If such number of Rights shall not be all the Rights evidenced by this Right Certificate, a new Right Certificate for the balance remaining of such Rights
shall be registered in the name of and delivered to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please insert social security </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or other identifying number </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(P<SMALL>LEASE</SMALL>
<SMALL>PRINT</SMALL> <SMALL>NAME</SMALL> <SMALL>AND</SMALL> <SMALL>ADDRESS</SMALL>) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature Guaranteed: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Signatures must be guaranteed by a member or participant in the Medallion Signature Guarantee Program at a guarantee level acceptable to the
Company&#146;s Transfer Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby certifies that (1)&nbsp;the Rights evidenced by this Right Certificate are not
beneficially owned by an Acquiring Person or an Affiliate or Associate thereof (as defined in the Agreement) and are not issued with respect to a Derivative Position described in clause (iv)&nbsp;of the definition of Beneficial Owner (as such terms
are defined in the Agreement), (2)&nbsp;this Right Certificate is not being sold, assigned or transferred to or on behalf of any Acquiring Person or Affiliate or Associate thereof and (3)&nbsp;the undersigned did not acquire the Rights evidenced by
this Right Certificate from any Person who is or was an Acquiring Person or an Affiliate or Associate thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The signature in the Form of Assignment or Form of Election to Purchase, as the case may be, must conform to the name as written upon the face
of this Right Certificate in every particular, without alteration or enlargement or any change whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event the certification
set forth above in the Form of Assignment or the Form of Election to Purchase, as the case may be, is not completed, the Company and the Rights Agent will deem the Beneficial Owner of the Rights evidenced by this Right Certificate to be an Acquiring
Person or an Affiliate or Associate thereof (as defined in the Agreement) and such Assignment or Election to Purchase will not be honored. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL> C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>UMMARY</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL> <SMALL>TO</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>REFERRED</SMALL>
S<SMALL>HARES</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2023, the Board of Directors of <B>T<SMALL>EMPEST</SMALL> T<SMALL>HERAPEUTICS</SMALL>,
I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), declared a dividend of one preferred share purchase right (a &#147;<B><I>Right</I></B>&#148;) for each outstanding share of common stock, par value $0.001 per
share (the &#147;<B><I>Common Shares</I></B>&#148;), of the Company. The dividend is effective as of October&nbsp;23, 2023 (the &#147;<B><I>Record Date</I></B>&#148;) with respect to the stockholders of record as of the close of business on that
date. The Rights will also attach to new Common Shares issued after the Record Date. Each Right entitles the registered holder to purchase from the Company one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series&nbsp;A Junior
Participating Preferred Stock, par value $0.001 per share (the &#147;<B><I>Preferred Shares</I></B>&#148;), of the Company at a price of $25.00 per one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share (the
&#147;<B><I>Purchase Price</I></B>&#148;), subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement dated as of October&nbsp;10, 2023 (the &#147;<B><I>Rights Agreement</I></B>&#148;), between the Company and
Computershare Trust Company, N.A., as rights agent (and any successor rights agent, the &#147;<B><I>Rights Agent</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
general terms, the rights plan works by imposing a significant penalty upon any person or group that acquires beneficial ownership of 10% or more (15% in the case of passive institutional investors) of our outstanding Common Shares without the
approval of our Board, or, in the case of any person or group that already beneficially owns 10% or 15%, as applicable, of the Common Shares as of the first announcement of the Rights dividend, that acquires one or more additional Common Shares
after such first announcement. The Rights Agreement would not interfere with any merger or other business combination approved by our Board. For those interested in the specific terms of the Rights Agreement, we provide the following summary
description. Please note, however, that this description is only a summary, and is not complete, and should be read together with the entire Rights Agreement, which has been filed with the Securities and Exchange Commission as an exhibit to a
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated October&nbsp;11, 2023. A copy of the agreement is available free of charge from the Company upon request </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>ETACHMENT</SMALL> <SMALL>AND</SMALL> T<SMALL>RANSFER</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the Rights will trade with, and will be inseparable from, the Common Shares. New Rights will accompany any new Common Shares issued
after October&nbsp;10, 2023 until the expiration, exchange or redemption of the Rights. The Rights will not be exercisable until the earlier to occur of (i)&nbsp;ten (10) calendar days after a public announcement that a person or group of affiliated
or associated persons, has become an &#147;Acquiring Person&#148; (as such term is defined in the Rights Agreement) or (ii)&nbsp;ten (10) business days (or such later date as the Board may determine) following the commencement of, or announcement of
an intention to make, a tender offer or exchange offer which would result in the beneficial ownership by an Acquiring Person of 10% (15% in the case of a passive institutional investor) or more of the outstanding Common Shares (the earlier of such
dates being called the &#147;<B><I>Distribution Date</I></B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the Distribution Date, the Common Share certificates, or, in the case of
uncertificated shares, notations in the book-entry account system, will evidence the Rights, and any transfer of Common Shares will constitute a transfer of Rights. After that date, the Rights will separate from the Common Shares and be evidenced by
book-entry credits or by Right certificates that the Company will mail to all eligible holders of Common Shares. Any Rights held by an Acquiring Person are null and void and may not be exercised. In general, an &#147;Acquiring Person&#148; is a
person, the affiliates or associates of such person, or a group, which has acquired Beneficial Ownership of 10% (15% in the case of a passive institutional investor) or more of the outstanding Common Shares. Beneficial Ownership of the Common Shares
is generally determined consistent with the provisions of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Securities Exchange Act of 1934, as amended, which determines Beneficial Ownership of securities under the federal securities
laws, except that (i)&nbsp;any Common Shares beneficially owned by a third party with whom the Acquiring Person has any agreement, arrangement or understanding (whether or not in writing)&nbsp;(A) for the purpose of acquiring, holding or voting such
Common Shares or (B)&nbsp;to cooperate in obtaining, changing or influencing control of the Company and (ii)&nbsp;certain synthetic interests in the Common Shares obtained using derivative instruments, such as swap arrangements that do not carry
with them the right to control voting or disposition of the underlying securities, are in each case also considered Beneficial Ownership of the underlying Common Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>XERCISABILITY</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rights are not exercisable until the Distribution Date. The Rights will expire on October&nbsp;10, 2024 unless the Rights Pan Agreement is
extended by Stockholder Approval until October&nbsp;10, 2026 (the &#147;<B><I>Final Expiration Date</I></B>&#148;), unless the Rights are earlier redeemed or exchanged by the Company, in each case as described below. Until a Right is exercised, the
holder thereof, as such, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Price payable, and the number of Preferred Shares or other securities or property issuable or payable, upon exercise of the
Rights are subject to anti-dilution adjustments from time to time. The number of outstanding Rights and the number of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Preferred Share issuable upon exercise of each Right are also
subject to adjustment in the event of a stock split of the Common Shares or a stock dividend on the Common Shares payable in Common Shares, or subdivisions, consolidations or combinations of the Common Shares occurring, in any such case, prior to
the Distribution Date. With certain exceptions, no adjustment in the Purchase Price will be required until cumulative adjustments require an adjustment of at least one percent in such Purchase Price. No fractional Preferred Shares will be issued
(other than fractions which are integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a Preferred Share, which may, at the election of the Company, be evidenced by depositary receipts) and in lieu thereof, an
adjustment in cash will be made based on the market price of the Preferred Shares on the last trading day prior to the date of exercise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>ERMS</SMALL> <SMALL>OF</SMALL> P<SMALL>REFERRED</SMALL> S<SMALL>HARES</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preferred Shares purchasable upon exercise of the Rights will not be redeemable. Each Preferred Share will be entitled to a minimum
preferential quarterly dividend payment of $0.001 per share. In the event of liquidation, the holders of the Preferred Shares will be entitled to a minimum preferential liquidation payment of $1.00 per share, or an amount equal to the payment made
on one Common Share, whichever is greater. Each Preferred Share will have the same voting power as one Common Share. If Common Shares are exchanged via merger, consolidation, or a similar transaction, each Preferred Share will entitle its holder to
a per share payment equal to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the payment made on one Common Share. These rights are protected by customary anti-dilution provisions. Because of the nature of the Preferred Shares&#146; dividend, liquidation and voting
rights, the value of the one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> interest in a Preferred Share purchasable upon exercise of each Right should approximate the value of one Common Share. The Preferred Shares would rank junior to any
other series of the Company&#146;s preferred stock in the event such other preferred stock is issued by the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>RIGGER</SMALL>
<SMALL>OF</SMALL> F<SMALL>LIP</SMALL><FONT STYLE="white-space:nowrap">-I</FONT><SMALL>N</SMALL> <SMALL>AND</SMALL> F<SMALL>LIP</SMALL>-O<SMALL>VER</SMALL> R<SMALL>IGHTS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any person or group of affiliated or associated persons becomes an Acquiring Person, proper provision may be made so that
each holder of a Right, other than Rights beneficially owned by the Acquiring Person or any affiliate or associate thereof (which will thereafter be void), will thereafter have the right to receive upon exercise that number of Common Shares having a
market value of $50.00, based on the market price of the Common Shares prior to the acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company is
acquired in a merger or other business combination transaction or 50% or more of its consolidated assets or earning power are sold to an Acquiring Person, its affiliates or associates or certain other persons in which such persons have an interest,
proper provision will be made so that each such holder of a Right will thereafter have the right to receive, upon the exercise thereof at the then current exercise price of the Right, that number of shares of common stock of the acquiring company
with a market value of $50.00, based on the market price of the acquiring company&#146;s stock prior to such transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>EDEMPTION</SMALL>
<SMALL>AND</SMALL> E<SMALL>XCHANGE</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the earlier of (i)&nbsp;the
time a person becomes an Acquiring Person and (ii)&nbsp;the Final Expiration Date, the Board may redeem the Rights in whole, but not in part, at a price of $0.001 per Right (the &#147;<B><I>Redemption Price</I></B>&#148;). In general, the redemption
of the Rights may be made effective at such time on such basis with such conditions as the Board in its sole discretion may establish. Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the only right
of the holders of Rights will be to receive the Redemption Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after any person becomes an Acquiring Person and prior to
the acquisition by any person of 50% or more of the outstanding Common Shares, the Board may exchange the Rights (other than Rights owned by an Acquiring Person or its affiliates or associates, which will have become void), in whole or in part, at
an exchange ratio of one Common Share, or, under circumstances set forth in the Rights Agreement, cash, property or other securities of the Company, including fractions of a Preferred Share (or of a share of another class or series of the
Company&#146;s preferred stock), per Right (with a value equal to such Common Shares). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>MENDMENT</SMALL> <SMALL>OF</SMALL>
R<SMALL>IGHTS</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Distribution Date, the Rights Agreement and the terms of the Rights generally may be supplemented
or amended from time to time by the Company without the consent of the holders of the Rights. After the Distribution Date, the Rights Agreement may not be amended in any manner which would adversely affect the interests of the holders of the Rights
(other than those of an Acquiring Person, affiliates and associates of the Acquiring Person and certain transferees thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d547808dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g547808dsp16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tempest Releases New Data Demonstrating Superiority of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1120 Arm Across Multiple Study Endpoints in </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Randomized First-Line HCC Study </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab +
bevacizumab versus standard of care atezolizumab + bevacizumab in a global Phase 1b/2 study</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>30% confirmed ORR achieved in TPST-1120 arm compared to 13.3% for atezolizumab + bevacizumab in the control
arm, a substantial increase specific to the TPST-1120 arm compared to the previous data cut of 17.5% versus 10.3% in the control arm</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Results show a favorable PFS and OS hazard ratio for TPST-1120 arm versus atezolizumab + bevacizumab control
arm </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Biomarker data for the TPST-1120 arm demonstrate:</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>increased confirmed ORR of 43% and DCR of 100% in subpopulation of patients with a beta catenin mutation;
and</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>consistent confirmed ORR of 27% in <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative patients, as
compared to 7% in the atezolizumab + bevacizumab control arm </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>40% of patients on the TPST-1120 arm remain on treatment, as compared to 16.7% for atezolizumab + bevacizumab
control arm </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Company to host webcast conference call today at 8:30am ET </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brisbane, CA, October&nbsp;11, 2023 &#150;Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> therapeutics that combine both targeted and immune-mediated mechanisms, today announced new and updated
positive results from the planned data analysis of an ongoing global randomized Phase 1b/2 clinical study in which TPST-1120, Tempest&#146;s PPAR&#945; antagonist, shows clinical superiority in multiple study endpoints when combined with
atezolizumab and bevacizumab in a randomized comparison to atezolizumab and bevacizumab in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (&#147;HCC&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This comprehensive analysis of more mature clinical data shows an even greater benefit than the
earlier interim analysis of the TPST-1120 triplet therapy over standard of care alone, both for the entire study population and in subpopulations of patients, the latter of which was predicted by TPST-1120&#146;s proposed mechanism of action,&#148;
said Stephen Brady, president and chief executive officer of Tempest. &#147;First-line HCC remains an indication with substantial opportunity to improve patient outcomes and, based upon these data, we are excited about the opportunity to move
TPST-1120 into a pivotal study. Given these new data and the Phase 1 evidence of activity beyond HCC, we look forward to advancing discussions with potential partners who share our vision for TPST-1120.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These new data were provided by F. Hoffman <FONT STYLE="white-space:nowrap">La-Roche</FONT> (&#147;Roche&#148;) from a clinical collaboration pursuant to
which Roche managed the study operations for this multicenter trial. Tempest retains all product rights to TPST-1120. Data from 40 patients randomized to the TPST-1120 arm and 30 patients randomized to the control arm, with a median <FONT
STYLE="white-space:nowrap">follow-up</FONT> of 9.2 and 9.9 months, respectively, show: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Confirmed objective response rate (&#147;cORR&#148; or &#147;confirmed ORR&#148;) of 30% for the TPST-1120
triplet arm versus 13.3% for the atezolizumab + bevacizumab control arm; duration of response (&#147;DoR&#148;) has not yet been reached </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hazard ratio (&#147;HR&#148;) favors the TPST-1120 arm for key survival endpoints </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Progression free survival (&#147;PFS&#148;): median PFS of 7 mo (5.6 mo, 13.8 mo) for TPST-1120 arm versus 4.27
mo (2.8 mo, 7.3 mo) for the control arm; HR of 0.7 favors TPST-1120 arm and is not yet mature </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Overall survival (&#147;OS&#148;): median OS not reached for the TPST-1120 arm (10.84 mo, NE) versus 15.1 mo
(7.49 mo, NE) for the control arm; HR 0.59 favors TPST-1120 arm and is not yet mature </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New biomarker subpopulation findings are consistent with the mechanism of action of TPST-1120
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients with <FONT STYLE="white-space:nowrap">b-catenin</FONT> activating mutations (21% in this study (n=7))
showed a cORR of 43% and a disease control rate (&#147;DCR&#148;) of 100% in the TPST-1120 arm </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Distinct from the control arm, the TPST-1120 arm was consistently active across both <FONT
STYLE="white-space:nowrap">PD-L1</FONT> positive and <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumors, with a cORR of 27% in the TPST-1120 arm compared to 7% for the control arm in <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative
tumors </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40% of the patients in the TPST-1120 arm were on treatment (16/40) compared to 16.7% in the atezolizumab +
bevacizumab control arm (5/30) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">72.5% of the patients on the TPST-1120 arm were on study (29/40), compared to 46.7% on the atezolizumab +
bevacizumab control arm (14/30) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TPST-1120 remains well tolerated, with safety data comparable between the two arms </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The randomized arms were generally well balanced at baseline </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Secondary endpoints include DoR, PFS, and OS, which are not fully mature as of the data cut. In Roche&#146;s IMbrave150 Phase 3 trial, confirmed ORR benefit
correlated with overall survival (OS) benefit.<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enrollment began in fall of 2021 and the cutoff date
for these data was April&nbsp;20, 2023. Tempest expects the data set to be jointly presented by Roche and Tempest at a medical meeting at a later date. ORR was determined by RECIST v1.1, and confirmed responses included at least two scans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call&nbsp;&amp; Webcast Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tempest
will host a webcast conference call today, October&nbsp;11, 2023 at 8:30am ET. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To join the conference call via phone and participate in the live Q&amp;A
session, please <FONT STYLE="white-space:nowrap">pre-register</FONT> online <U>here</U> to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the
investor section of the Tempest website at&nbsp;<U>https://ir.tempesttx.com/</U>. The webcast will be available for replay for 30 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the
Randomized Clinical Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1b/2 global randomized HCC study is part of Roche&#146;s Morpheus program and evaluates TPST-1120 in combination
with atezolizumab and bevacizumab versus atezolizumab and bevacizumab, the standard of care, in patients with unresectable or metastatic HCC not previously treated with systemic therapy. The trial enrolled 70 patients to the TPST-1120 arm and
contemporaneous control arm at approximately 25 sites worldwide, including in the United States, Europe, and Asia, who received either the TPST-1120 combination or atezolizumab and bevacizumab with primary efficacy endpoint of objective response
rate, and key secondary endpoints including PFS and OS. Under the terms of the clinical collaboration agreement, Roche is managing the study operations for this global, multicenter trial and Tempest retains all product rights. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TPST-1120 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TPST-1120 is an oral, small molecule, selective PPAR&#945; antagonist wholly-owned by Tempest. Tempest&#146;s data suggest that TPST-1120 treats cancer by
targeting tumor cell metabolism directly, as well as by modulating immune suppressive cells and angiogenesis in the tumor microenvironment. In a Phase 1 clinical trial in patients with heavily-pretreated advanced solid tumors, TPST-1120 as
monotherapy and in combination with the <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor nivolumab demonstrated tumor reduction (including according to RECIST criteria), as well as biomarker modulation. TPST-1120 was well-tolerated both as a
monotherapy and in combination with nivolumab. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Hepatocellular Carcinoma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCC is an aggressive cancer with rising mortality and is projected to become the third leading cause of cancer death by 2030.<SUP
STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;Every year, more than 900,000 people worldwide are diagnosed with HCC.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;Incidence and mortality are highest in East Asia and are
increasing in parts of Europe and the US.<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> In the US, HCC represents the fastest-rising cause of cancer-related death.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nine out of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C infection,
<FONT STYLE="white-space:nowrap">non-alcoholic</FONT> fatty liver disease (NAFLD), <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis (NASH), alcohol-related liver disease (ALD) and cirrhosis resulting from these conditions.<SUP
STYLE="font-size:75%; vertical-align:top">6</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if diagnosed in the early stage, an estimated <FONT STYLE="white-space:nowrap">70-80%</FONT> of
people with early-stage HCC experience disease recurrence following surgery.<SUP STYLE="font-size:75%; vertical-align:top">7</SUP> Early recurrence is associated with poorer prognosis and shorter survival.<SUP
STYLE="font-size:75%; vertical-align:top">5,</SUP><SUP STYLE="font-size:75%; vertical-align:top">8</SUP> Tumor size, number of tumors, and portal vein invasion are associated with an increased risk of recurrence.<SUP
STYLE="font-size:75%; vertical-align:top">6</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Tempest Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the
potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company&#146;s two novel clinical programs,
TPST-1120 and TPST-1495, target PPAR&#945; and EP2/EP4, respectively, and are advancing through trials designed to study the agents as monotherapies and in combination with approved agents. Tempest is also developing an orally available inhibitor of
TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company&#146;s website at <U>www.tempesttx.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements (including within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended,
and Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) concerning Tempest Therapeutics, Inc. (&#147;Tempest Therapeutics&#148;). These statements may discuss goals, intentions, and expectations as to future
plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest
Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148;
&#147;would,&#148; &#147;could&#148;, &#147;expect,&#148; &#147;anticipate,&#148; &#147;plan,&#148; &#147;likely,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;intend,&#148; and other similar expressions. All statements
that are not historical facts are forward-looking statements, including any statements regarding the availability of data from clinical trials, the favorable results of clinical trials, the ability of the company or its collaborators to present such
data at certain conferences, and the ability of the company to advance discussions with potential partners to explore the development of TPST-1120. Forward-looking statements are based on information available to Tempest Therapeutics as of the date
hereof and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement.&nbsp;These and other risks are described in greater detail in the Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> filed by Tempest Therapeutics with the Securities and Exchange Commission on August&nbsp;10, 2023.&nbsp;Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or
update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest
Therapeutics&#146; views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in
reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sylvia Wheeler </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wheelhouse Life Science Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>swheeler@wheelhouselsa.com </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aljanae Reynolds </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wheelhouse Life Science Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>areynolds@wheelhouselsa.com
</U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If approved by the FDA </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ducreux, et. al.,&nbsp;Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the undexpected burden of thyroid, liver, and
pancreas cancers in the United States. <I>Cancer Res.</I> 74, 2913-2921 (2014). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">World Health Organization. Liver Cancer Factsheet. Globocan. 2020. Available at:
<FONT STYLE="white-space:nowrap">https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf.</FONT> Last accessed: April 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Llovet, J. M., Kelley, R. K., Villanueva, A., et al. Hepatocellular carcinoma. Nature Reviews Disease Primers.
2021, 7(1), 6. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office for Health Improvement&nbsp;&amp; Disparities. Liver disease profiles: November 2021 update. Available
at: https://www.gov.uk/government/statistics/liver-disease-profiles-november-2021-update/liver-disease-profiles-november-2021-update. Last accessed: April 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Hack SP, Spahn J, Chen M et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk
hepatocellular carcinoma after curative resection or ablation. Future Oncology. 2020 <FONT STYLE="white-space:nowrap">May;16(15):975-989.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Saito A, Toyoda H, Kobayashi M et al. Prediction of early recurrence of hepatocellular carcinoma after
resection using digital pathology images assessed by machine learning. Modern Pathology. 2021. 34, <FONT STYLE="white-space:nowrap">417-425.</FONT> </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>d547808dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g547808g1009212232581.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tempest Adopts Limited Duration Stockholder Rights Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BRISBANE, Calif., October&nbsp;11, 2023 &#151;Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing <FONT
STYLE="white-space:nowrap">first-in-class</FONT><SUP STYLE="font-size:75%; vertical-align:top">i</SUP> therapeutics that combine both targeted and immune-mediated mechanisms, today announced that its Board of Directors (the &#147;Board&#148;) has
adopted a limited duration stockholder rights plan, effective immediately (the &#147;Rights Plan&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen Brady, president and chief executive
officer of Tempest, stated: &#147;Today we announced exciting new randomized data in first-line HCC from our lead program, TPST-1120. Unfortunately, Tempest, like many other biotechnology companies, continues to experience a significant and ongoing
dislocation in the trading price of its common stock. We intend the Rights Plan to enable all of our stockholders to realize the long-term value of their investment. The Rights Plan should reduce the likelihood that any person or group gains control
of Tempest through open market accumulation without paying all stockholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of all
stockholders.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board did not adopt the Rights Plan in response to a specific takeover threat. In addition, the Rights Plan does not prevent the
Board from engaging with parties or accepting an acquisition proposal if the Board believes that it is in the best interests of Tempest and all of its stockholders. The Rights Plan is similar to other plans adopted by publicly held companies in
comparable circumstances, and does not contain any dead-hand, slow-hand, <FONT STYLE="white-space:nowrap">no-hand</FONT> or similar feature that limits the ability of a future Board to redeem the rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the adoption of the Rights Plan, the Board declared a dividend of one right for each outstanding share of the Company&#146;s common stock
as of the close of business on October&nbsp;23, 2023, the record date. The rights will be exercisable only if a person or group (an &#147;acquiring person&#148;) acquires or launches a tender or exchange offer to acquire beneficial ownership (which
includes certain synthetic equity interests) of 10% or more of the Company&#146;s outstanding common stock (15% for certain passive institutional investors as described in the Rights Plan). Any stockholders with beneficial ownership of the
Company&#146;s outstanding common stock above the applicable threshold as of the time of this announcement are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights Plan. Once
the rights become exercisable, each right will entitle its holder (other than the acquiring person, whose rights will become void) to purchase, for $25.00, additional shares of the Company&#146;s common stock having a market value of twice such
exercise price. In addition, the Rights Plan has customary flip-over and exchange features. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Rights Plan will expire on October&nbsp;10, 2024 or, if Tempest&#146;s stockholders approve the Rights
Plan, on October&nbsp;10, 2026, unless the rights are earlier redeemed by the Company. Additional information regarding the Rights Plan will be contained in a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed by the Company with the U.S.
Securities and Exchange Commission. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Tempest Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the
potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company&#146;s two clinical programs,
TPST-1120 and TPST-1495, target PPAR&#945; and the prostaglandin E2 receptors, EP2/EP4, respectively, and are advancing through trials designed to study the agents as monotherapies and in combination with approved agents. Tempest is also developing
an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company&#146;s website at www.tempesttx.com.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements (including within the meaning of Section&nbsp;21E of the Exchange Act, and Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;)) concerning Tempest Therapeutics, Inc. These
statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions
made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words
such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;would,&#148; &#147;could&#148;, &#147;expect,&#148; &#147;anticipate,&#148; &#147;plan,&#148; &#147;likely,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;project,&#148;
&#147;intend,&#148; and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding the timing of data releases from the TPST-1120 program and the impact of the adoption
on the Rights Plan. Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance. Factors that may cause actual results to differ from those expressed or
implied are discussed in greater detail in the &#147;Risk Factors&#148; section of the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2023 and other documents filed by the
Company from time to time with the Securities and Exchange Commission. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be
relied upon as representing Tempest Therapeutics&#146; views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any
forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor
Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sylvia Wheeler </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wheelhouse Life Science
Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>swheeler@wheelhouselsa.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aljanae
Reynolds </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wheelhouse Life Science Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>areynolds@wheelhouselsa.com </U></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><SUP STYLE="font-size:75%; vertical-align:top">i</SUP>&nbsp;If approved by the FDA</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tpst-20231010.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/11/2023 9:52:51 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:tpst="http://www.tempesttx.com/20231010"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.tempesttx.com/20231010"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tpst-20231010_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tpst-20231010_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>tpst-20231010_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/11/2023 9:52:51 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>tpst-20231010_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/11/2023 9:52:51 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tpst-20231010.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g547808dsp16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g547808dsp16.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MY]#EG>4K\SCY>@U3Y>WYY1M8,J>:XC&.RQ;MJCV KL52ZY?911%DOMR5CK/
MWB;5O!GB_0O&&BW4]IJ>@:M9:C%/#(Z8CCN$,\3*I V/"&4XYP:\;-L%"M1B
MY?N^5MKE2_EL:T,4\-*]/]XY6BU*^B^1_7!X9U4:WHFD:KC;_:.FV=^BCHBS
MP(W!/J6K\MQD5AZE6E#WE3DXW?6STOZ'O8>M*K&+<5&ZO9'0]Q['^5<<8<UI
MWLX]/0Z-AU:B"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M  =CWB,C:0.BLR?]\$K_ $K@-22@ H :P^5AT^4_AQ3CHUY,%)0M)Z*.K^1
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M:Z>9;SQK)"^R159=T;*<, 1GD5XU2+IMPFN5Q;379K1GH0JQK+F2\^GKT+I
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MOYDG\,>JO_./_P"':7@;_HH>O?\ @EM/_EG2_P"(G5?^@6/_ (-G_P#*BO\
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MT*OP=_9G^+/Q]\:1>+/B#;:OI?A^6\2\U76=>,B:EJ"QL$^QVT,R*_V?9&%
M*+@8^ITS'B' 8+ .C@Y14^62C&',GJ[K1QT5VST<ERO%5ZD9XM-JZNY.+V;7
M279(_<[PSH.F>&-#TOP_H]HEEIFCV-OI]E;HH0);VL2PQ\#H2J9/?GFOR.MB
MZF-Q%:O5^-SDM[[/3MLM#]"IT*6%HJE22C%6;25M;)/YZ&PX"A<#'S?XUQU/
MX]/R:_)&E'2F_)/\S\4/^"DA"?%/P0Q!8)X$A;:'\L\:WJV.?Z=Z_9N ,SGD
M^$J8RG#GE&4X6YN7XH16Z4MO0_+N+Z3JUG!?S+\*DCL/A#^P=X0^('PW\(^,
M+WQIK5A?^(M*AU*ZMX=+CNHEDF+%@)I+N, XP.0.E>%G/B'7AF&N&4=8?\O9
M_P D?^G1[.6934J8%;QNI:67\\EW2_$])7_@FMX)/'_"?ZZ,?]0:S[?]Q.M/
M^(F5(4H1>'CM%?Q9]K;>R,Z?#M5U)V<MY:6A_P#)DUO_ ,$V_!5O<07'_">:
MZ6MY+:Y13H]J XMF4QQ-_P 33I\H%>;B>)I5XN/U:,=;?')VTM_(;X7(JU&2
M=W:-FM(_I(_2#0M+&BZ-I>DK(TPTW3[.Q69U5'E%I!' )&168*S;,D!CC/4U
M\=BZOM)U)[.4G*R\VWU2/J\+1=&$8O[*2^Y6Z-FH..*XX4W[-2ZJ_P"!V,@G
MM8;E#'-&LJ,"&1U5E*GAE*MP01Q@BMZ%>5-\M[<NS]#CK8:-3I_7WGRE\2?V
M./@M\0I9KRXT,^']3F+$W^B,MHYE*%0\T.UEN5'78-O/.:^IR_BC'9:[QJ<R
MDK-7LY):VO9VUZV/+K</X;&*U2*CR:Q]V^NW22/B_P :_P#!-S6K>.6Y\">-
M+;4PH806FKV,FG3#/ !=7D5]HYW$CI7U."XUHUVEBXNFK:N3<EM?[,6]_(\/
M%\.2P]_JNMMDE%=;=9=CY"\3_#GX_?LZ:A%?WMKKOAU+297@UW1-1:?3KB:)
M@\6)8W:.V8LH(:50J]6X%?2T\;D.:T986DZ4Z^)3ITTH3OSS]V'Q1BD[M6NT
MEU:/FZD,XP4XU9<\:-!J4_>A;ECK+1-MZ+HFS]"?V0?VP-5\?:K;?#/XC313
MZ^Y>VT/Q);;EM=8>T1F\F[1E$@NI/+P9 FUB>P.:^&XAX;GEZE54+*'Q*T5H
MGRZ6F]M['UF1YQ]8Y8\V_F_Y;_RH_3C '?'_ -:OADK;*UC[%U8I;[>I(. /
M8?RI/3Y"3ND^X>GU_H:0S\C/^"FG_(3^&?\ UYZY_P"A1U^I>&_QXK_KY'_T
MU,_/N,?]^RW_ *]5?S1]5_L+?\F[^%O^OW5?_1L5?)\<_P#([7_<'\F?39%_
M 7S_ #1]A+]Y?H?Y5\C6_P!ZPWI/\CWI$]=! 4 % $<J@QLIZ$8ZXQ@COVJ*
MD>:$H[71,HQE%QEHGO;0\%^/?P/\-_'#P1?^%M9007RHT_A[5_*$DNF7HC^6
M6&0*QBW.%#D@_*.E=V6XNI@YQLDTM'==+)=UV..K@:35U*=U_>T_(_!;45^,
M_P"RW\0+GP[=:SK7A>[MYP^GWMO+,VB:];<8GL2X\G8>GE%5/&*_3,OG@,?2
MBL4DXR73ECNVNKNM$O0^7QWUS#MJE]G:ZD^B[>I][_"G]MWQ_/':VOBK2].U
M^ )#&;I,:9=E515WL(WN5>1L9))CR2>!T'FX_@[+X\]3 RK*4VY).IS15VW9
M1C!Z)625]#2CF^/481G&G[J2^!WT27<^S]%^.O@'Q/;(VK:#)"77,D=U8P7T
M:XX_UFY@XP/Z8&,#YS^Q,UH2M&\81VTJ>K_Y=V/6HYGS?Q(P7R7ZLORZS\ +
M]&&H:3X77<>?M/AZVC(!ZY9;5N,Y[U4L+FU*RC-O39.7ZQ1K/%8:I9RLFE;3
ME7ZF%/I?[*#?O+G3/A\,<YDLQ&P/?*K"*Q=#.']BJ_1?\$S]M@5\4DK=+Q_S
M,R;4_P!CG3 2P^'$!0@$"R,I'_ %MG/Z5/U+/G_"H57+II+;Y$/$9;'::3_Q
M1_S,R?XY?L<^&U)35O!$1@&X+;>&;F=@4Z;/^)203365Y]+^)3G#UC4_1,7U
MG!+X7>WG'_,ATS]LG]E;^T8])L/%.DV$LA41SCPS?6]LI8X7<T>FKC'TJ)9-
MF:3<E+W==%4Z>L5^8XXFG=);=-O\SZ^T?5M.UG3[;4]'O+#4--NT6:SO-/F2
M>&XA90RR*Z  '!SMSGMUKPU]:O\ O;+RM+]3WJ:@UHDK&J@4C>!]X YY&1C^
MZ>E$J47NVO1V*G[BT5K$R<+],_A1&*IKEBVTN[NS.+;2>B]!U44% !0 4 %
M!0!%M&3V_3I6=1VE#R3%3]US]4?@W_P4&X^.=QVQX9T;VZ0U^S\+\RX?J<G\
MM?\ +R/SS.J&'GF$*DW)2C*GLTEIMH?LE\#3_P 6G\!C^[X;TS\,VZU^79MS
MK,,3SZ/GEMH?995.,L)3C':"27](]7KS3TAK_=/X?SIJRWT2(J? _E^95*<.
M,X^0Y[8!';CK4<]&O*$+ZTI*:LUNG9=7W-:S7U>HGHG"2_\ )6?SN>.0#^UQ
MJ'R@AOB]HLN". \.NZ64X[#/6OW;!2I?V%3PB<E35"-M5?W?>6M^Z[;'Y1B%
M06,FFVK2?5']#UL#]GM^ /W,1XXQ\BU^%5:])5:J]F])R^S'N_,_4*2KJE3L
MX648VT>UE;H6 O\ G/3%9^WI+_EV]/[J_P S7]^NL-/)_P"0>7S_  C\3GC\
M:'6H\NSC;HK+\+E1NOBMS+MMY;BA2O<9]3[=*RA*G*:Y.:_G;MY$OVO3E7;1
MD<A.!R.&7IV -=CA%TY*5TDGY;(*%.<)RE.UN625K[_,_%C_ (*0_P#)4/"7
MMX8D_2Y>OUWPN5>&7X]4$G%2HWNF_P#G]V/SCB226,5NG-_[:?I+^R\"?V?_
M (9!>"- )^G^F7(K\TS=O^W,9[327-4O;3_EX^Y]GP[47U2"?=_^DP+O[0?P
MET[XO?#'6?"]U DNHK"VH:+,<*]OJMHK_9G5]I(0[Y%91C.\\U&69OB,MS"G
M&A*,:<FU*+5U;E;3LFM;O<QS_ T\3!RLU*-VDG;^3R\C^?SPW\//%/B#X@Z;
M\,HK>XDU>/7)=*N[%UGA&FI+.8=0O%1E*L94M897(QN2&W'\)+?O\LVPF$R>
M.,@XK$J*;OR6_A<VW,G\2[GQ<,LG6_=-2Y==N9>7\O9G]'GPN^'VC_#;P/H'
MA#1XECM=(LHHI"J>6L]\ WVN\92H/FRR$@L>JHGI7\^YQF%;,,?C,PJ-*KBV
MG)1^'W8QBK*[MI%7U>I^@95A88+ 8;#Q3M2BU[V_Q2>NB[GS+^WV!'^S[?ID
MG'B;13R<GF+4S^G2O<X%KULMS3VN%4>>I"<7SKF5IRI<UEI9Z*W8\[/*J=%P
MGHM-M-E-=SPG_@F2 -.^*F/^?OPW^D.J5]1XCX:,%E6-=U6QDL1[37W?W:H1
MCRJVFF^K/$X/HT*6(S1TG)N2P_-=I[>TM:VW4_5BORT^Z.?\6#_BEO$?)7_B
M1ZKR.",6,_3-;8?2O1MK:<;+YG/BVH8:LWM&)^ '[*-K:WO[2'A:VOK>"\MY
M=2U:.2&YB2:-PEW<[2R.""WX5^X<4U\13X6I<MHM+#ZI-?\ +MGP%"5&KC8K
ME6[Z+^8_?(^$/"N#_P 4YH@Q_P!0NR&,?]L*_#9X[%PP<K5I)*+]U2ER[]KG
MWTL%AYT%%PT2>FG?T+$/@_PM$5=/#^C*ZX97&F6*LIP/NLMN",4_K6(K4::G
M5E;ECIS2Z+3JR*6!PU*W+35UW2_R-V.U@A41Q1K'&OW8T541<=,*@ &*B,I1
M27,W;JW=G7:*7*HJ*\E;\AQ&UL#H1GGG&.*45%>3OL-14*<M]_T&')'IMY],
M8KFK*U:E;^9?DC&C4DH2M;1?YGXI_P#!23Y?BEX)( RO@2$<\C US5NWTK]F
MX G3I86I*K'FA%S5K)Z^SC;1Z'Y_GT9SQBVOOM_?;/TI_9;13\!OAH3G/_".
MVI&"1SEN/I7YQQ7C*<<UJ2ITURS]FDN6.EJ4%LGH?99'6J_58TY<B2YME_?D
M?08B4]B,>^.G2O'C5BZ:ERI)I:.*['M<W)M;[AH08.3@D <-C&.F/2N&.(PL
MG:,I_P#@4?\ Y(4VTER)+EVNB4$J.2 !^&*[(1IS2Y>9V_KS,$JS=O=T]1A;
M:"_\*KG ZD@XK2,6I>SV2+ES4X/O$Y34_&_A72=?L?#&HZW86FO:A#]HLM,F
MN(X+F:W#F,RQ^:R(5\P$8W;O136BP-6I%U*4'ZV;6^ND4SD6-C3GRS:5O3]6
M=(),M\TD2E2<!6ZXX&=R@GZC(]ZXDJZ;^LI<BMR\B:=^MVTNG8ZW-54EA9*4
MH_$G;;;[+?4E.",$ [NP).<>^1BFXT?[_P!Y"AB%U@N7NG_D<IXL\+^'_%&@
M:IH7B"PL]1TF\LKF"ZM[L*\:1R0NCE2PS&VTGYMP(KLRRK]2S#!XG"SJQKX>
MO2J4U>ZYX34HW2>NJ6ECAS:C5J97CX5(TXPEAZL92Y;/E<))M.VEEUT/YW_A
M+&^D_M$>"8=">0)8?$K3;6Q*.&-SID^N0P"W^0 ,!;,03@< U^YYCBJF89;.
MKFG)3JN$;N$>1*]F])7>_P#D?GV04*%&45!R=N\D_LL_I,B&8UW<$*,XXQQ7
MX).K..(=.%G!-=.E^Y^EPI0G!;KYEE1@ #H!Q^%:/?L:J*@E%;1T0>GU_H:0
MS\C/^"FG&I_#/VLM<_1HZ_6_#>@G@LUQ*O[2A6HJ/:TH23NK=GIJ?#<61HO%
MY?[2Z:IU;6:75=SZK_86_P"3>/"P]+W5?_1T5?#\6N=;-)SJ64H1@U;1>ZG;
M0]O)9QC2BH;:_FC[%"@$>V?TKYEP4Y4ZK^."=K;:Z/0^@;T]"2K)"@ H :X.
MTA2%/8D;@,>V136EO(F6D7Y$13&<,P&,;>-HZ]L5$GR;:6+IO3;^M#YI^-/@
MGX6_%58_AQ\2M/MK>\UBUE?PMJ\ICCG26 ^3/#:WKJOV>]20"1;8LP:.6%P^
M794]'!XVO0:=.326K2_K3Y?<<^)H49+WDK_\,?DI\5_V0_C;\ ;^?6O 8NO&
M_@NV=I8FT]-VJ)$K%EAOM,DD?+)'M5Y(IR&()"CI7V64\2N,XPK[1T5Y/HDE
MM#U/FJ^%Y')Q6EW;[_4Q_ O[5=KHA&D^./#E_I;Q 122Z<H=H9#RPN["[$36
MCJ3A@)9=Q!88# #Z[$9S@JE'W%'FL^LO1?8/,JQJP^&ZMZ'NL'QJ^&?B" ?8
M/%-I&\H_X][MC:RJQ[%)(2#@$<JQ&<CM7GX*='%>TE-)<LVEN]-&NB[G%*K6
M@K:KMJC@O%&H:==0E[/4-/G1MYW0WD3L01QE5Y'XU]3@<)@I6NH_<^[\SR,3
M7Q5GRMZ>:[(^5/$I"W<K_,P#'G?NCYZ?<<&OH(X;+L/!5>6.EEM);_-GE1KX
MWGWE97ZQ/-+]@7(V8'<C<,>^"YKAQ%7 I/EA'3_%V]#U,-7Q":NWIYK_ ".<
MG5 W!./]D[7_  <<BO"KU<-[R4(]>_\ D>[0KS2C=[6_K8_8O_@F+X^\0:WH
M_C?P%JES<76E^'FAO-(::21GM1+>/:-:!V+>6J/&<#GCL*_+,YP]+#J$J:2:
M;OITM=Z7U/N,%B%)VO\ U?T/UR12H /48Z# R!V&3BOEG*-]-+=#T):KT'J,
M#Z4K6^1$-(KR%H*"@ H * "@ H C/!^G'TKFQ#Y.5[67ZA#JO,_!O_@H2%3X
M[S1EMI;PQHY4MP"PA^51C)R?I7[-PGBZ=/):E.3M:-;O_D?G&=4JDL9'E3WA
MV_S1^R/P/79\*O HSD?\(UI6#TZ6RY_*OSC.IQGF.)<=N>5OOT/K,BISI82T
M]+\MMNS['J]>2>V-;A3^'Z&CEYM"9NT7Y%=^ ^WKY;8!X&<<<XK'#X6-&KS7
MO>RV\T^_D.NF\/.W2,O_ $EG\W_Q;UJ/P[^TMXM\0LJ7$6A?$1M4E@$AC>4:
M7?Z?=I&"8S@2M&4W ';UPW2OZ RW#T'EM*+GR\U**ORO2ZMM?H?D&+P]9XRH
MXIZ2?;_,^YHO^"E]A%%''_PK*Z/EHB9'B&,9V*%SSIOM7R,N :4Y2E]:E[S;
M_A+J[_\ /T^CAQ=.G&-/V2]Q*/\ $?16_P"??D2C_@IGIX_YIA=\?]3%$.G_
M '#*C_B']-?\Q;5O^G*_^6C_ -<)_P#/E:?]/'_\K ?\%,]/9U0?#"[4X9BS
M^(HDC"J">&&F$EN.F*J?AO2=!UOK+ERW5O8KHF]_;?H:4^)*U=J48<JVMS]O
M^W$?=WP&^+\/QL\ 6GCF+1GT2*\O+FT2S>[%YM^R[,LLXAB+9WC@QKCW[?"Y
MAE-/+,2Z,&FXZ[6?EI=KTU/H<#F4ZL4Y+MU]?[J/8WVI@C'S'!X8X 4MD!5/
M.5 YP.>O8^3.LZG-2BN7E3E>_1:;6/9]LYP=MTF_P/Q7_P""C[ ?%#P:I60;
M_"ETY8>2JKY=W&J@>;,A);SCV&-OOQ^U>%6.P^%R['PJM)RE0:6O_3[M%GYO
MGF'G4Q:=FK7TT\O,_2;]EF1E^ GPQRFT'P\NT/GDM?WBMGRPX! 0'K@[NHK\
MHSRI[;/<=*EHN>;7I[27>Q]7D4)4\/%;63?X1_*Q]#>1@*,YV[AG&,!CG&,_
M3\J\=QDZZJK[+_2QZ]:"J[^GY?Y''6WPZ\&V6O2>)[?PYHT6ORN99-6BL4CO
M3,RB-I#,'/)B55Z=L]Z]6MFN*EA/JOMINFMH<RMM9?9OH_/;0BCA:5/7E5UY
M>GF=K$I50"Q8C/S'&3DG'3T'%>12<^2$9[J]_O\ (ZI66B7*ELCXB_;]X^ -
M^,X/_"1Z,1G. %AU,GD ]*^RX8JQHX^,Y:1C"W_DT+=^Q\EGM.<J34;W^7]_
MS/"?^"9+'^S_ (I\#:;GPTR,#D,#%JHX_%:^I\0<;3Q6%R2--_PGBK[]?8VW
M2['F<&4:E*OFG/M)8>VW3VO9GZLU^8'WISWBW_D5?$?7C0]5Z<GBRFZ"ML,U
M"O2>RC)/[CCS!-X+$I;N#M;Y'X#?LDY'[3'A$ HW_$UU<[48F1/]*N,;T*@+
M^9K]FXJQU*KPM1C%J]L/W_Y]OR1^;X'#U88Z',G9-]OYO4_H/'0^U?AM3W\%
M*W6+M]Y^JP]VC&_1/\V6EX5?8#]!5TE:G37:,?R0A:L"-N"/IBN:<I1KPBM%
MR_JPE\#]2+@ ?I^%:U5:I!]G^21GAH^Z^W_!9^*G_!2C]W\5? ZG8JMX"B)R
MZ*P8>(-90KM)Q]Q4;J/OX]Z_7_#Q4\5&IA*CY5)U))V;VIQ>VFSTWZ'Q/$<)
M4JGM::UB[=OMR-'X6?M]6/PU\!^&/!4GP_N=3/A[3HM/6_BUV*$77EY_>M!]
M@?R<Y^Z)'^M9YKP/0QN/E)5[*7)9>RORVA%=:J['%@<[K8:,8\K7+_>\V_Y6
M>B_\/-+$?\TQN\#M_P )%$.G3_F&5S5O#VG0A%?79--15O8KT_Y_/8[Y<25M
M+1M;^_\ _:$8_P""FVG#I\+KOC_J8HN,?]PNG+PHP^'BY1Q#7+_TX737_H(9
M:XCQ#:37_DW_ -H?2_[.7[5UM^T%JNO:5#X1E\/?V%IEOJ#3G55U+SFGNWMQ
M"T:6<)A*HH?.6/S8QQD_*YKP_P#V-)1C5YE=K6*AL^72TI7V\CWLOS;VR7/&
MS7F^W^$^P(AB,8P021W  !X)# ']*^=YDY7V[?(]BI54T[=5;]#\C_VSO@'\
M:=2\<3_%/PQ/<^(],M-ALM/TOS8-7T1(W#*EG$DP%W&"-Y<R18)(\LXW'[7)
M,3@'"G2J2C&48I-2NME;M;?YGR69T<0G*5-/?I;OZGC/P^_;F^,WPU5-#\8:
M7'XHM[#$36WB!+K3->A5"%*2WJ6LJ.H48"^23GG<:^CQG#.69E&#H/V,XWYE
M".ENCLVDGTOVZ'A83.<9EDYRJ)RC-**O)*UM=U&1],6'_!2KPDUL)-1^'VNP
M7+*#Y%C?6]U"&';SYX;?"Y[[.G:O,_U"I],8U;_IRO\ Y=T._P#UPJ?\^EI_
MT\?_ ,K/"_B[_P % _%GCG1K[PQX!\/1>$_[0@FM'U&2^;5-1EBN$:(QQVT%
MK"()B&X82/@G.#W[\MX-PN!Q>&Q52M[58>K"H^:FDK0DI=*DK;>?H88GB>MC
M</6P:I\OUF$J2]^_QQ<=G!+KW7JCH/V(OV;?$E[XQT_XN>,-)NM+T31_,N_#
M]EJD9CU2_P!2:)A!>&V)(AACG99E9G);8!@9R.7C'.J$?:87#S7+=QDHMZ)3
M6C3CI=*VY.29=6IM.2:27E_*]M3]EU4JN.AQTZ8]*_+:<'"4JDGT_(_0J*Y(
M);6)5X ]A_*M;IZK;H4]V+_2@1^1/_!35T34_A@7.U#:ZNK,>B"2Y@AR?H7!
MQ7ZOX>XZGA,NS>G-I.=:@UOTC+LF?G_&-&I4QF7.%[1IU;[=UW9]5_L*@_\
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MAXR !G) Z],X]J %H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M5^<1I2CUV\S[U4U"VFW]=BST_#^E:K2WD5M\@H * "@ H * "@ H * "@ H
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MD\9Z]Z\WF?<[G)_</_I_2I$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H KW/W!_O"@!XZ"@""'_6'_@5 %R@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
% * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g547808g1009212232581.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g547808g1009212232581.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ <X# 2(  A$! Q$!_\0
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M"_T&Y.V^LW_Y8L?XU/8-W!XS]:YV/P_\._''[W2KEM)OWY,*,(SG_</!_P"
MUVPG%QO.-_,YY1=[19=L/B1K%V0'M[-<^BM_C6XWBC4FC!!A7([)7&W'PG\4
MZ:Q;2-;M[A1T64%&_4$54FTOXFV2[7TV.X4=XQ&_\B#5_N)?#8C]ZMSI-0\2
MZRRG%\Z?[@"_TK@=<U*_NF/VB^N91Z/*Q'Y9J>X_X3T@B7P[<?5;1C_(UDSZ
M5XNNF^?0;_/M9L*Z*<J4>QC.-21C2@ D@"JKUO+X.\73GC0-0Y]8=O\ .KL'
MPQ\97/\ S"#'[RSHO]:J=:'<<*<D<8P)Z"D\OC+=*]+M/@MXEGP;BXT^V'O(
MSG]!_6NN\._!FQTV]CO-6O3?M&0RP+'LCR.YY)/TKGE7IKJ;*$WT.O\  T%Q
M;>"=(AN@1*MLN0W4<<"NAI  !@# %+7G-W=SI6B"BBBD,**** #M7@?@C_DJ
M2_\ 76:O?.U>!^"/^2I+_P!=9J[<+_#J>AS5_CAZGOE%%%<1TA7@/C^5(/B5
M+,^0D<D3-@=A@FO?J\"\?1)-\2I(I!E))(E89Z@X%=N!M[1W['-BO@7J>AK\
M6/"H0#S[K@?\^[4O_"V?"O\ SWNO_ 9JF7X7>$RBDZ?)R/\ GX?_ !I?^%6^
M$_\ H'R?^!#_ .-3_LOF/]_Y&QX>\4Z9XGCFDTUY66%@K^9&5Y/UK:K(T+PS
MI?AN.:/3(&B64AGS(S9/XFM>N:?+S>YL;1YK>]N<?\3_ /D1+WZK_.N/^'>B
MP^(/ VL:=,/]9-\C?W6 X-=A\3O^1$O?JO\ .L3X,_\ ("U#_KX'\J[(-K"M
MKN<\DG72?8YOX=ZU-X8\4SZ%J)*13R>60W1)!T/XU[5<3Q6UO)/,X6.-2S,>
MP%>4_%KPVT4D7B*S4J00EQM['^%JR/$/Q#?5O!-IIL987LHV79'H/\:J=+ZP
MXU(==Q1J>RO"738JH+CXC_$'<=WV,-D^B0J?YFIOBM%';^*[2&)0L<=LBJH[
M &O0/AMX9_L+P^MQ.F+R\ D?(Y5>RUP7Q<_Y'*W_ .N"?SK6E44L1RQV2,YP
M:I<SW9[5IW_(+M/^N*?^@BK-5M._Y!=I_P!<4_\ 015FO+>YW+8\#\6?\E8?
M_KYB_I7O?>OGOQWYY^(]X+7=]H\U/+V]=V!C%:OD_%3^]J?_ 'W'7I5J/M(0
M]Y+3J<=.IR2EI?4]O)KP3XB:@GB'QNEM8GS1$%MU*\[GSSBK,NF?$_4(S;3G
M4C&_#!IT0$>Y!KKO WPV_L&X34]5>.6^4?NXDY2+WSW-9TXPP]YN2;Z6*FY5
MK12LCO-/M_LFG6UL>L42H?P&*RO&G_(FZM_U[/\ RK>K!\:?\B;JW_7L_P#*
MN.F[S7J=,M(L\D^&WBK2_#$M\^I/*HF50GEQENG7I7H'_"V?"O\ SWNO_ =J
MX+X9>&=*\237Z:I;M,(50IB1EQGKT->B?\*M\)?] ^3_ ,"'_P :[\3]7]J^
M>]SDH^UY%RVL0#XL>%20//NN?^G=J[:*198DD7[KJ&'T-<A_PJ[PF""-/DX_
MZ>'_ ,:[".-8HEC0850% ]A7%5]EI[._S.F'/]L6O!?'&@ZEX6\5R:Q:JXMI
M)_/AN$&0CYR5/ISZ]:][IDD<<T;1RHKHPPRL,@_A3H5G2E?<*M-5%8\NT?XR
M6S1)'K-A+')C#36WS*??:>1^M=EIGCGPUJK*EMJT D;I',3&W_CV*I:G\-/#
M&I,S_8#:R-U>U<I^G3]*XO6?@W=0QO+I&H+<XY$%PH5C[!AQ^8%;VPM3:\69
M7KP\SV($$ @@@]#2UX%X/\7ZIX6UN/3-0>4V/F^5-;S')A.<97TQZ=#7O@K"
MO0E2E9ZHUI5545Q:***Q-#P*W_Y+1_W%F_F:]]KP*W_Y+1_W%F_F:]]KMQGV
M/0YL-]KU"BBBN(Z0HHHH BN+>*ZMY+>>-9(9%*NCC(8'J#7@OC?X>7?A>X?4
M=,B>ZT<G<0.7M_8^J^_YU[_7-^)]6N/#GE:J8FN=,R(KV)1EHP>DB_R(]Q6U
M&I*$O=,ZD8R6IY+X7\77\6R*VU68 =(I'W#\ W]*])@\5:@L2F5(9#CG*D?R
MK$U7X;^&O&%N=4\/7:6<TGS$PC,1/^TG53],?2N/N_#?Q"\+9$:2WUJO1H?W
MZX_W3\PKJYZ53=69CRSAL]#TN3QU+ /GL$;_ '92/Z5EW?Q96UZZ,[?]O '_
M ++7F$GC6^C8Q7^GHD@X(^:,_D:S[O78;L9\ET/U!K6&'HO=&4JM5;'I-Q\:
MYESY.A)GMON3_1:SS\;M6652='LC&#RHD?)_'_ZU>:/<H_0-^50,P/2J>'H]
M$$:M3JSZD\*^*;'Q9HZW]F&0@[)8G^]&WH?\:W:\E^!UC<Q:=JEZZLMM/(JQ
M$]&*@Y(_/'X5ZU7EU(J,VD=L7=7"BBBH*"BBB@ HHHH .U>!^"/^2I+_ -=9
MJ]\/2O)O#'@;7],\=+JEU;1+:"21MRS*3@].*Z\/.,833>Z,*T6Y1MW/6:**
M*Y#<*\$\<_\ )4#_ -=H?YBO>Z\@\:^!/$>L>++C4=/MXFA;;L<SJIR!77@Y
M1C-\SMH<^(BW%61ZZG^K7Z"G5X?_ ,(7\1_^?JX_\&7_ ->C_A#/B/\ \_5Q
M_P"#+_Z]'U:'_/Q![:7\K/<**\:TSPC\0(-5M);FYG,"2JT@.H;OESSQGFO9
M!6-6FH.RE<UA-R6JL<A\3O\ D1+WZK_.L3X,_P#("U#_ *^!_*NH\<Z3>:WX
M5NK"PC5[B0KM5F"@X/J:R_AMX<U/PWI5W!J<*1R23!U"2!LC'M6L9Q^K.-];
MF3B_;)]+'77]C!J5A/9W*AH9D*,#[UY%X?\ A?J,'BQ6U*%?[,MY"ZR;P?-Q
M]T8SFO9J*RIUITTU'J:3I1FTWT$ P,#H*\-^+G_(Y6__ %P3^=>YUY9\0O!6
MN^(/$D5[IUO%) L2J2TP4Y!]#6N#G&-6\G8C$1<H61Z5IW_(+M/^N*?^@BK-
M064;0V-O$XPZ1JK#W J>N9[FRV/ _%G_ "5A_P#KYB_I7O=>3:_X&U^_\?MJ
MUO;1-9F='W&90<#&>*]9KJQ,XRC!)[(PHQ:E*_<*6BBN0Z K!\:?\B;JW_7L
M_P#*MZLGQ+8W&I>&]0LK50T\T+(@)P"2/6J@[239,OA9YM\%?^/G5?\ <3^M
M>OUX-:?#OQU8[C:+]G+#YO)O0N?K@U9_X0SXC_\ /U<?^#+_ .O7?7I4ZE1S
M4T<M*<H1Y>5GN%%>'_\ "%_$?_GZN/\ P9?_ %Z[KX?:/XBTB&^77Y9)&D93
M%ON/-P!G/?BN:I0C"-U-,VC5E)V<6CLY94AB>61@J(-S,3P!7%Z'\3M$U:^F
MM9Y!9,)"L#RMA)5SP<]B?0UVK(LB,CJ&5A@@C((KSGQ'\)-/U"1[C2)_L$S<
MF%EW1$^PZK^'Y5-%4G=5-!U.=:P/1E=74,A#*1D$'(-#LJ*68@*!DD]!7AR^
M!?'VBL5TZ:3RQT-K>[0?P)'\J)/!WQ$U@>5?2W!B/47-Z-OX@$Y_*MOJT-_:
M*Q'MY?R,RO&%Q#KWQ"G.F8E666.%&3H[# )'KS_*OH6)2D2J3DJH&:X7P7\-
MK;PY<+?WTRW>H*/DVKB.+Z9ZGWKO:G$U8RY80V0Z$)1O*6["BBBN4W/ K?\
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MZ-&WMH+2W2"WB2*&,;41%PJCT J6BBN,Z HHHH **** "BBB@ HHHH ****
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MX)Z';WB37-]>7<*G/DMM4-[$@9(KTJ*-(HUCC4*BC"J!@ 4VV=Y+6)Y%VNR
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140500330336128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001544227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 10,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tempest Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1472564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 Sierra Point Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">798-8589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TPST<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>d547808d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tpst-20231010.xsd" xlink:type="simple"/>
    <context id="duration_2023-10-10_to_2023-10-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2023-10-10</startDate>
            <endDate>2023-10-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-10-10_to_2023-10-10">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-10-10_to_2023-10-10"
      id="Hidden_dei_EntityCentralIndexKey">0001544227</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="duration_2023-10-10_to_2023-10-10"
      id="Hidden_dei_CurrentFiscalYearEndDate_duration_2023-10-10_to_2023-10-10">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="duration_2023-10-10_to_2023-10-10">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-10-10_to_2023-10-10">2023-10-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-10-10_to_2023-10-10">Tempest Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-10-10_to_2023-10-10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-10-10_to_2023-10-10">001-35890</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-10-10_to_2023-10-10">45-1472564</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-10-10_to_2023-10-10">2000 Sierra Point Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-10-10_to_2023-10-10">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-10-10_to_2023-10-10">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-10-10_to_2023-10-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-10-10_to_2023-10-10">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-10-10_to_2023-10-10">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-10-10_to_2023-10-10">798-8589</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-10-10_to_2023-10-10">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-10-10_to_2023-10-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-10-10_to_2023-10-10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-10-10_to_2023-10-10">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-10-10_to_2023-10-10">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-10-10_to_2023-10-10">TPST</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-10-10_to_2023-10-10">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-10-10_to_2023-10-10">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "N04M799!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ KD%+5YE<G",0!@
MG"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "N04M7@81J-H<$  #7$0  &               @($,"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ KD%+5Y^@&_"Q @
MX@P   T              ( !R0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "N04M7EXJ[',     3 @  "P              @ &E#P  7W)E;',O+G)E
M;'-02P$"% ,4    " "N04M7'#AEZC\!   \ @  #P              @ &.
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ KD%+5R0>FZ*M    ^ $
M !H              ( !^A$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ KD%+5V60>9(9 0  SP,  !,              ( !WQ(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  *10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d547808d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d547808d8k.htm">d547808d8k.htm</File>
    <File>tpst-20231010.xsd</File>
    <File>tpst-20231010_lab.xml</File>
    <File>tpst-20231010_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d547808d8k.htm": {
   "nsprefix": "tpst",
   "nsuri": "http://www.tempesttx.com/20231010",
   "dts": {
    "inline": {
     "local": [
      "d547808d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "tpst-20231010.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tpst-20231010_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tpst-20231010_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2022": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "report": {
    "R1": {
     "role": "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-10-10_to_2023-10-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d547808d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-10-10_to_2023-10-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d547808d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.tempesttx.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-23-253882-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-253882-xbrl.zip
M4$L#!!0    ( *Y!2U>@E8:?S2   *+%   .    9#4T-S@P.&0X:RYH=&WM
M/6ESXS:RW[=J_P/*V=FR7^FV/>-CQJ\\&D_BEQG;93NUN^]+"B(A"1F*9'A8
MUOOUK[L!D."APQ[Y2*)4$DLBCD:C[VZ [__[?N*Q.Q'%,O _;'5;G2TF?"=P
MI3_ZL)4FP^;!%OOOD[__[?TX@8;0V(^/7"$_;(V3)#QJM^\'D=>*A=,:!7=M
M>-#N=7J]+=TPC9O)+!1QUGK(XT$KB$9M\Z30W ]\/YUDC:?3:8N&QPYN$K6Q
M1QL:-:&5B*1C^MU[TO]6Z#;=I4[=P\/#-CTU32LMLPEZG<YN&Q\/>"Q,\R2,
MDT+S1$P ZB2Y;SG!!('?[7:ZG0R06-:! 4-WV__^^N7&&8L);TH_3KCO9).D
M2307I,,V/#4-91SL];KO%L"O6V0=[N>U[4);'U8K_OWQ^DO>/*EOGS=M)Q'W
MXV$037@"%(,C[3<[O6;OK35($^BA,)"ACV7C'#1WNQDN87*Y:*DE+.)3MT27
MNO';MGJHF\ZG%*3Q+2)VP5W\F\C$$R<'S9_?M]5'^&TB$LYPA*;X/95W'[;Z
M@9\(/VG> GEN,4=]^["5B/ND32.R-O9KZT$98^\'@3L[>>_*.Q8G,T]\V')E
M''I\ABP@MD[8>WE_A,U%I#]+UQ6^^@Q-+A3],Y]/L*^01Z<3X;OP7_+9XR,-
MQ'UR+8;P.(T(Q[\BM3:['?CWUR2POFV=#+D7B_?MPN"5R:3[8>LG@N-7F/'7
M,Q\P,NO#E!'WSGU7W/\L9EL62',:/!"T#O#._MY>K_?N@?#UTRA"?,C8X=Y_
M!(_.?/<33\2ORR>U%C%OE >OH]GL]H"ZJXMHE[8W$D,!4SHBAN\HCXYB$ALP
M$2-1=H1B\,-6+">AA]1/OXTCA /%5=,(I=9][)K'/'*B .EL9<GW!#+UY'V[
MN!Z]^L**Z7L<I)'Z2E+@2..:MG@%7)MN@B@P^RI=_&$H1<0(!%$KH_KG/Q>I
MKMP9H:X=/X0=#=SL*XBG*$%:.<EA,SWS9SFL[IRVYDDV;39/NX"=#)LY]MJV
M&&F#N($_EM#!7DWNR9%_Y,!:1+15?#Z5;C(^.FCM2__8:NN)87(\X=%(^DW\
M?,1XF@3FETB.QOHG'"XT@Z'D;XX%/04S(\R&2(+PR/HZ")(DF- O@R "T,TO
MW?">Q8$G7?9#A_[9.OGG#]VWG>/W[7#>1+O+)^H]>B)KV#T8A%47P(:P-<U8
M_I\XZAYDWX=\(KW9T:V<B)A=B"F[#B;</Z9G4P7W(/#<XYKM^>7B_/;L$[NY
M/;T]NYD/3N>9P+DYZ_]R?7Y[?G;#3B\^L;-_]W\ZO?CQC/4OOWX]O[DYO[SX
M+AA[ZX#Q7SP>@S&;!'Z#?6KU6ZS7V=\[+,%E3;H*918)8AE'U5+FVT=19JL#
MS8K$>:RXM-=]4UW]BER:+\8(B;H-ZSX757V^O/[*WL<A]S-!-):):,(OC@#E
M.8UX",IDGBGT*7!2M(0L<VQU-4VF7E%%OV\C*"<;BGD2BED+CX,4NCZ[N&77
M9U>7U[<O+W.NTBA.N9^P)& WPD&:4QCK[K(@8MW];7?GY:$,ABP9"P0PC60B
MH?_9O3/F_DBP4R=A\+A[N+LW'\YGVUXT?Q"<:Q$&4<*VS7<PQST .V'B#EJR
MB!X+=^=HOI]DA,,5V5"/-.:9\EL_;(&O>^3" !/H/G;Y; 80"7_KY-))@H&(
M])YW&@P[5^7*1J"L7Z#T]M9!<7/I1SFUUV(D8XQ@)!?PY,%*YE8%D=CM6( J
M$VDBG;C!SGVGM81&'B8D.NO Q/;9/0=A@!A EHNRE3,>LS@4#OI$+I,^DTG,
M0'P !T9EX;:A[3FT_3V(P? 4'WB".<+ST#:BD"U()_P><M<UW_5<>JU.X'D\
MC,61^;"81BR"0N-.8:/;Z;S1N#OJ:#"/.L;G0\ B]<<MNI*[>V\P"I"XI:=W
M(@(>X)[&KEIP;4L]3N\!XQB8Z[N4!X3_:=@CTR3D(]$<1()_P]"M=,41OPN
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MI6'GN#N]IU"HYSX#R@?UY\$XT21NU"]D&D3?8D21G(1!3+6>#+4"%<7#\U#
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MUE=&0 /JWKSX^>7K*1#&! ;-2GM)RIHOE86KPM_XZ-GAK#J[]/E()L#JC@I
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MDE@#TD!8H  /PP*MM(\@X)$S!U\AAW1HS!<X_B>N@ED+>80QK@3$R.1G9(-
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MP>4H#1=FQ27LD.F:NL@]ZB"07BT70GR4M39D-W&8']>]S(+\ZTQ$D(>IVNT
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MGS%,_>&.,!5\_J+[&URDCY3^'U!+ P04    " "N04M7??.(?);5  "ZL@0
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M[290+ /6A,^^%)/\G$]KHI+"MFBR@OW%7'=13Q/"O?%SJIRSM*)M);$<I2?
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M$LWXPJA61=)LQ$]W/[GIT"65Z=KXCI::3MU;-0JDP0!NO/VN::H Z,R4N+X
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M34%D&C)MV(:.%4&S1=*6>7(5:[#@[64XU=VDBS7UY2RD!7!71^,0I9YVIK&
M5IM3+!Q+&:BU21YQT^BK0V;#QG2A"Z-X#ZOSV8BY,9?4,QN9,9.:DUVQL O^
MB%0$D@_DM>'WL%ZMY;2Q<1!LA5M6HC_)_)3>A;6)YN=?\=[*&Q<=C<W$Y[D6
M,O"Q\6ZO*2'122W\V&>':LA;>(TTKG)S![J&TO"!:C4]CNEU2MNM\U,BNRM+
MD(U&E7"CTFQE\/4%MI627_.\FFG**M0>1+Z!1ZC"'(L+U^E%(%(6*=7S-KBP
M3=^N_UA?6.E@IROH,&PPQ&">G9S$ EQXR1(&7H=6T-RI$7925E>Q7V'XL'G
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MQ:K_O ?1<8V6_]V@W"]94^U'P#7A,^#BQAFF1/,1MP"W5;9^6Q:X@983N'[
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MFQ &&GKQ0H@54<Q4Q3"-W>=-CIP_5(IA-VQ&!UQ>E/1X(FN2SHM"2V(_C4<
MW:$F;C_&?06=N)7!5^5?"IXL@PL,R9-!*53:%.Z.,6;%1$)5T@7W:&C_%>!
MT&O"CV'GEHQCT,VWVCP+GN(<JQ^6C'TEQ*K.YAA(79#3.?5N#2HV61'#=L$J
MY@#GR@!!V,M&U@U</!\%V-TZV-2QK=W[QLY-[EK^2'4X3%TC;6UG'P_(TNS@
MLQ+2$JO]:.^:@H_<)\176=51;@3$I##V1D95VS(QUZZ)OM.D-X\.D(O#F=^/
M.S:,BQHC"=RX >4IMWE5KV3';^VR(]TF23^9MB7P4CLJ5-EM(Y.CH@KYI69=
M1H1 ZI9AV7Y?J?M-;NK<Z8]V!$B[%(Q@>ZMU")T'QW?^L&N:)+^S6$OZ=O?
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M;6:ME==)SZ;J2WBX[J$<\A&"4(#\C!.%'#0D^+=NU-4L9D!L*"#E_/?,LAF
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M"KU;HSO#ROE@427AQ-BCH[E6*W1]S'1[O2 )Q"TIE^Q11[4]7W._S(4UK&C
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MW2<)>?Y-/OHY>2]?/OGZV1F%5KM]DA=O-"#9OO\G+K2$>/HV?H@I#JV1WN*
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MQ&9K_\3^)'T5HD=&/5R[TA@;-+"3OI,$,(=XSH6R4X;A#("DT^Q95B/#GTS
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M?_Z_7!MS7C3 /C'B[HS04[=AP*G]4W55$EYC[A%^<C\(%Q!!/AW7_Y*SHA3
M;@B?1(^:VVZ'/G "$U.ICE11N,0"HW@,82>*%"$<TB0NSK'<IG_6?2P\$K=!
M/K^"^JA[8N?&GIJME\#,#K@],87]S^J%>1E_7SI@0:T>@Y&Q>>L.5HY0W@XB
M<57M_9W9 ?4 =!//-H.U0MY:@AG;!C3*8*IY'HDQ!@#?!-S&+IY A:Z[H^9N
MHW894JTX)R 6.S'NU*S@)?0>F:Q\8BH,'WJ>D@6IT#?3%+M8\( X'V$AA#@F
M/8&_75'K5K? 9BSZX2E6X!-CR?;6$LX2\[47D'5KS*3GED<-\850<G=-=41K
M$;$ASKN!C+D\YG:UIFM2P-+^MP^S?9H<I(29BCDE%I[QN:X?,-M.J_O'5V_V
M&/+E5O)VZZBF1SQ\X>D_YK<' SZ&L;3&"YB[[2UN>^X(G1NLRAV)#"SX.'@:
MQ\;@WU?FP)KO]2>45X1S+H/P>UI2MKHE3W-,P0T%?QM]VTZ;?OD6*]GHI?1J
M;%0:DG.6#BN,P$2;2"1)OMO6 C)".W=<\LCWJ.Q,9H*)#O\GGE1/1*"GP/KC
M2/V"P6/FPE)14W#;$H#N)3VOPI>ALTZ;1,9]_PO>.KO+UGN.M!.\YKX67.>\
M9%B=(+IV>VM:C1Q?(FH4!U*T[[O(9K,<.S>;%PZ92X (LQX_2_$>E!..U"HB
M+JVX3HZ-!K5P<$0W]A#"CO(/_P;'\7I[BU>,LM5#0FF 18)+A\<C_"$57YGS
MTE3#@MG1>D9-3 J-&6V_#E ?O&((\H-$7MYJ\\P ]G(!U>+0$!H<>$%JP,PL
M[F1H=ZH4E*=]N]AABKW=_)2L@NTMA=$/:2K5KY]NHGW_.5)Y[RY#6X 4C;;5
M$>,QOHG)OKVEQ"OC7%?]$H06Y]@+"]=RU$Q8=B$@*BKH&''C@CFK)<EKTPM=
M@VGWN\+VR\!?(UX;C3.P&8=U,?,J"3DQKYM:F#_)Q]7 [)HTOA@MYEP8N+U5
M3*?&-+/-KQ?.E,@#P]*SOML\4?8'>F_,W3VH9@I+Z.:)%F+)J(,YHP#,6AKC
M<,)F"&0PR.YM0O-/!A#\68]X XBM^ %E#MZJMN*3,$CMU4JEK%1LNM;".#>@
MO4&LG2V =WL+CTS9\3884'L(\.A)\1M<GI)9X[$$@36Y8[%CYUD84(653?EL
M&3W(X9^=?1*SB+K-ALC!B@]^>\LN'958B=*Q!%@*C:;'NI<<=EK/CHJ>;1RA
M[)WK<I3EC/7!MEH)<+.M$=Y#MXY7YN6YM1T $6H'^?AF4*NM@<+T)!$K]B8^
MA73:L(5Q /B!(V[K %U8 /]*X'#EUSF'DAY?80</_[$.[X\5#Y5P6I#<AN5O
M'5R/HT"-1+Q\K]'($@=W ]+JJ-)(S-;,L!C<(4*CICXLN5W.UGZR]M*\TPY4
M2GK/O,GH(&-PG-=F#-#2I)A-:#'OV?U.G0]CPS*Y^,'^WJ5X%O2Q'.6SJBD0
M>H=7>C9O(!:WF"/@=5+D"V<^9U3*(4!X64;0X6E WQ0X=X]_98^TP;Y2_H4L
M@ABD#<"YR+F0)W0]R68IKR6@I>3E]A:O>>Q&\<F28@0ID@F- .>4ZF@@'UDA
M _:/K*MO262_RDJ$MWF$60.CT(RA!^Y1)*0'3Q ;+R<G'LO2 &&(S0.5BTH+
M:X\%!0U3ZJSD66U,T.:H,,.)\BI25QA9?=$&^A"/7+\3'@F5 LRQJD]3<'K$
MF[Q\TSR?LSZG,5,D]!SM,+)>X!>6D-*6E?E<D/([.1M&+17<5(K?H(C2+)@3
M*P,0?Z]')NR6 >U9&&;U7^@=1J!WL,:R-8=537G*M&C.SHC)LF[=%#*7.3,!
M(.1.I2R;PN/?_ Y?RBN%,IJJH/I[\AXJ(_["&TUK9WD [3) 5>$"'$EJDNH9
M<IZ!_A3]^F?.T'L]BW\[/#OJGYX28CD;8OTEE&%*DW>6AE0+R2Y0'74)(3=B
MQ9'Q!O)LLH=)&\F_!>@.#1-._K?#@NZ*"GIYQP?<%:-\UPF\_G%SL*:>T<O-
M? VD[PH Z,8?X*&UET&U'QRF_9C?^08AX4\'&+[1\_YOMI;?&E)]Q<H=9=/\
M&Q!Z]SB,)[8!9^#1?P,[<)_C>&);<*#]I&]@*^YQ$Z)@Z<<TKI_K[>Y8;[<2
M!?A<;_=L"MRQ:,UIWR<S9*6N0D'W!,-9S[2I]UW QCC+DQPI;I)3I"P:1^*M
M&RH&^,O77]Y_.?F<?'F?]$Y/S5^A1B*!D-@F!K1S5G%^G8K].5:L4/Z<%BD8
M57:+@I*[C(_?#DAM2%!!?IMQ<W%PPM[NXR=SS7:"B/K:3T[Z!_U#X"+Q8YU=
M_UKC?]H_E]1NDT\FP'!.]1D8@GW@O?E%EKXA26ELYXK^R[ST)I-Z_I];_P^H
MB:^_+$E9/<0EW#F>Y(S4+^=)F3%U>38:U< =!\D "V:]W?V[V3'L@'K99HC4
MH6#"Q&GF#TB517S(U%.7\JQ%27CT495;O%]1U_EE-<06+@XH3O.=S:H"F&<?
M\G;WS*+497Z=MF0=S JZMK412Y31'%35;S8SLQ*]04][ 9LY$NR&]2YP 1'N
MB,1TF#^&9"XNQFW[<]YHCS%QU.J<^K\R.?3==W=U:.^:77JSN>3,'1R%^W$E
M)T69O[C(X=+]M+_W<M6I@V.YPK6\E:.Q?^,;="HY7-\KC<:%[OWZVI<G'Q:9
M$6+S7&[SHUIF=AA-,H7PB;%TS^UXP-;-DFE.@,[:,1N6<P&)?,Y'1HT >B4R
MH>2XKL[K;$K 1_O<9&(\#^SRE\^X;TM%4/< GG@FPETC,AX5AL+\9@P38048
MU 7?HJ*(("RNE@:IS'B]VS4X4DKCJF=J55?#>"AN'K2L>E3>S)C)L*@%"G/K
MXI+838\K[C!!:/X!/70XR18- %XO=;N7G-Y;",[KK9U9\@6KEKV:5"I/X)$"
MO#(8ZIZPI-V?9GO2Y&BH93>E7/Y7B/FG2S;US)5ZGZNY?F#,**@W+W]&)&Y1
M@BS=;)2L_ZE_@ PL9U^2XZ\G!Q][I_UO)EY6"(NQ#E%9S/,C!\M83]<YEZHO
M*>*Y99SL9@9&]9.E%?E&K!NCD95_C_#M8,=NZKXG78L>-8]TC584@6_A\]&:
M#UW72\V@_K7(FSF;:L.P8(G(-UKO\*C&L:@)(CK5N.5NW_N)X#B2T>-FJ G:
M>!,I,KA^\/"E!;XC'W0QO@8CE NZ[L\<TS/X1JR*^Q#(.\=,[_>I;^2O,/N9
MR=)_')\<'IV%C(%'O<_]\+/>T;O61^_>G?1/3^7C79N9><(;XL:[\B5+AGOO
M%_"094B;K4D7'\!_WLSO2[DW7EOB2:G,()L@*7F=3[-"V".4/,,F!](JT":?
M? %%P=I\8ERX&DMIGB76D[T@SQ+KV]V0>P_A;S_3P#]'.IXC'<^TV@^C)I^S
M#?\NV8:=?0Z]WR[ML+T5Y_#Z]T\[;&^IO$.L3'OGE5W9+B8GLOZQ#KR:C 1:
M1*TI!8E =C<6)D,9OC'9QT(9$%OA%<N+S71?JRW7)V14C'!(W'>\RR,!(H?H
MC,9$#6=YX*XN*I@E5--G43:XM8[$?1:L/MLSS_;,OZ4]\_VS/7/OZ9"C+V>'
M!W=+?-Q9@3M> -8PDE3JH:H0EI9E7+?QWLEH+P&+"_R22:P(9]@D5S4PIY0N
M(C[.ACESV,15&=*1UM=L8RTF69TZ^DSHOFK[;>>E^>.YI9=!2A6BJ''\F(]O
M*QURY/\2F5Y@K>SL"F B#LAREV_&*O+ACF;69 X,C1$YR8T?'^<@U)0BQ+:$
MS0#A3RU[Y>;LM-347BOJ[:W[-=Z(I=5;KB@_,TZ-@Z,756DDT.CI,JC\^5DX
MWZ]P[NCA=+"I"I-3'L_7SY][)_]8LXW3:?B]LR_V$PFD<O*]]?E)_WW_Y*3_
MSL5890@?>R?]TU8;J,>4I5_*>.,'$FAOJZP>85-.Q]XU!B[X,VEF]?FX?^KV
M5#[^V#_I'?>_&HUL9Y=N;QU*%/E /MRC;K1+ND(DZS2%X':DQMNT!%M"TS>S
MV5VJ$[7I96(LV\G:31^"QV.*AIISA*V\D>&;6!2;;A9%Z4\=FPX2,,:[ /@<
M0L1Z;V=G%$).M&27>:Q_!VQ@O'_'20X-<)%Y*)QHZ)S#3SW*,V#MI9]G%DD_
MG%24?!\L&J-*H-ZAQ&#%]A:1QI\YK89Z(IM S_7Y'%;4O 328MY"2*C ,9:K
M(>\E_4QR8K9'2D=)UM(F'7>E< SZ2-"JK]F>>QG99J050X!/6'%0N'O$(S6-
M"/I<>.3_K8%J*FQ+G,\'6]%&H_6$6%'?)D(V?MU&.&MUM+E-0YOP&9U];0(+
MCT*(]]N'YD9M:#9A>&]OF8'D0(C*/.2**G(V,3;G557_UH#16DR!E]0<_@S=
M(C1:S0)(KVC+ #FS%NMY72UF%.?DF);N.4 ]D)J+8@9[N__R/^$GTPK.X?Z;
M_Q0#%HUTZ$,-P3DT_6U1CGE$45[F#6BQ750/B]H3Z;X4$H<(#SEV[+Y$DFO\
M&>I%X&I,PQ=W3VEB;,#1=:N+0B-S,;/ \V+>-2D @.5UEE$C<[)W7-0-\&.6
MU<+X"E/5-YR/C>B+-%A6$ 6R?-F(F./-[+SWF%F/B9O3"-SVFSS![B[@5;68
M4%P2:\F@YHWKS9#%TSB3M6/8M"K#*-%!(3V_<:W)\[%KO0<^FIE$U>2V2,VY
M+:"QX(!%Q89FT,^%YY*6KYI,JBO4YHNIN2O71F4Y.;27,+C!3,9LQ45U!=YN
M*K!_;*[DA!9$3LL)Y##X650Z%_B)]&%S@8N$4(YL%-3EH6=K%%L=G0#2RAH1
M2WR>P% _<C\[=72T\)J^T,G"MAJEBHN+D=W\]XMB4) @-F(,R;_G1LT:RVL.
MZAO]X96JXH<7_R7Z@<2N+W#WA<&P9Z8_L[RRF3TJ9FVRRZR88%IF;#Y%<^H"
M @YM?8WR@O%\2U-7/]Q'Q@PZ18J%>]8[^ @UZ,MP#V+WGO2.3HVM?W.?8KDG
M]/W#"'-S5$ *>93G:*+-:^CJ .>*#JSEVRZ;W)@NO&'5-&U+ISUZA;;WAD.K
M-*\[S3V1-G&E[6AP<]OQ+'5\R<CV;(G5O>O?MC\Y3L&X40*3NL=G]:0@V[$:
M#A<8EK$,[Q!EV]E_N6N$_<0(56/#C8PCSX8J=.P:&,'MBV,2NRV- (I"@C-F
MZM@LC<,S(_ZRT:UTS['7C;FT9!6$21FR!58V?@M%R:Y/,F]G9B4RSFQ'NKY-
M,I@B=EO@:!AYAA .&^7P3O.K7250426:;<Z=7J*6<;ZN L9IE.>EQ)2FV6^(
MEIM+Y[ Q*0RWU_@)"4)2-N80+28V2QRU&+IRG&1(Q R(;(4)L6OU)Q^W;DMB
M1Q\L1O61<]1P/M&<)R0O#VR_5LO J 'X'*:Z#VGXU8J UJJWI9P')8^9@=M;
M<,CM=SCXT "CNW3 *5Q5^@LSXOH:!:611$ES;6R;:4K22@+!ZA:33$92>0$M
MF%,56J_FM[H^W_NNB,8>N]@9.4YM14#B?N[K8VV*EJ.P(<'VEIK2T(AE(#X&
MYGUIQ^#!\&T-I27.A]=.,]@+:IB4FR-1@)!608A X_2DU0.P%$PZ$0T(1?!Z
MAE'[H^M )4#P^K!,V-%)5\I>L&.VMV;<P@QM')'M.',KVAN+Z94O8]\D5 G:
MMF,S?=1*$FCOYV&%UE[GNUN'8'O++  OUD2I R+CAY@,)C_81O5;KYPL)FO$
M)/9?CUZ\%E.3VD %YJXU=7M#=('V?WS]'3E34] C(UE=.[BF<WZJIX-[U=A8
M%[5#-A<PZTEVU: - DT ")TCZA0.LG]1.G WX$<8-0J)N&M:HZL+OFBMXXLG
M ZPHYPYD=0VSEMP,H4-D/W>N+LBM,'\A?PQ3A>9//,J=WJZ%GPMG/APB>7&*
M5PZAZ#7T=2!'"727/S>P)-Z*(0'-)H +G1.-U6!.</:4$H?\M*(<3Q;<LPGJ
MZ.IJHLZ6S:$Y T6Z C;7I?G2W)A9X@5:21H,:L!M,A88A!@YE%&!C3%@S9J4
M;B/83E?93"\G2Z911>Z;^8L1;'*(IR[JP=TU< *\1&9ZHZ*9"9:)IX5[,T&
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M]^E6"J]H3F=NS)=W_S ??CS[_.F7_P]02P,$%     @ KD%+5Y3JV3+T&0
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M\D,1BI%,D5L)#/6:X'$@X1N)ZY;3RMNKED,:(X)3P_8+ID VK,@?! I%)4D
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M$HV\I&M&8FK55E@'P/M! )L::PA%69QD@!X@:;VFN8&>AF6&(!_U/FD^4Z"
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M1)%8)I3+5G$*<BI=V((>$,JH?+2U.A38=**Q/9%@'( I33OJ\2P1VE2@5_H
MU FRSUYKOZ4=YCQ1^ 27>5^[S-HF[<(="[80/'9T3Q,U*!VW6DZK!1:"4-@[
ME^MSBAKXDH]#:O*AM<'BG^NT'Y1GT L]T]6"1"F1"(::@+)" 00HZZ)-C!:"
M%@@QV=]TH(4Q+M#8(XVK38K<(?_<?^[T#DU,H6<LEKYC>HN,5Z#]\Q%,".;6
M,'N[M$D-&_*@S7KN#/9+48T_-7)T@PZ7T@=KI=@02:=1P@=<,%4'X;)(4W@3
M$+%@5*(#%=NR"AM-,E&!)+^+6A5E"AA_3SL!# (.INX#@Q4])A9#%0(]/ 7:
M2GI6/HYX"KBHC,]V;SH?KB]!POVQ5\(6@M@H)@NOZU^AO-0WYKNX-&@'AM01
M$AG'X/##D[I#%I%@RP!TT8DOR71[/IN^^5:1+6P\DZ,26QL%BPV*"T9-T@[U
M,R8I6?I/J"\X:C7>MEX5'4'UFI4D*#'HQ:;[&G&&4:]8D@BP% 9S(8MU.$(W
M&"%ADPRLC'CQ7&8Z,H3LTGI*;T:1G23*DX7K%"F0@3&YAB%M*VYR,@&A1$5T
M.F#Y_+T\=/0<GCGSMV;F ]+[>*]C0Q_(K\8RH0 -B4UXB<3(Y(Q3$3=UA2XM
MD"*7]AP@$%U?=.^*I<F? M.7U?2K>OV_C0&^:F"$R*,G"A0]F%5S?67S/NYJ
MXXDM_+FAB:WZMID3O7FT93$(B3H;?/>Q* "CHP%V:MB;A$5R&+H0!"/@-ZGP
M]E#-1&"C)-0X.,[%FS"\!-P:@_C''EH*ALFQM@.7F^5-H";O]2^UPANCQMKE
ME>E9;P1#S'HZN4%OY^64>VO)^:5/!\>'CCD(H>H)^:Q[M]?LWATLMR0:LZ*T
M62GHLFP\T;X#!LL30+VVU?1"*-,])HL R%B8QE*W#J\TCBED@J$-_6 1^T<D
M!8DJ'S]AO#RL$,N#@(63@&)U<-_]%P;K[5(-GBA(D^1EE$5HTOO8Z3?[@][-
M1R3X!-STR@3 '?)_RSA*.ZT'2D=P ,^#<Q]*[F((#2=2!-EYA3-A1S%P.5)9
M:(.ERQM:A$8QW#N?SZOA4!T-W88H_A_"\H-N 6]<*_6%CA+'@)L^T/B;",L)
MN3?@"P&;!7D%+H6C3'=Z(S!32XJIE3Q:Y!9CB4P%B#NX!"#N:QO2)-#:70OL
M/JHP,+5@%MVO*!Y!Y'4\?6#L\?X!>< <QO"%[]#Y=$MO.NJL>%/Q@OWR"]@N
MWJ=+B*MWVVIB6"K(-)KSIJ-IS$D3*^[(C_'07? E"F$RPG3RL[$"B>'0"1(A
M69E:BNDLH@D9<@KOCC+,[X*6"#C>!?HA].$G'E&1ZN9L.MX%PZ%%M!%DS AD
M%PA#"ET:4];!ZR3HYA(= 'T\ K"YMB$P/QI(,<J#G[I!WIYULIH<I? $&"S9
M--(3F')07T,CF\ORQ@Q5$8RI<E:/!5*R-)C+/JR'7Y'?M^GSTI<D6SF=0D!'
M8*"3#P -3>H\1%\O$J$Y*H("-2,,RUKJ&VKC-X5?8->F1P-'VT_ SO0HW*+A
M 1MN3LXP%S Q5+T"!FH6^/GY&N:VTK6\3QHNZ2N.N:2Q4KT-#\G0R;[J=01/
M]4H@OZ#NK%RC[9\M/6I]AZ47ZO!']2*A.9\X4H? !N8O2!H>([I-ER+L90?K
M"/(MJM?R/<+\"(@@T)-D+8PXIM7QB_7"IYRL0-.HM/6Q&',379OD&3D9F#_+
MX.<',U3#C>84E>)<X1*;K;RS],Z2SD3 2(RWYLD#ZOQ5-DE)>*G7](DAH'W!
M2.=D>=B,K@'9AA'R<T+$DTX)P=3JURC0X2)A+9:<[8HC*S:P&NY%+CHJMD2)
MHU<;^Y4J%1!JF"VFDZ?\?.O'8,0 C(4.9AC^ \E&PZ"?@](ZP]2AV1)B#5C\
M"%D6D8K; G+ ./.JT%_:,$*JK862JY6*EMT%@M'=T@L'4]*+Y5"_RAX1Y&.V
M)K#>-Y!N^H1 2;O5^&<>'Y%!):A?I5H>DRZI+#*'K;J\4-.IU.V_\*^3C;/$
M)*[;ME#%Q R_>B)*<1OR9#L,"H9M (C&C0OXW%D]B0P39"G_(K"9D:EA8!T&
M2O3/)(;0XGI-'T"VF<BDA_!\'7@;W:F)O(F_YQ-!]Y#/HW>>'!TP6TH(=![*
MZUS=686\P831PIA0.$26!VEH5 (1S#!MR32HZB=M(;.9%'.+=#J4#NF!1Q@!
MQ04=0Y,S@&:&!^:6B5RLGXM58]H[J*R9LB@!9@HMIZ'13*>Z.<R6/6@H8TQ&
MCT!;""RC'N$.>$&]1NVT5M*BN11DB<GGPH;:+_10]) O/'T:D?8U2$ 70%YC
M67R3!$3/EH%<H(  /7/R32SL_B+ (IU?)@(V/-ZPT!?Q*&@80!, ZUJ.0(AX
M.F#7\8%I;9_.FN6^C$OS^3R9Z[7^]SR?3)!P]!<9.HQ;=_&/TK83_ J&LV#W
M8A&JP/_S-_-):/HS_>//YR"[]&(?H@E!]/DE_U94\9;RWWE[Z[8>>Q&.!!8?
MZ$Q[I1U]-8GI'UKTWZG&3+O]ZB]8@WZPL<S\CYV>^MR2\V=7F3\-A*=L:36]
M41$;'.K8XH?+SKK.F.W^KBL%_U[W]S+S8I%]=9A(79#MKJ,G^I/*XI!3'7E>
M3GEK$PC[QPZ85BYK'_XO%L8$;/<3Q[0_F>/MM6U36W!L+GKX_L!QSR=RZ+!K
ME^&Y=('+[G1H1%<64()$5NHDJ*R /'$L CDA<8'.%85S4()DH#5,V'\1 W4=
MG<-V=%TG>/V4!#0OSXNJ*M698#WWSB_TZ/?PD<X!/SH \!VW]QM[QWMMMKO7
M:A^8TX:W0'QV[<OW!\1?L-2'70D>I!-V&X]Y*'\W)6+75 -A\/ !'1TPG$"6
M?0S44 &.7!1*+9=U\@ .3T^>$,*P-?%C3[F2QYX[BIO4)='$D%9S9$=*F@:L
MS7:[09-IX'<-/8W('[DV$')-M?VF7/]$M]R83ILM4)]9!?6] O4Z $LI==A/
M+OOD.NP?(@C$PF'W+OL'?/Q9!@$/,S'C#NNXCI6J5VL.4'?9C8[BWPL=>+DT
M=2AW,4PC3MQZ#16NPXYVVZ\=]F:+HV<7B'RO.+JEH\6ILMY(O5[QQU_+S64
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M,#AD97@S,2YH=&U02P$"% ,4    " "N04M7??.(?);5  "ZL@0 $
M        @ '!,P  9#4T-S@P.&1E>#0Q+FAT;5!+ 0(4 Q0    ( *Y!2U>4
MZMDR]!D  )Z"   1              "  84) 0!D-30W.# X9&5X.3DQ+FAT
M;5!+ 0(4 Q0    ( *Y!2U<% U_B,0X  )DI   1              "  :@C
M 0!D-30W.# X9&5X.3DR+FAT;5!+ 0(4 Q0    ( *Y!2U?"8%<C/P,  % +
M   1              "  0@R 0!T<'-T+3(P,C,Q,#$P+GAS9%!+ 0(4 Q0
M   ( *Y!2U>X1ZP+L08  *=)   5              "  78U 0!T<'-T+3(P
M,C,Q,#$P7VQA8BYX;6Q02P$"% ,4    " "N04M7@L=5\]\$   "+@  %0
M            @ %:/ $ ='!S="TR,#(S,3 Q,%]P<F4N>&UL4$L%!@     (
-  @ ^P$  &Q! 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
